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ABSTRACT
The second messenger cAMP is involved in the mediation of a wide range of 
signals in response to a wide range of external stimuli, including processes as varied 
as neurotransmission, metabolism and embryonic development. Each of the 
components of the cAMP signalling system are encoded by families of genes. In the 
case of cAMP phosphodiesterases, the enzymes that hydrolyse cAMP, this variety 
produces proteins with different targeting, expression and kinetic characteristics. A 
full understanding of the differing functions of these isoenzymes may in the longer 
term allow drugs to be designed which allow specific interventions in human 
pathologies. To realise such an approach, it is important that each isoenzyme be 
identified and characterised. This thesis concentrates on the characterisation of four of 
these isoenzymes, namely PDEIB, PDE3B, PDE4AI and PDE4A10.
In chapter three of this thesis, I use immunoblotting of cell fractions to 
examine the particulate association of transiently expressed full-length PDE3B. I show 
solubilisation of full-length PDE3B for the first time. In addition to this I determine the 
solubility of two deletion mutants which delete a putative membrane association 
domain. I demonstrate that a mutant with a deleted putative membrane association 
domain is still particulate, which strongly suggests that PDE3B possesses additional 
membrane association determinants. I also present data which suggests that PDE3B 
can be stimulated by protein kinase B.
In chapter four I examine a PKC-mediated induction of PDEl in Chinese 
hamster ovary cells. There was no sequence information for Chinese hamster PDEs. 
This compelled me to design molecular probes to phylogenetically stable pieces of 
PDEl. Sequencing of amplification products of these probes reveal that PDEIB is the 
induced PDEl form in Chinese hamster ovary cells. Selective isofoims of PKC appear 
to mediate this stimulation.
Chapters five and six of this thesis are devoted to furthering knowledge of the 
number and primary structure of PDEs. In chapter five I identify mammalian 
homologues for the rat PDE RDI. Thus, RDI becomes only the second PDE4A which
m
has been identified in human and rat. The putative membrane association sequences of 
RDI are perfectly conserved across a range of mammalian species, supporting the 
notion that the sequences may have a conserved functional role. Serendipitously, this 
work exposes a rodent-lineage specific deletion of apparently ancient PDE4A 
sequence. This finding, which may be associated with functional alterations, may be a 
first step in the production of single state PDE inhibitors, since it suggests a possible 
target for such inhibitors. The deletion may also be of considerable interest to 
molecular taxonomists as a phylogenetic marker with the potential to solve previously 
intractable controversies over rodent phylogeny.
In chapter six of this thesis I identify, clone and express a novel human 
PDE4A splice variant, PDE4A10.1 then make a survey of endogenous expression of 
this PDE in native brain and cell lines by RT-PCR. Furthermore, I identify almost the 
full open reading frame of the rat homologue of this splice variant. This PDE is 
therefore the third PDE4A which has been identified in both rat and human.
The work in chapter six also makes a wider contribution, by describing a 
novel method for producing precise overlaps in clones of DNA made by a 
modification of shotgun cloning. Shotgun cloning was already the easiest way to 
fragment a large piece of DNA into smaller ones. The innovation to shotgun cloning 
that I describe makes it easier and extends its utility. The overlaps of DNA fragments 
that result will allow the shotgun fragments to be ordered as they appeared in the 
original DNA sequence and if the ordered fragments are sized, this will produce a 
restriction map for the contig. This approach is considerably faster than existing 
methods for producing DNA contigs and restriction maps. If it is taken up, the ease 
and speed of this new technique should significantly hasten sequencing projects such 
as the Human Genome Project.
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INTRODUCTION
1.1 Intracellular signalling with cyclic nucleotides: cyclic nucleotide 
generation
The cyclic nucleotides cyclic 3'5' guanosine mono phosphate (cGMP) and cyclic 
3'5' adenosine mono phosphate (cAMP) are second messengers which are found 
ubiquitously in mammalian cells. These cyclic nucleotides are involved in the 
transduction of signals by a wide variety of hormones and neurotransmitters and other 
agents. cAMP mediates a diverse range of effects. It can bring about acute, reversible 
changes in dynamically regulated processes such as neurotransmission, muscle 
contraction and it regulates metabolic processes such as glycogenolysis and lipolysis. 
Yet, in other contexts, cAMP can have long term effects on, for example, embryonic 
development, cell growth and differentiation. Most of the cellular effects of modulation 
of cAMP concentrations are due to the stimulatory effect of cAMP on protein kinase A 
(PKA) activity. PKA then phosphorylates key target proteins leading, ultimately, to 
alterations in cell functioning (1).
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1.1.1 Agonist stimulation of G-protein coupled receptors (G-PCR)
cAMP signalling is initiated at the cell surface by regulation of G-protein coupled 
receptors (G-PCR). These numerous 'serpentine' receptors contain seven 
transmembrane domains each of about 22-28 amino acids. The N-terminal of the 
receptor is extracellular, of variable length and glycosylated, whilst the C-terminal tail 
is intiacellular and, in certain receptors, this region contains phosphorylation sites for 
PKA and G-protein coupled receptor kinases (GRK) (2). Ligand occupancy of the 
receptor brings about interaction with tlie heterotrimeric guanine nucleotide regulatory 
protein (G-protein) family (3). These proteins consist of a^y  heterotrimers. There are 
multiple isofonns of each subunit and these isoforms have subtly different specificities 
for interactions with other signalling molecules including the other G-protein subunits 
themselves, such that the isoforms usually form heterotiimers with only a few of the 
other possible subunits (4). The alpha subunits are GTPases which bind to Py-G via 
the a-G N-terminus, in a region which partly overlaps with the effector-binding 
region. The C-terminus of a-G is involved in specificity of the individual receptor/G- 
protein interactions (4). Receptor interaction with the adenylyl cyclase stimulatory G- 
protein Gs causes a confonnational change which allows the a-G^ subunit of the G- 
protein to bind GTP and dissociate from the py-G heterodimer (3). Following this, 
binding of the a-G^/GTP subunit stimulates the transmembrane enzyme adenylyl 
cyclase (see below). The conformational changes caused by GTP binding, which cause 
a-Gs dissociation have been elaborated in crystal structures of a-G of the light- 
activated heterotrimeric G-protein transducin bound to GTP and GDP (4). The 
activated conformation persists until GTP is hydrolysed to GDP by the intrinsic 
GTPase activity of the a  subunit of the G-protein (4). This form is 'recycled' by 
reassociation with the py-G heterodimer (3). In addition to Gg linked G-PCR there is a 
family of receptors which are able to inhibit adenylate cyclase activity by interacting 
with the inhibitory guanine nucleotide regulatory protein, Gi (5) and certain receptors 
show a promiscuity in the G-proteins that they will couple with (2). The Py-G 
heterodimer never disassociates and so acts as a functional monomer (4). This 
monomer is an active signalling molecule with many targets, amongst which are
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examples of both positive and negative regulation (4). Regulatory targets include type-I 
adenylyl cyclase, which it inhibits, and type-II adenylyl cyclase, which it stimulates 
(6).
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Figure 1.1.1. Schematic of G-protein coupled receptor mediated 
activation of Protein Kinase A
Ligand occupancy of G-protein coupled receptors (R, cell membrane is shown 
hatched) brings about activation of adenylyl cyclase (AC) through a G-protein mediated 
process (G). Adenylyl cyclase catalyses the synthesis of cAMP from ATP. cAMP, 
through association with the regulatory subunit of PKA, brings about catalytic subunit 
activation. PKA signalling then occurs by phosphorylation of substrate proteins. 
Phosphodiesterases allow the system to be reset by catalysing the breakdown of cAMP 
to 5'AMP.
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1.1.2 Adenylyl Cyclases
G-proteins activated by cell-surface receptors alter cAMP signalling in a way that 
depends on which of the family of adenylyl cyclases (AC) the G-protein is co-localised 
with. To date, nine different classes of AC have been reported. AC enzymes are 
typically more than 1000 amino acids long with molecular weights of approximately 
120kD but the distribution of AC forms varies (6). Members of the mammalian AC 
family all have a similar stmcture which is reminiscent of certain channels though no 
such activity has been reported for these enzymes (6). The structure consists of two 
sets of six transmembrane helices (M l and M2) with very short connecting loops. M l 
and M2 are separated by a much larger intracellular loop (Cla and C lb). There is a C- 
terminal tail at the end of the protein (C2a and C2b). C la  and C2a are very highly 
conserved and are thought to encode the catalytic domain of AC (6). Different AC 
fonns often have contrasting regulatory properties (7). For example the activity of the 
AC I and III isoforms can be stimulated by calcium/calmodulin whereas the AC V, VI 
and IX isoforms are inhibited by calcium (6,8). The sequences that encode these 
regulatory domains are found within the intiacellular loop and the long C-terminal tail. 
Furthermore, different AC have different catalytic properties and it has been suggested 
(7) that this can determine cAMP flux controls in the cell. Thus, in cells with 'high' 
cycling conditions brought about by AC with a high basal activity, such as AC-II, 
PKA is kept inactive by PDE with a high activity. In such a situation, elevation of 
cAMP levels can be brought about by stimulation of AC or inhibition of PDE. In 
contrast, in 'low' cycling conditions, where the AC basal activity is extremely low, as 
in the case of AC-VI, activation of AC is the only acute method by which the cAMP 
threshold can be breached since inhibition of PDE will cause a chronic build-up in 
cAMP concentration due to the low activity of AC. Thus cell-specific responses to 
ligands could in part be due to the cAMP 'poise' of the cell, as determined by the 
isofonns of AC expressed in the cell (7).
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1.2 Hydrolysis of cAMP and cGMP by members of the 3'5’ cyclic 
nucleotide phosphodiesterase (PDE) gene superfamily
cAMP phosphodiesterases antagonise effectors of adenylyl cyclases by 
hydrolysing 3',5' cyclic AMP to 5'-AMP. Tliis is the only enzymatic route by which 
this can occur. In some cells (but not for example in hepatocytes (9)) cAMP can also 
be extruded through an energy driven process (10).
Mammalian phosphodiesterase activity is supplied by a large gene 
superfamily (see table 1.2), the members of which are all distantly related to the yeast 
PDE2 gene (see figure 1.2.) There is a second yeast PDE gene, PDEl, which has no 
mammalian homologues. Mammalian PDEs exhibit a common structural pattern with a 
conserved catalytic domain of -300 amino acids and more divergent sequences in the 
N-terminal and C-terminal ends (11-18). PDE activity is classified into seven types 
(PD El-7). These divisions were originally made on the basis of inhibitor/activator 
selectivity of phosphodiesterase activities eluted from purification columns. Since tire 
identification of PDE genes, the genetic conservation which underlies these 
biochemical differences has become apparent such that it is now clear that the seven 
PDE types are groupings of highly homologous PDE genes. PDEs are highly 
conserved in evolution, such that species' homologues of a specific gene or cDNA are 
much more homologous than different PDE genes in the same species.
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Type Effectors Substrate Selective
Inh ib ito r
Number of 
Genes
Splice
Variants
1 Calcium /
CaM
cAM P/
cGMP
nicardipine
vinpocetine
3 8 +
2 cGMP
stimulated
cAM P/
cGMP
EHNA 1 1
3 various cAM P/
cGMP
cilostimide
m ilrinone
2 2 +
4 various cAMP rolipram
R P73401
4 1 5 +
5 cGMP zaprinast 1 1
6 cGMP none
known
3 3
7 cAMP none
known
1 1
Table 1.2 General characteristics of the seven types of mammalian 
phosphodiesterase (19)
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Figure 1.2 Conservation tree o f phosphodiesterase genes
The conserved catalytic sequences of PDE genes in GenBank, were aligned according to 
instructions in the GCG suite of software. The most conserved sequences are chosen 
because substitutions here are more likely to represent neutral drift rather than 
adaptation. Thus, this figure represents the best estimation of the evolutionary ancestry 
of PDE genes. Genes are numbered according to the most recent nomenclature (see 
section 1.2,1,). Species are: BT bos taurus\ CK Candida albicans; DD d ictyoste liu m  
discoidewn; DM drosophila m elanogaster; GG gallus gallus; HS homo sapiens; MM 
mus musculus; RN rattus noiyegicus; SC saccharomyces cerevisiae; VF vibrio fischeri
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1.2.1. Phosphodiesterase nomenclature
To describe the various PDE species and to provide a rational framework to 
allow accommodation of new forms, a Nomenclature Committee was set up in the 
early 1990s (11). This led to a change in PDE naming from a roman numeral-based 
system (type-I etc.) to one based on arable numerals (PDEl etc.). The new systematic 
PDE splice variant nomenclature is based upon (i) the first two letters indicating the 
source species (e.g.. HS - homo sapiens; RN - rattus norvegicus), (ii) the name 'PDE' 
for cyclic nucleotide phosphodiesterase, (iii) an arable numeral for the gene family,
(iv) a single letter for the gene (e.g. A/B/C for each of the three PDEl gene families),
(v) an arable numeral for the splice variant and (vi) a single letter for the report. 
Usually the same last numeral (v) is used to describe the same isoform in different 
species, for example the human splice variant most closely related to RNPDE4A1 is 
HSPDE4A1 (An important exception is HSPDE4A4, whose rat homologue is 
RNPDE4A5).
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1.3 cAMP DEPENDENT PROTEIN KINASE A (PKA) MEDIATION OF 
cAMP SIGNALLING: MODELS FOR THE SPATIO-TEMPORAL 
PARTITIONING OF THE cAMP SIGNAL.
The generation of an intracellular response to elevated levels of cAMP is due 
to the action of protein kinase A (PKA) (20). Inactive PKA is a heterodimer consisting 
of both regulatory (R) and catalytic (C) units. cAMP activates PKA by binding to the 
regulatory subunits. This allows dissociation of free, active catalytic units which then 
mediate all of the various downstream physiological effects of cAMP signalling.
Spatio-tem poral partition ing  of the cAM P signal, so-called  
compartmentalisation, has been suggested as a mechanism for how in a single cell, 
two receptors coupled to adenylate cyclase can cause different effects on cell function 
via cyclic AMP signalling to PKA (21,22). The machinery for cAMP production can 
be localised to discrete regions of the plasma membrane in polar cells, as has been 
reported for various G-protein linked receptors and adenylate cyclase (3). The 
intracellular receptor system for cAMP, protein kinase A (PKA) may also be localised, 
in that the PKA-RI form is cytosolic but the PKA-RII form is almost exclusively 
particulate-associated by interaction with members of a family of A-kinase anchoring 
jPLi'oteins (AKAPs)(21). These are a heterologous collection of proteins that have a 
common property of being able to bind PKA. AKAPs target pools of PKA-RII 
because different AKAPs have altered cellular distributions and associations with 
subcellular structures (21-23). Thus a system has been described which provides for 
distinct locations defining the sites of cAMP production and detection. Non-unifonn 
intracellular distribution of cAMP has now been measured (24). A clear inference is 
that localised PKA-RII will be exposed to different cAMP concentrations leading to 
distinct responses dependent on whether the local cAMP concentration can breach tlie 
activation threshold of each PKA pool. If PDEs are targeted similarly to the other 
cAMP signalling components then selective PDE regulation immediately becomes an 
alternative way to manipulate tlie fonn of the cAMP response by defining spatially and 
temporally which PKA pools can respond to the cAMP signal, by selectively 
protecting specific PKA pools by lowering the local cAMP concentration (see figure
Chapter 1: Introduction 13
1.3).
The existence of the numerous evolutionarily conserved PDE forms is in 
itself consistent with the notion that such selective regulation of PDEs will take place 
because if these splice variants did not have differing roles they would not all be 
retained in evolution. Now evidence is accumulating regarding the distinct regulation, 
localisation and biochemistry that could form the molecular basis of spatio-temporal 
partitioning of the cAMP signal due to phosphodiesterase heterogeneity. Some of 
these examples are discussed below.
Chapter 1: Introduction 14
PKA1 t
[cA M P ]
IV V
S IG N A L  1 S IG N A L  2 
STIMULATE PDE1
AC1 PDE1 1st!
PKA1
N O  S IG N A L  1
hight[CAMP]
low  
S IG N A L  2
Figure 1.3. Model for compartmentalisation of the cAMP signalling 
system: potential for specific regulation of these channels by PDE.
(a) Components of cAMP signalling machinery, including receptors (R) G-proteins 
(G), PDE and PKA are targeted to subcellular locations (see text). These could form 
discrete groupings of signalling machinery (depicted as group 1 (white) and group 2 
(black), in the diagram.) each populated by different isozymes of the various 
signalling enzymes (black and white in the diagram). At the cell membrane (hatched 
box) ligand occupancy is transduced by a G-protein mediated process to activate 
adenylyl cyclase producing enough cAMP to breach the activation threshold of both 
PDEs resulting in two downstream signals, (b) Selective stimulation of PDE is then 
able to selectively block a channelled cAMP signal, in the 'high' cycling cellular 
context (see section 1.1.2)
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1.3.1. Experimental observations of compartmentalization due to PDEs
Specific PDE inhibitors have been used to implicate PDEs in many signalling 
mechanisms. Recently two reports have explicitly approached subcellular 
compartmentalization due to PDEs by use of PDE inhibitors. Jurevicius et al (25) 
showed that duiing P-adrenergic stimulation PDE activity stopped local cAMP pools 
diffusing into the cytosol. They found that in the absence of PDE inhibition, P~ 
adrenergic-elevated cAMP levels in particulate fractions rise more than in cytosolic 
fractions. In contrast when PDE inhibitors were added simultaneously with 
isoproterenol treatment, a more equal division of cAMP accumulation was detected 
(25). These differences were shown to have a functional conelate in that treatment of 
the cells with isoproterenol alone had a much more spatially discrete effect on calcium 
channel gating than when isoproterenol was added in conjunction with PDE inhibitors.
Thus PDEs are indeed able to insulate compartments of the cell from each other.
More recently (26), comparative analysis of the effect of inhibitors on the 
same cell line has led to the first evidence that different PDEs occupy different 
compartments and have different roles in the same cell. Chini et al (26) used PDE 
inhibitors specific for different PDE families to study cAMP signalling 
compartmentalization due to different PDE isoforms in rat kidney mesangial cells. In 
these cells, response to immunoinllammatory stimuli brings about accelerated 
proliferation and generation of reaction oxygen metabolites (ROM), both due to 
elevation of cAMP. It was found that PDE3 inhibitors raised PKA activity and 
specifically inhibited proliferation. In contrast, PDE4 inhibitors specifically blocked 
ROM whilst also raising PKA activity. All the effects of these inhibitors had potencies 
similar to their effect on PDEs.
1.4 PDEl calcium/calmodulin stimulated PDE gene family: survey of 
complexity and distribution
PDEl enzymes can hydrolyse both cAMP and cGMP, with their activities 
being stimulated by Ca-VCaM at physiological concentrations (12). Three genes 
(A,B,C) encode these enzymes, with additional complexity generated by alternative
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mRNA splicing in PDEl A and PDE 1C such that there are currently eight reported 
PDEl isozymes. The PDEl genes are most closely related to PDE4 and PDE7 in the 
PDE gene superfamily. P D E lA l, PDEIB (27,28) and PD E lC l-5  (29-31) are all 
expressed in discrete sections of the brain whereas PDE1A2 is identified in lung and 
heart (32).
PDEl A fonns are about 59-61 kD in size, PDEIB is 63kD and PDEIC fonns 
range in size from 71kD for PDEICI to 86kD for PDE1C2 (12).
PDEl A and PDEIB each have a K ^for cAMP which is approximately ten 
times higher than their for cGMP which is in the low micromolar range (12). In 
contrast, PDEIC has a for cAMP which is roughly equal to that for cGMP (31).
PDEl forms possess the conserved PDE catalytic domain along with PDEl 
specific sequences in the N-terminal. The PDEl A and PDEIC genes appear to be 
alternatively spliced (see table 1.4). PDEIC deviates from the noimal pattern in that its 
splice-variants have gene-specific conserved sequences further towards its C-terminal 
than the catalytic domain. PDEIC also deviates from most other spliced PDEs in that it 
undergoes C-terminal as well as N-terminal alternative splicing. PDEl conserved 
sequences have been shown to mediate regulation by PKA, Ca^+ZCaM or to be 
involved in autoregulation (see below).
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Letter in Transcript Clone Name Accession Size Reference
figure name Number famine acids)
PDE1A
BTPDE1A1 59kD CaM- L34069 514 (33)
PDE
BTPDE1A2 61 kD CaM- M90358 530 (32)
PDE
HSPDE1A3 Hcami U40370 535 (29)
PDE1B
BTPDE1B1 63kD CaM- M94867 534 (34)
HSPDE1B1 PDE U56976 536 (35)
MMPDE1B1 L01695 535 (28)
RNPDE1B1 M94537 535 (36)
PDE1C
HSPDE1C1 Hcam3b U40371 634 (29)
MMPDE1C1 L76944 631
RNPDE1C2 L41045 768 (31)
HSPDE1C3 Hcam3a U40372 560* (29)
MMPDE1C4 L76947 655* (30)
MMPDE1C5 L76946 604 (30)
Table 1.4. PDEl isoforms
A complete list of PDEl isoforms is shown. 
KEY:
* The reading frame is open at the 5' end
Chapter I: Introduction 18
1.4.1. Regulation of the catalytic activity of PDEl
Ca2+/calmodulin is able to stimulate all PDE 1 enzymes at least 10-fold. This 
effect is almost exclusively on the V^ax (12). The mechanism of action of calmodulin 
binding is apparently to relieve inhibition by binding adjacent to an inhibitory domain 
found in the N-terminal of PDEls. PDE1A2 apparently has a higher affinity for 
calmodulin than other PDEls, owing to a second calmodulin binding domain in its 
unique, due to alternatively splicing, N-terminal sequence (33). Since the levels of 
calmodulin in cells do not vary it is likely tliat calmodulin binding is regulated directly 
by the level of Ca^+in the cell (12). Such regulation is expected to allow interactions 
between Ca^+ and cAMP signalling. Such interplay is seen in the signal transduction of 
olfaction, where many signals trigger an increase in cAMP and an accompanying 
increase in Ca^+ by influx through cAMP gated channels. This calcium amplifies the 
cAMP signal by stimulation of adenylyl cyclase III but it has been suggested that it then 
also serves to reset the system by stimulation of PDEIC (12,30).
PD E lA l, PDE1A2 and PDEIB are all phosphorylated by PKA (37,38) and 
PDEIB can also be phosphorylated by CaM kinase II (37). Phosphorylation at serine 
120 of PDEIA reduces the affinity of the protein for calmodulin. Thus, PKA can 
induce more cAMP production by inhibiting PDEl. An increase in Ca^+concentration 
enables 'escape' from this feed-forward loop. It is not clear what the physiological role 
of this is. It has been suggested that in post synaptic endings feed-forward will allow 
rapid amplification of signals which cause a small increase in cAMP concentration. 
Ca^+ could then reset the system (12)
1.5. PDE2 cGMP STIMULATED PDE GENE FAMILY
Similarly to PDEl, PDE2 enzymes hydrolyse both cAMP and cGMP. PDE2, 
however, is more closely related to the cGMP specific PDE gene families, PDE5 & 
PDE6, than it is to other cAMP specific PDEs. To date, one cDNA for a PDE2 gene 
has been identified (39). This gene is expressed in a number of sections of the brain, 
in heart, trachea, lung, spleen and T-cells (39). In certain cell lines this sequence is 
only ever partly protected in RNAase protection analysis, implying the existence of
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alternative splice variants. This is consistent with the finding that PDE2 can exist in 
both cytosolic and membrane-bound forms (40). A unique feature of PDE2 amongst 
PDE genes is that catalytic activity can be stimulated through the binding of cGMP to a 
flexible domain in the N-terminal region of PDE2 (41). This organisation of the gene 
was originally suggested when protease treatment of PDE2 was able to dissociate PDE 
catalytic activity from the cGMP binding site (41,42).
cGMP binding is thought to occur through a tandem repeat conserved in 
PDE5 (42) fonning a domain which is able to bind cGMP. Consistent with this, site 
directed mutagenesis of key amino acids in this putative domain reduces the affinity of 
PDE2 for cGMP (43). It has been suggested that binding of cGMP brings about a 
conformational change in the cGMP binding domain and that the flexibility of this 
domain allows transduction of that confonnational change to the catalytic domain (41).
1.6. PDE3 cGMP INHIBITED cAMP SPECIFIC PDE GENE FAMILY
There are two genes in the mammalian cAMP specific PDE3 gene family, 
these are named PDE3A and PDE3B. In the PDE gene superfamily these are most 
closely related to the other cAMP specific genes PDEl, PDE4 and PDE7. PDE3 gene 
products exhibit high affinities with a for both cAMP and cGMP in the low 
micromolar range. This means that, in contrast to other PDEs (see section 1.6.2.1), 
cGMP can competitively inhibit cAMP hydrolysis at very low concentrations. Indeed 
PDE3 enzymes were originally termed 'cGMP-inhibited' PDEs after this 
characteristic. This name survives in many of the clone names of PDE3 (for example, 
the longest transcript of rat PDE3B which is called rcGIP-1 for rat cyclic (^MP 
inhibited PDE).
PDE3 enzymes can be specifically inhibited by several drugs including 
cilostamide and OPC3911 and this has enabled understanding of the cellular functions 
that PDE3 is involved in. Such functions include (44): (1) myocardial contractility, 
which led to animal and clinical trials (45) for the PDE3 inhibitor milrinone in 
treatment of chronic heart failure; (2) inhibition of platelet aggregation (46); (3) 
relaxation of airway and vascular smooth muscle (47,48); (4) insulin mediated
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adipocyte aiiti-lipolysis (49) and (5) insulin secretion (50). The last two of these are 
discussed in greater depth below.
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Transcript name Accession
Number
Clone Name Size
(amino acids)
Reference
PDE3A
HSPDE3A1 M91667 HcGIP-2 1141* (5 1 )
HSPDE3A2? 658 (5 2 )
RNPDE3A U38179 RcGIP-2 1141*
PDE3B
HSPDE3B U38178 HcGIP-1 1112 (5 3 )
RNPDE3B Z22867 RcGIP-1 1108 ._..(54) .............. _
Table 1.6. PDE3 isoforms
Information is shown on PDE3 cDNAs submitted to GenBank. cDNAs which are 
open at the 5' end are marked with an asterisk. In the case of RNPDE3B, the 
completeness of this reading frame is inferred by comparison with HSPDE3B.
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1.6.1. PDES isoenzyme structure and distribution
The first cDNA that described a PDE3 form was isolated from a heart cDNA 
library and designated PDE3A (51). A cDNA (rcGIP-1) from a second gene, which 
was designated PDE3B was then identified in rat adipocyte libraries using a PDE3A 
probe (54). Though this reading frame is open at the 5' end, isolation of the human 
homologue of this PDE (HSPDE3B) indicates that the first ATG in rcGIP-1 is the 
initiator methionine. The first genomic sequence infoimation on PDE3B has shown 
that human PDE3B is composed of 16 exons dispersed in more than 110Kb of the 
human genome (53). The two PDE3 genes have a gene primary structure which, 
beyond the common catalytic domain, shares elements not identified in other PDEs. 
Thus, they both possess a -150 amino acid hydrophobic region in the N-terminus, as 
well as conserving the sequence which connects this domain to the catalytic domain 
(see figure 1.6.1). The role of these N-terminal domains in membrane association of 
PDE3B is discussed in chapter 3. PDE3 forms also possess a unique 44 amino acid 
insertion within the conserved catalytic region. The function of this region is not 
known but it is essential for PDE3 catalytic activity because even though its removal 
yields a catalytic domain more homologous to other PDE catalytic domains, this 
construct is inactive (55). Both PDE3 cDNAs encode proteins with predicted 
molecular weights of -125kD. However, recombinant and native proteins of both 
genes migrate more slowly on SDS-PAGE gels than expected (56). This has been 
attributed to a cluster of positively charged residues conserved in the C-teimini of both 
genes (54). In contrast to PDEl and PDE4 there is no evidence for alternative splicing 
of PDE3 which could yield proteins with unique pieces of sequence. However, for 
PDE3A at least, truncated splice variants of the gene appear to exist botli in RNA and 
as expressed protein (52).
PDE3A is expressed in heart and vascular smooth muscle while PDE3B is 
expressed in adipocytes, hepatocytes, renal collecting duct epithelium and developing 
spermatocytes (54,57). Both PDE3 forms are expressed in the brain (57).
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PDE3A
PDE3B
Figure 1.6.1. Schematic of domain structure of PDE3
The figure presented above shows the domain structure of PDE3A compared with 
PDE3B (based on a figure by Degerm an et al (58)). The numbers represent the 
percentage of amino acid identities in between equivalent domains. The cross-hatched 
box is the hydrophobic putative membrane association domain of PDE3 (54) (see 
section 3.1). The black domain is the putative catalytic domain. The PDE3-specific 
catalytic insertion is the hatched box within the catalytic domain
Chapter I: Introduction 24
1.6.2. Regulation of PDE3 catalytic activity
1.6.2.1. Regulation of PDE3 by cGMP
Several studies report that inhibition of PDE3 by cGMP signalling is of 
physiological importance. Nitrovasodilators, which up-regulate cGMP levels through 
stimulation of guanylyl cyclases, potentiate signals that are mediated by cAMP 
signalling and it has been proposed that this is due to cGMP inhibition of PDE3 leading 
to elevated cAMP levels (16). Examples of signals elevated in this way include anti­
aggregatory effects of prostacyclin in rabbit platelets (46) and DNA synthesis in 
thymocytes (59). Thus regulation of cAMP levels can be positively or negatively 
coupled to changes in cGMP levels, dependent on whether PDE2 or PDE3 isozymes 
are present. This 'cross-talk' is likely to be particularly important in cellular contexts 
where cGMP levels are regulated, as is the case, for example, in the regulation of 
vasodilation (48).
1.6.2.2. The anti-lipolytic effect of insulin is mediated by stimulation of PDE3B
One of the physiological effects of insulin is antagonism of catecholamine 
induced release of free fatty acids (lipolysis). Early investigations by Beebe et al (60) 
studied lipolysis stimulated with thirteen cAMP analogues. Lipolysis stimulated by 
cAMP analogues which could be hydrolysed by adipocyte PDE could be antagonized 
by insulin. In contrast, lipolysis stimulated by analogues that PDE3B cannot 
hydrolyse was insensitive to insulin treatment. These results suggest that PDE3B 
mediates the anti-lipolytic signal of insulin and militate strongly against the other 
possibility that insulin might directly influence components of the signalling pathway 
downstream of cAMP/PKA. Subsequent experiments with specific PDE3 inhibitors 
such as cilostamide or OPC-3911 showed that they block insulin mediated anti- 
lipolysis, whilst PDE4 inhibitors are unable to mimic the inhibition (61,62). Thus it 
appears that PDE3 mediates the anti-lipolytic effect of insulin. The inactivation of PKA 
that ensues results in dephosphorylation and reduced activity of hormone sensitive 
lipase and lowered rates of lipolysis (63,64). An added level of complexity is that 
PKA itself is capable of stimulating PDE3B. A sustained PKA mediated PDE
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stimulation was observed within -2  minutes. Insulin mediated stimulation of PDE3 
was also detected for a sustained time period but was maximal only after 15 minutes. 
Furthermore, stimulation with insulin and PKA synergistically activated PDE3, before 
rapidly tailing off, presumably due to hydrolysis of cAMP. It has been proposed that 
PKA stimulation of PDE3B acts as a short-term feedback loop for catecholamine 
stimulated lipolysis, whereas insulin can have more sustained effects on the levels of 
lipolysis in adipocytes (58,64).
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►5'AMPATP cAMP
PKA
I
HSL ►- HSL-P
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Figure 1.6.2.2. Mechanisms for the anti-lipolytic effect of insulin
Insulin antagonises catecholamine induced lipolysis by stimulating PDE3B, apparently 
by a PI 3-Kinase mediated signal (see section 1.6.2.2). The effect on PDE3B is 
phosphorylation of serine 302. Intriguingly, upregulation of PKA stimulates PDE3B 
on the same site, as part of a putative negative feedback loop. The effects of insulin 
and catecholamine regulation of lipolysis are ultimately mediated through PKA 
regulation of the level of phosphorylation of honnone sensitive lipase.
KEY:
PDE3IK= PDE3 insulin stimulated kinase 
HSL= hormone sensitive lipase
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1.6.2.3. The attenuation of insulin secretion by insulin-like growth factor 1 (IGF-1) is 
mediated by stimulation of PDE3B.
It has been shown that in both isolated pancreatic islets and an insulin- 
secreting cell-line, insulin secretion stimulated by glucose is reversed by IGF-1, 
apparently through a mechanism that reduces the concentration of cAMP (50). 
Expeiiments with selectively hydrolyzable cAMP analogues have implicated PDE3B in 
this attenuation of insulin secretion (50), much like the initial experiments on 
mediation of anti-lipolysis (60). Thus, insulin secretion induced by treatment with 
cAMP analogues can only be attenuated by IGF-1 if the analogues can be hydrolysed 
by PDE3B. These results suggest a direct role for PDE3B in the IGF-1 pathway rather 
than the possibility that IGF-1 might directly influence signalling components 
downstream of cAMP. Again similar to the experiments on anti-lipolysis, use of 
specific PDE3 inhibitors to block the IGF-1 signal confinned the role of PDE3 in this 
pathway. The PDE3 involved was identified by confocal imaging which showed 
specific expression of PDE3B in the (3 cells of pancreatic islets of Langerhans. 
Furthermore, it was found that PDE3B activity was higher in immunoprecipitates 
following treatment with IGF-1. Thus, it seems that two aspects of insulin 
physiology, the regulation of insulin secretion and the regulation of lipolysis, are both 
controlled by modulation of cAMP concentrations by PDE3B. It remains to be seen 
how much of the rest of the two signalling pathways is conserved.
1.7 PDE4/</w«ce cAMP SPEC IFIC  PDE GENE FAM ILY
The mammalian PDE4 gene family is highly homologous to the drosophila 
dunce locus which is involved in learning and short term memory processes as 
described below. Indeed, the first isolation of mammalian PDE4 cDNA was due to its 
homology with a drosophila dunce probe (65). Interestingly, PDE4 enzymes are 
potently inhibited by rolipram, a compound which exerts anti-depressant effects in 
man. The pharmacology of this compound and other PDE4 specific inhibitors 
indicates that PDE4 selective inhibitors may be of therapeutic use in a number of 
human disease states (reviewed in (19)). Moreover certain of these compounds are
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able to distinguish between different conformations of PDE4 and it is emerging that 
these conformations, which can be selectively inhibited, are associated with different 
signals (see section 1.8).
Studies on rat (65-67), human (68) and mouse (69) models indicate that cAMP- 
specific PDEs, which are homologous to the dunce PDE are encoded by 4 genes in 
mammals, namely PDE4A-D. Individual PDE4 genes are evolutionarily conserved so 
that a human PDE4 gene is more closely related to its rat homologue than to the other 
human PDE4 genes (68).
The human PDE4 genes are found on three human chromosomes (one gene on 
each of chromosome 1 and 5 and two on chromosome 19). The murine PDE4s are 
located in the conesponding chromosomal regions of the mouse genome (69-72).
cDNA clones from each of the PDE4 genes have been isolated from both human 
and rat (65-68,70,71,73-91). Results for these studies indicate that each of the four 
PDE genes encode a multiplicity of transcripts. The most complete example of each 
transcript is listed in table 1.7. Figures 1.7.a and 1.7.b show these transcripts as 
alternatively spliced variants of the PDE4A-D gene loci. As can be seen, such 
transcripts have a structure consistent with their being generated by alternative mRNA 
splicing and, possibly, the use of alternative transcriptional start sites, with two splice 
junctions conserved from the dunce gene (92,93). Each of these splice variant 
transcripts are, presumably, under the regulation of a separate promoter. The almost 
universal use of the splice junctions conserved with the dunce PDE gene allows an 
informal distinction to be drawn between 'long' forms, which diverge at the first 
splice junction (splice site consensus: (F/L)(D/E)(L/A/V)(D/E)NG; junction 1 in 
figures 1.7a and 1.7b) and 'short' forms, which diverge at the second, more 3' splice 
junction (splice site consensus: E(D/E)(T/S/A)(G/C/Y)(L/Q)(K/Q)LA; junction 2 in 
figures 1.7a and 1.7b) (81). Nonetheless, there is little conservation between dunce 
and mammalian splice variant sequence. In contrast many of the individual splice 
variants are conserved between humans and rats (Table 2). For example, each of the 
three rat PDE4D transcripts are also present in human (87). For both humans and rats, 
there are some mRNAs for which no known counteipart has, to date, been identified
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in the other species. Given the conservation of splice variants between mammals it is 
probable that these mRNAs exist but have yet to be isolated.
Analysis of PDE4 splice variants, and the proteins that they encode, 
demonstrates that different transcripts from a single human or rat gene encode proteins 
with different expression patterns, biochemical properties, regulation, and intracellular 
localisation (see below). This complexity may yet allow highly selective therapeutic 
inhibitors to be designed to individual variants.
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Figure 1.7.a Alternative splicing of human gene loci PDE4A-D
Transcripts of each human PDE4 gene are presented as splice variants of their 
gene locus, compared with dunce. Positions of U CRl, UCR2 and the catalytic 
domain are shown, with aiTOws showing the positions of the 'long' (1) and 'short' (2) 
splice junctions conserved from drosophila. The longest example of each transcript is 
presented in each case. Each letter refers to the transcript's entry in table 1.7. The 
numbers above each splice variant represent the number of unique 5' sequence in the 
transcript in amino acids. Note that some transcripts do not encode any unique amino 
acid sequence.
Chapter 1: Introduction 34
S L
G65i
D 101 f
F21 f  
H3 0  T
A 21
PDE4A
L79 t
K38
PDE4B
PDE4C
T 15 1
R 44 PDE4D
UCRl UCR2 Catalytic
t, t
Figure 1.7.b Alternative splicing of rat gene loci PDE4A-D
Transcripts of each rat PDE4 gene are presented as splice variants of their 
gene locus, compared with dunce. Positions of U CRl, UCR2 and the catalytic 
domain are shown, with aiTows showing the positions of the long' (1) and 'short' (2) 
splice junctions conserved from drosophila. The longest example of each transcript is 
presented in each case. Each letter refers to the transcript's entry in table 1.7. The 
numbers above each splice variant represent the number of unique 5' sequence in the 
transcript in amino acids. Note that some transcripts do not encode any unique amino 
acid sequence.
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Boundaries of conserved sequences (numbers refer to HSPDE4A4)
position % amino acid identityA/C UCR 30-50 87UCRl 141-200 73UCR2 224-302 70Catalytic 332-688 74
Figure 1.7.c. Alignment of PDE4A-D
PDE4 isoforms HSPDE4A4, HSPDE4B1, HSPDE4C1 and HSPDE4D3 were aligned 
on the GCG PILEUP multiple alignment software, using the default settings. 
HSPDE4A4 and HSPDE4C1 were chosen to present their conserved splice variant 
specific sequence. The other two cDNAs are arbitrarily chosen 'long' forms for the 
PDE4B and PDE4D genes. A/C UCR, UCRl and UCR2 are labelled and underlined. 
The box provides information on the conservation of these sequence modules, with 
numbering for HSPDE4A4.
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1.7.1. Genomic organisation of PDE4/dunce
The existence of alternatively spliced transcripts from PDE4/dunce genes
thesuggests that[genomic structure of these genes will be complex (Figure 1.7 a,b). This 
is most conspicuously so in drosophila where the exons are dispersed in > 135Kb of 
genomic sequence and where there are more than three genes contained within dunce 
introns (92). In terms of mammalian genes, partial genomic sequences for the rat 
PDE4B (94) and PDE4D genes (94,95) define in genomic sequence the extent of the 
'short' forms in the gene and some promoter sequence. More recently a study has 
mapped the organisation of genomic sequences for 'long' forms for PDE4A (82). 
Nevertheless virtually all PDE4 promoter sequence remain uncharacterised. Isolation 
of such 5' regulatory regions of the PDE4 genes will allow analysis of the 
transcriptional regulation of these genes. Pertinent to this thesis, a final important point 
is that without exception all splice variant specific coding sequence is found together in 
the genomic sequence, virtually always on a single exon.
1.7.2. Primary structure of the PDE4/dunce enzymes
Analysis of the primary amino acid structure of dunce and PDE4 isoforms, 
deduced from the nucleotide sequences of their respective cDNAs, has revealed 
several highly conserved domains (19,68,96,97). The core catalytic unit is similar to 
all other PDE enzyme classes (97). Houslay et al attempted to map the ends of the 
PDE4 catalytic domain by compiling a list of all known PDE4 truncation mutants and 
attempting to identify the minimum requisite sequence for catalytic activity (19). The 
mammalian PDE4 putative catalytic domain is well conserved at its extreme N- 
terminal, starting at methionine 332 (MSQIT.... numbering for HSPDE4A4). 
However, PDE4 sequence immediately downstream of this domain is not well 
conserved. Furthermore, the MSQIT... motif is not essential for catalytic activity 
because some truncation mutants retain activity without it (19). Thus it is possible that 
the true PDE4 catalytic domain starts further downstream. In chapter 5 of this thesis I 
present some more experimental data which supports these findings.
There are two other highly conserved domains which are found further
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towards the N-tenninal of the catalytic region. These have been designated UCRl and 
UCR2 (for Upstream Conserved Regions 1 and 2) (Figure 1.7a~c) (68). A third 
domain (A/C UCR in figure 1.7.c) is conserved only between PDE4A and PDE4C, 
found upstream of UCRl. UCR 1-2 and the catalytic sequence are strongly conserved 
among the mammalian PDE4 isofoitns, showing greater than 70% sequence identity. 
UCRl is a region of -55 residues, the first half of which is polar and the second half 
hydrophobic. UCR2 is a hydrophilic region of -76 residues. The functions of UCRl 
and UCR2 are not fully understood. It has been reported that they can bind to each 
other and suggested that this might be under dynamic regulation by phosphorylation 
(19). Together with the observations that PDE4 N-tennini appear to alter tlie activity of 
the PDE, it has been proposed that changes in UCR1/UCR2 conformation might in 
turn alter the conformation of the catalytic domain either by direct interaction or by 
transmission of the conformational change through LR2 (see below)(19). Consistent 
witli there being modular roles for UCRl and UCR2 the second splice junction occurs 
between UCRl and 2 and thus 'long' forms contain both UCRl and UCR2 whereas 
'short' forms delete the entire UCRl region.
UCRl is separated from UCR2 by LRl (Linker Region 1) which consists of 
-33 residues which show no homology between isoforms. UCR2 is in turn separated 
from the start of the catalytic domain by LR2 (Linker Region 2) whose length varies 
according to the PDE4 gene (9-34 amino acids). LR2 contains some regions of 
sequence, such as a proline rich region in PDE4A which are not conserved between 
the PDE4 genes. If LR2 does serve to transmit conformational changes in 
UCR1/UCR2 to the catalytic domain it is clear that gene specific regulations may be 
located in these sequences (19). In chapter 5 of this thesis it is shown that the N- 
terminal of LR2 is highly conserved in a subset of PDE4 isoforms. The significance of 
this is then discussed.
As well as conserved regions, various PDE4/dunce isoforms have unique 
regions of sequence found at their extreme N-term ini, generated by alternative 
RNA splicing. These alter the function of specific isoforms as described below (98).
In contrast, the C-tenninal of PDE4 is conseiwed in all functional forms generated by a
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particular PDE4 gene and this has enabled gene-specific antisera to be raised that are 
able to detect all full-length splice variants of a gene (99-102). When analysed by 
immunoblotting, virtually all PDE4 forms migrate more slowly than would be 
expected for their calculated molecular weight on the basis of their primary structure.
The reason for this aberrant migration remains obscure but as with PDE3 may be due 
to positively charged runs of amino acid residues towards the C-terminal of the 
catalytic domain.
1.7.3. Drosophila dun ce
The dunce mutation of drosophila n ielanogaster was the first gene isolated that 
specifically affected behaviour (103). At least three protein products are coded for by 
at least six alternatively spliced RNA transcripts. Flies with mutations in dunce have a 
complex phenotype which can include female sterility and deficits in learning and 
short-term memory (104). Biochemical analysis of brain extracts from dunce flies and 
subsequent studies on the dunce cDNA demonstrated that the dujtce mutation effects 
the activity of a cAMP phosphodiesterase activity with properties similar to that of 
cyclic AMP specific mammalian PDFs (105-107), which is now unsurprising given 
their sequence conservation. Indeed defects in learning and memory in dunce flies are 
rescued by the overexpression of a mammalian PDE4 cDNA in drosophila (108). 
Nevertheless the dunce PDE is not inhibited by two mammalian PDE4 inhibitors, 
rolipram or Ro-20-1724. The structural reason for this remains obscure.
Analysis of dunce mutants has provided clues to the possible functions of the 
mammalian PDE4s (107). The ease and speed of genetic manipulation of drosophila 
(such as gene-knockout, mutational interactions) and behavioural analyses makes it an 
attractive system for genetic studies. Such techniques have been used to study 
participants in developmental pathways that modify tlie dunce phenotype of abnormal 
synaptic plasticity (107,109). As well as expected interactions with drosphila adenylyl 
cyclase (rutabaga) and PKA (D C O ) mutations, unanticipated interactions such as that 
with the poorly characterised sto n ed  cistronic locus are more intriguing (109). Splice 
variant specific exon knock-outs have allowed the individual contributions of each
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splice variant to the short-tenn memory/learning /female sterility dunce phenotype to 
be dissected, the first demonstration of different physiological roles for different PDE 
splice variants (93). This is a promising precedent for studies on mammalian PDE4 
splice variant sequences that seek to implicate these regions in spatio-temporal 
partitioning of the cAMP signal. Regrettably this system can tell us little about the 
roles of mammalian splice variants because little splice variant sequence is conserved 
between mammals and drosphila. Similar analyses in mouse will be a considerable 
undertaking.
1.7.4. A survey of the splicing complexity and distribution of PDE4A 
transcripts.
Before the work in this thesis there has been only one PDE4A splice variant 
for which both the human and rat homologues have been identified. This is the 'long' 
fonn HPDE46 (HSPDE4A4) and its rat homologue RPDE6 (RNPDE4A5). However 
this statement is unlikely to reflect the true complexity of splicing of this gene. There is 
evidence for two further rat and two further human splice variants, none of which are 
homologous to each other. RD1 (RNPDE4A1 ) (65,76) and RPDE39 (RNPDE4A8)
(77) encode, respectively, a 'short' form and a 'long' form of PDE4A. TM3 
(HSPDE4A5) (68) cDNA apparently codes for a 'long' form of PDE4A though the 
sequence has two mismatches, three frameshifts and two larger insertions when 
compared to other PDE4A sequences. The existence of the unique 5' TM3 exon in 
PDE4A genomic sequence is nevertheless highly persuasive that a cDNA closely 
resembling TM3 may be transcribed (82). 2EL (HSPDE4A8A) (70,71) is a non 
catalytic 'short' form of PDE4A. The PDE4A 'short' forms RDI and 2EL both have 
unique splice sites away from that used by other 'short' PDE45-Two other splice 
variants that have been reported in the rat, RD2 (RNPDE4A2) and RD3 (RNPDE4A3) 
are reportedly cloning artefacts (68,76). The unique N-terminal of RD2 is spliced into 
the middle of an exon at a site which does not contain a consensus splice site (82). 
Neither of these splice variants' expression has ever been detected.
In chapters 5 and 6 of this thesis evidence is presented which adds two new
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members to the list of PDE4A splice variants for which human and rat homologues 
have been identified
1.7.4.1. RDI RNPDE4A1: a membrane targetted, selectively expressed 
phosphodiesterase.
This was the first mammalian dunce homologue to be cloned (66). Its expression 
is restricted to several regions of tlie brain (66,76,102). It has a 21 amino acid 5' exon 
spliced at a unique splice junction into the middle of UCR2. The first definitive 
evidence that alternative splicing can alter PDE enzyme properties (110,111) came 
from work on this splice variant. Whilst the genetic analyses of dunce splice variants 
are certainly consistent with alternative splicing leading to proteins with different 
properties, these results could still notionally be due simply to different promoters 
causing altered expression than to altered properties of the proteins themselves.
The initial studies with RDI showed that transient expression of this isoform in 
COSl cells led to the vast majority of novel PDE4 activity being found in the (high 
speed) particulate fraction, whereas transient expression of a recombinant PDE4A 
truncated form met^'^RDl, resulted in a cytosolic location (110). Subsequent 
immunological detection demonsti’ated (112) that RDI was exclusively associated with 
the membrane fraction, because the cytosolic PDE4 activity found following RDI 
transfection was met^ ’^RD 1, apparently expressed following aberrant initiation due to a 
sub-optimal Kozak sequence and the use of a strong promoter. Since met^^RD 1 is 
identical to RDI, apart from the unique RDI N-terminal sequence, this N-terminal 
region was clearly implicated in determining membrane targeting of this splice variant.
Such a notion was confirmed by conferring membrane targeting identical to RDI on 
the soluble bacterial protein chloramphenicol acetyl transferase (CAT) simply by 
fusing this CAT to the N-terminal 25 amino acids of RDI (111). Other segments of 
RDI were unable to mimic this. As these experiments were carried out using an in 
v itro  transcription/translation method, it is highly unlikely that RDI membrane 
association is due to direct insertion since this is a co-translational phenomenon. 
Furthermore, in studies done on intact cells, then no evidence of lipid acylation of
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RDI was found, excluding such a means for membrane association (102). Deletion 
mutagenesis has also been done to segments of unique N-terminal RDI structure. 
Deletion of the first 13 amino acids still allowed membrane association In contrast, 
deletion of the hydrophobic motif PWLVGWW obliterates membrane association, 
clearly implicating this sequence as having a key role in membrane association 
(113,114). Structural studies are consistent with the downstream DQFKR supporting 
this role (discussed below) (114).
The iR-NMR derived structure of the unique N-teiminal region of RDI has now 
been deduced (114). It forms two independently folding helical regions separated by a 
mobile 'hinge' region, Cys^^-Pro '^^. An amphipathic a-helical region extends from 
Leu^-Cys^i, with non-polar residues L eu \ Ala^, Phe^ and Phe^ found along one side 
of the helix. The second helical region, extending from Pro^ '* Lys^\ has a distorted 
backbone due to the large hydrophobic residues in the motif (PWLVGWWDQFK).
This iiTcgular helix allows the rings of Pro^" and Trp^  ^to stack and thus the three large 
tryptophan rings in this domain spread out more evenly over the helical cylinder than 
might be expected normally, allowing Leu^^ to form interactions with the side chains 
of all three tryptophans. The same interactions force VaP^ out into the solvent at the 
opposite face, making this region a possible site for specific interactions with 
conformational freedom around both VaP"  ^ and Gly^ **. The helix is apparently 
stabilised by an ion-pair between Asp^  ^and Lys^ ' .^ Nevertheless it is not clear how this 
domain might allow association with biological membranes and this has led to a search 
for RD-1 binding which might contain direct membrane binding domains (19). The 
nature of this species has yet to be determined. However, the ubiquitous membrane- 
association of native RDI (102) and ectopically expressed RDI in COS-1 cells (110),
FTC 133 cells (115) or FTC 236 cells (115) suggests that the anchor protein, or related 
proteins are ubiquitously expressed.
The notion that interaction of RDI with its anchor protein may be mediated via 
hydrophobic interactions involving the tryptophan rich Pro '^^-Trp^o motif is also 
consistent with solubilisation studies. These show that though RDI is resistant to 
solubilisation by repeated washing or high ionic strength, it is readily susceptible to
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release by very low concentrations of the non-ionic detergent Triton X-100. These 
concentrations are much lower than are needed to solubilise integral membrane 
proteins from lipid bilayers. In contrast, hydrophobic protein-protein interactions 
between RDI and its putative anchor protein might easily be disturbed by such 
ti'eatment.
Such a model of interaction predicts that evolutionary conservation of RDI N- 
terminal sequence will be very high since sequence requirements for membrane 
insertion are far less stringent than for molecular recognition. That is, to be consistent 
with the proposed membrane association model of RDI, putative homologues of RDI 
would be expected to be highly conserved in their membrane-associating N-termini. In 
chapter 5 of this thesis the evolutionary conservation of the putative membrane 
association domain of RDI is directly analysed.
1.7.4.2. HPDE46/RPDE6
The conserved 'long' PDE isofonn RPDE6 and its human homologue HPDE46 
have a unique N-terminal splice region of -110 residues. RPDE6 expression is located 
in many regions of the brain, including hippocampus, striatum, cortex and 
hypothalam us (112). Both native RPDE6 and transfected recom binant 
RPDE6/HPDE46 are found in soluble, low speed particulate and high speed 
particulate fractions of the cell (100,112). The particulate fractions are unsusceptible to 
solubilization with detergent or high ionic strength, implying a strong interaction with 
cytoskeletal components (100,112). This distribution is very different from that of 
RDI (110,112) (see section 1.7.4.1), which is consistent with these differences being 
due to the divergent N-termini. HPDE46 localisation has also been visualised by 
confocal microscopy and this confirmed the earlier findings in that both cytosolic and 
particulate HPDE46 were identified (100). Both PDE46 and RPDE6 immunoreactivity 
in transfected COS cells was concentrated in foci on the margins of the cells which are 
enriched in specialised cytoskeletal structures. As well as this there is a more diffuse 
cytosolic localisation. As is the case with RDI the determinants of the intracellular 
targeting are harboured in the N-terminal splice regions. Thus, the 'core' rat and
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human PDE4A species meF^RDl and h6.1 respectively are exclusively cytosolic witii 
a unifonn, diffuse distribution (100,102)
The mechanism(s) by which HPDE46 and RPDE6 interacts with particulate 
fractions of the cell has not been fully characterised. Proteins are often recruited to 
intiacellular surfaces by specific molecular recognition mediated by compact globular 
protein modules such as PH (pleckstrin homology), PTB (phospho-tyrosine binding),
SH2 (src homology 2) and SH3 (src homology 3) domains which are integrated into 
many signalling proteins. An example of this is the Grb2-SOS interaction in the MAP 
kinase cascade and in PI 3-kinase subunit heterodimerisation. SH3 domains are 
unique amongst these motifs in that their recognition is exclusively based on primary 
protein sequence (rather than phosphorylation state of proteins or lipids for the other 
domains). SH3 domains interact with other proteins containing proline-rich motifs 
with a minimal PXXP motif which forms into a distorted 3io helix. Arginines are also 
often found in these motifs. RPDE6 and PDE46 contain several arginine/PXXP motifs 
within the N-terminal splice region and LR2. RPDE6 has now been shown to interact 
with certain SH3 domains fused to GST (116), with a specificity indicated for SH3 
domains from cytoskeletal proteins such as fodrin and cortactin and also with SH3 
domains from tyrosyl kinases such as fyn, lyn and src. The physiological effects of 
these interactions is not known but it is clear that they could regulate not only the 
targeting of the PDE but also conformational changes discussed in section 1.8.1.1.
Other rat PDE4As including the 'core' species met^^RDl and the 'long' form 
RPDE39 do not interact with SH3 domains which suggests that these interactions are 
conferred by the N-terminus of RPDE6, not LR2. However, as discussed in chapter 
5, rodent LR2s are markedly different from other PDE4A LR2 sequences and these 
differences include the proline rich domain which might be used in other PDE4As and 
might dius explain observed differences in the properties of HPDE46 and RPDE6
1.7.4.3. RPDE39
RPDE39 is the second reported 'long' form from the rat (77). It has a unique 
N-terminal splice region of 21 residues. The subcellular distribution of native and
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recombinant RPDE39 is similar to that of RPDE6/HPDE46 in that it is located in all 
(S2, P2 and PI) fractions and is resistant to solubilisation with non-ionic detergent, 
again implying an interaction with cytoskeletal components. However, unlike the 
cellular' distribution of RPDE6, RPDE39 appears to be highly restricted, to date having 
been detected only in testis.
1.7.5. A survey of the splicing complexity and distribution of PDE4B 
transcripts.
To date, three PDE4B splice variants have been isolated which are expressed in 
human and rat. These are 1) the 'long' form TM72 (HSPDE4B1) (68) and a truncated 
clone DPD (RNPDE4B1) (66), 2) the 'short' form PDE32 (68) /HPB106 
(HSPDE4B2) (79) and rat PDE4 (67) and 3) the 'long' form HSPDE4B3 and 
rPDE74 (RNPDE4B3) (90). Little work has been done on the subcellular localisation 
of isoforms generated from the PDE4B gene. Immunological analyses done on rat 
brain extracts (101), using a PDE4B generic antisera, indicated the presence of both 
particulate and cytosolic forms. These implied that the PDE4B isoform^PDE-4,.
was exclusively membrane associated and DPD cytosolic. However, when 
the three human PDE4 splice variants were expressed in COS-7 cells they all showed 
similar distributions between the particulate (-20%) and cytosol fractions (19,90).
PDE4B transcripts have been detected in brain, liver, lung, kidney, heart and 
blood (117,118). PDE4B1/3 brain expression, as measured by immunoblotting, is 
most abundant in the hypothalamus, cortex, . cerebellum and brain stem,
whereas PDE4B2 is most abundant in cerebellum, hippocampus, striatum, cortex and 
hypothalamus (101).
1.7.6. A survey of the splicing complexity and distribution of PDE4C 
transcripts
PDE4C is the least characterised gene in the PDE4 family. Only one splice 
variant has been isolated with homologues in both human (HSPDE4C1 (85)) 
/HSPDE4C4 (91) and rat (RNPDE4C1) (76) to date, and it is possible that none of
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these reflect the full open reading frame of the native protein, since HSPDE4C4 and 
RNPDE4C1 are incomplete reading frames and HSPDE4C1 apparently contains 
artefacts of cloning (85,91). HSPDE4C2 is a 'long' form which does not encode any 
novel amino acid sequence and HSPDE4C3 encodes a 'long' form with a reading 
frame open at the 5' end. HSPDE4C5 resembles HSPDE4C4 with three insertions of 
sequence which are not found in other PDE4 sequences. In contrast HSPDE4C6 and 
catalytically inactive HSPDE4C7 omit sequences found in the other PDE4 sequences.
None of the proteins encoded by any of these PDE4C splice variants, nor 
even endogenous PDE4C have been detected by immunoblotting and thus it is not 
possible to size-match the endogenous and recombinant forms as has been done for 
splice variants of the other PDE4 genes. HSPDE4C4, HSPDE4C5 and HSPDE4C7 
have been detected as transcripts in RNA from a number of cell lines, in contrast 
HSPDE4C6 expression is restricted to testis (91). Generic PDE4C expression has 
been the subject of a number of studies. Such expression is detected in U-87 cells
(78), melanoma G361, fetal lung, skeletal muscle, testis (91), brain, liver, lung, 
kidney, heart (117,118)
1.7.7. A survey of the splicing complexity, expression and subcellular 
distribution of PDE4D transcripts.
To date, three PDE4D splice variants have been identified in both human and 
rat. These are 1) the 'short' form Dun 11 (HSPDE4D1) (86,87) and 
ratPDE3.1/RPDE13 (RNPDE4D1) (67,76) 2) the 'short' form PDE82 (HSPDE4D2) 
(86,87) and ratPDE3.2 (RNPDE4D2) (73), 3) the 'long' fonn PDE43 (HSPDE4D1) 
and ratPDE3.3 (RNPDE4D3). Two other clones have been isolated for the human 
PDE4D gene. These are PDE39 (HSPDE4D4) and PDE79 (HSPDE4D5). The PDE79 
reading frame is open at the 5' end.
1.7.7.1 Expression patterns and subcellular localisation of PDE4Ds
The 'short' fonns RNPDE4D1 and RNPDE4D2 are expressed in sertoli cells 
(67,88,89) but only RNPDB4D1 is found in heart tissue (94). RNPDE4D3 is found in
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the brain and FRTL-5 cell line (88,89,119). PDE4D4 was identified in rat brain 
cDNA(68). PDE4D forms are widely expressed in the brain (118).
Transient expression of all five human PDE4D isoforms has allowed their 
subcellular localisation to be examined (87). These studies demonstrated that PDE4D1 
and PDE4D2 are cytosolic isoforms (For PDE4D1 >93% of its activity being found in 
the high speed supernatant fraction). In contrast to these 'short' form HSPDE4D gene 
products, the three 'long' foims, HSPDE4D3-5 were all partially particulate, though 
the degree of this varied. The molecular basis of these differences is obscure but 
nevertheless this data does show that as with PDE4A spliceforms, the unique N- 
termini clearly can alter the localisation of the PDE. No study has yet examined 
subcellular localisation of native PDE4D
Studies examining the solubilisation of PDE4D have also been undertaken. 
PDE4D3 and PDE4D5 are sensitive to solubilisation with detergent whereas only 
PDE4D5 is sensitive to solubilisation with high ionic strength. All three of the long 
PDE4D forms were completely solubilised by both such treatments combined. Such 
data indicate differences in the mode of anchorage of these long PDE4D isofoims and 
further imply that alternative mRNA splicing of the PDE4D gene produces protein 
products capable of different intracellular targeting.
1.8 EVIDENCE FOR DISTINCT CONFORMEES OF PDE4: 
REGULATION OF PDE4 CATALYTIC ACTIVITY
PDE4 enzymes specifically hydrolyse cAMP with a for cAMP of between 1- 
5|iM. This value is rarely altered in an isoform. PDE4 activity however, has been 
shown to be stimulated by an increase in the Vmax following treatment with a number 
of extracellular stimuli including insulin (120) and TSH (88,119). The mediators 
which transduce these signals appear to include amongst others, kinases, phosphatidic 
acid and metal ions. It has been proposed that these regulate PDE4 by altering the 
conformation of the protein in some way (19). Initial evidence for the existence of 
PDE4 conformers arose from analysis of complex kinetics of cAMP hydrolysis in an 
uncharacterised PDE4 species in hepatocytes. This PDE exhibited a downwardly
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curving Lineweaver-Burke (double reciprocal) plot. Such plots are consistent with 
PDE4 enzymes existing in an equilibrium between two states which bind substrate to 
produce a single conformer but that this, following product dissociation, releases the 
enzyme in only one of the original conformations, thus disturbing the equilibrium.
This is the mnemonical mechanism (121) where one state of the enzyme is 
remembered following catalysis. If the rate constants for binding of substrate are 
different between the two forms then Lineweaver-Burke plots will be non-linear with 
either apparent negative or positive co-operativity. Conformers in a mnemonical 
mechanism may also have different affinities for rolipram, offering one possible 
explanation for the complex, apparently negatively co-operative kinetics seen in a 
number of PDE4 isoforms when expressed in certain cell backgrounds (see next 
section).
1.8.1. Inhibition of PDE4 by rolipram
Rolipram is a specific inhibitor of PDE4 isoforms. Though rolipram has anti- 
depressant properties, it is not used in clinical intervention. However, this compound 
remains of interest because it has been proposed that both its variety in its potency as 
an inhibitor against PDE4 and its binding affinity (19,122) may be due to the 
compound 'sensing' shifts in PDE4 conformation. Whatever the molecular basis of 
these differences (discussed below) a range of studies have shown that functional 
responses to rolipram conelate with either low or high binding affinity (122) and that 
therefore further understanding of these confoi*mational shifts will allow production of 
more specific inhibitors.
1.8.1.1. Rolipram as a sensor of conformational shifts
Binding studies on brain and some other (but by no means all) tissues have 
identified high affinity rolipram binding sites (with Ka values in the low nM range) 
(122-125). These bind rolipram far more avidly than is implied by PDE4 inhibition 
analyses (where the IC50 is typically O.l-lOpM) (68,77,78,122-129). Binding is also 
stereoselective, with the enantiomer R-(-)-rolipram around 20 fold more potent than S-
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(+)-rolipram (124). This also contrasts with rolipram inhibition of PDE activity where 
stereoselectivity varies (122,123,125)
The identity of the native high affinity rolipram binding site is not known. 
However, expression of a truncated PDE4A species in sa cch a ro m yces  ce rev is ia e  
confers high affinity rolipram binding on homogenates from these transfected cells, 
indicating that PDE4 may harbour these sites (130). Interestingly, this PDE 
simultaneously displayed complex kinetics which diverged from linear Lineweaver- 
Burke plots. Instead downwardly curving double reciprocal plots of activity versus 
cAMP concentration were described. Aberrant kinetics such as these can arise in 
various ways including partial competitive inhibition, apparent negative co-operativity 
and multiple enzyme components differing in inhibitor sensitivity (see below) 
(75,130). It has been suggested that these complex kinetics may account for the 
apparent anomaly between directly measured rolipram binding affinity and the affinity 
infened from analysis of inhibition kinetics (19). Similar kinetics have been identified 
when this construct is expressed in COS-1 cells (129) but, despite this, analysis of a 
similar N-terminally truncated PDE4A construct expressed in a second strain of 
saccharom yces cerevisiae, or in COS-7 cells, yields simple competitive inhibition by 
rolipram (126).
Fractionation of COS-7 cells overexpressing PDE46 (HSPDE4A4) yielded (100) 
two enzyme populations with similar for cAMP. Cytosolic PDE4 activity observed 
(100) simple competitive kinetics of rolipram inhibition whereas that in tlie particulate 
fraction gave complex kinetics of a similar type to that reported by Toiphy (75,130) 
and by Owens (129). A possible explanation for this is that PDE46 exists in two 
interconvertible states (122,130,131). In this case rolipram is a sensitive monitor of 
the different conformations of these two enzyme forms. The molecular basis of this 
remains unidentified but regardless of this, the finding that HPDE46 can exist in two 
kinetically distinguishable states indicates that there must be a means through which 
the conformation of this enzyme can be altered. Intriguingly, identical experiments 
(100) to those just described for HPDE46, done on the rat homologue RPDE6 
(RNPDE4A5), identified only one state with simple kinetics. This implies that
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sequence found only in HPDE46 may be necessary for multi-state switching. In 
chapter 5 of this thesis, analysis of novel PDE4A sequence identifies new candidates 
for this sequence in LR2 and the N-tenninal of the catalytic domain.
1.8.1.2. The different confoi*mations of PDE4 are associated with different signalling 
processes.
Rolipram and other specific inhibitors of PDE4 are powerful tools for 
establishing the cellular signals that PDE participates in and the pathologies associated 
with these signals (reviewed in (19)). The deduction that some of these inhibitors can 
sense confonnational changes has allowed examination of the relative importance of 
these two confonnations in a number of signalling processes that involve PDB4. Most 
of the CNS effects, which include emesis (132) and certain of the peripheral effects of 
rolipram, including bronchodilation correlate with PDE4 which has a high affinity for 
rolipram (122). However certain other peripheral effects conelate more closely with tlie 
PDE4 conformer which has a low affinity for rolipram. An example is suppression of 
TNFa generation. This protein is produced in a number of auto-immune disease states 
and its suppression can ameliorate symptoms. Souness et al showed that inhibition of 
PDE4 could suppress TN Fa generation and that the effective concentrations of PDE4 
inhibitors correlated more closely with low-affinity binding to PDE4 (133). The 
observed lack of rolipram stereoselectivity for TNFa suppression was also consistent 
with this notion. Similar results were obtained in suppression of a bacterial endotoxin 
induced release of the proliferative cytokine interleukin-2 (IL-2) in murine splenocytes. 
Thus, suppression correlated with rolipram inhibition of a low affinity PDE4 
conformer with little stereoselectivity between rolipram enantiomers (134). Clearly, 
inhibitors which are specific for the low affinity conformer might be able to dissociate 
therapeutic effects from the undesirable side effects (such as emesis) associated with 
the high affinity conformer in the CNS. Thus, identification of sequences which 
participate in conformational shifts of PDE4 could have long-term implications for 
design of new therapeutics.
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1.8.2. Regulation of PDE4 by vanadyl-glutathione treatment
Vanadyl-glutathione complexes (135,136) have been shown to activate an 
undefined PDE4 activity. This led, simultaneously, to a pronounced increase in the 
affinity for rolipram. In guinea-pig eosinophil membranes (123) vanadyl-glutathione 
treatment both increased the sensitivity of the PDE4 activity in this fraction to 
inhibition by rolipram and also generated high affinity rolipram binding sites. It has 
been speculated that tliiol group modification mimics the molecular switch postulated 
for HSPDE4A4 and PDE4D3 (see below) and that this conformational change results 
in the accumulation of a conformation of a PDE4 species which is sensed by its 
elevated affinity for rolipram.
1.8.3. Regulation of PDE4 activity by phosphorylation
Phosphorylation sites have been analysed on the PDE4D3 (19,88,89,137) 
isoform and the HSPDE4B2 isoform (138). However, for the latter there is no 
information on the effects that this phosphorylation may have on function. There are 
several other less well characterised examples of PDE activities being stimulated by 
phosphorylation (reviewed in (19))
1.8.3.1. Regulation of PDE4D3 by phosphorylation.
Thyroid hormone (TSH) treatment of FRTL-5 thyroid cells has been shown 
to cause a rapid and transient elevation of intracellular cAMP levels (88,89). The 
transience of this response is due, at least in part, to the very rapid increase in 
PDE4D3 activity which can be seen within 3 min of TSH application and which 
returns to basal levels after -15 min (88,89). It has been shown that native PDE4D3, 
and that overexpressed in Sf9 or MAIO cells ., can be phosphorylated by
occurs
protein kinase A (PKA) (88,89,119,137,139). This apparently^t serine 54 in the 
UCRl region of this isofonn within a sequence motif found in common with all other 
PDE4 long' forms (137). PKA-mediated phosphorylation of PDE4D3 brings about a 
2 fold increase in enzyme activity and a much reduced sensitivity to stimulation by 
magnesium. Interestingly, such PDE4D3 shows aberrant rolipram kinetics similar to
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those already described for PKA phosphorylated HSPDE4A4. The dose-response plot 
of rolipram inhibition implied the presence of two distinct populations of the enzyme 
exhibiting IC5 0  values of -lOpM and ~2pM for inhibition by rolipram. Treatment of 
recombinant PDE4D3 with PKA or challenge of the cells with agents which increase 
the concentration of cAMP appear only to be able to increase the activity of the high 
affinity component. This is a further indication that rolipram may be able to sense 
different PDE4 conformations. As with HSPDE4A4, the for cAMP was 
unaffected (137). Again, these data indicate that PDE4 species can exist in two 
conformationally distinct states which can be sensed by rolipram binding affinity but 
in this case, the high affinity state has an identified functional correlate in that it is 
activated by PKA. It is not yet known whether the other PDE4 'long' isoforms can be 
activated by PKA phosphorylation on the conserved serine nor whether this regulation 
will be hierarchical in the way that it seems to be for PDE4D3.
1.8.4. Regulation of PDE4 activity by pliosphatidic acid
Stimulation of lipid signalling pathways results in an elevation of the levels of 
plasma membrane phosphatidic acid (PA), for example following activation of 
inflammatory cells (59) This has been shown to cause the activation of thymocyte 
PDE4 activity (59). Subsequently a similar activation was seen in the PDE4 activity 
from U937 cells which could be activated -2-fold by phosphatidic acid (140). 
Recently it has been shown that PDE4D3 and PDE4A5 are stimulated about 2 fold by 
PA (141). The effect on PDE4D3 resembles that of serine 54 phosphorylation in a 
number of ways. First, both the activation and binding of PA seen only in the 'long' 
form PDE4D3, not PDE4D1 or PDE4D2 which do not share the region (141), 
consistent with this phenomenon targeting the N-terminal of the protein. Second, PA 
treatment reduces the EC50 for Mg^+ in the same way that phosphorylation does
enzym e’(137,141). Finally, the PA-mediated^activation of about 2-fold and the unchanged Km 
for cAMP are very similar to the profile observed following PDE4D3 
phosphorylation.
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1.9 cGMP SPECIFIC PDE5
Within the PDE gene superfamily cGMP specific PDE5 gene is most 
homologous to PDE6. Only one PDE5 gene has been isolated to date. PDE5 protein 
has a molecular weight o f -178 kDa, indicating, by comparison with the cDNA, that 
the protein is expressed as a homodimer (142-144). In common with PDE6 and the 
more distantly related cAMP specific PDE2, PDE5 possesses a cGMP binding domain 
beyond the catalytic domain. Binding of cGMP to this site induces a conformational 
change within the N-terminal which then enables serine-92 to become a target for 
phosphorylation by PKG (143,144). The functional significance of these cGMP 
induced changes has not been elucidated.
Zinc, which binds tightly to PDE5, is necessary for its catalytic activity (145). 
Two zinc binding motifs have been identified in the primary sequence of the PDE5 
catalytic domain. These sites are conserved in all mammalian PDEs.
The physiological roles of PDE5 are not well understood. The PDE5 selective 
inhibitor zaprinast, has been used to suggest a role for this PDE in modulating the 
effect of ANP on renal homeostasis. Thus, zaprinast treatment results in extensive loss 
of sodium and diuresis even under conditions of low blood volume and pressure 
(146,147). PDE5 inhibitors are also now used in the treatment of impotence (148).
1.10 PDE6 PHOTORECEPTOR cGMP SPECIFIC GENE FAMILY
■ 6 ana
PDE6 shows most homology with PDE5 (see figure 1.2).
The PDE6 enzyme complex is composed of catalytic (a , PDE6A; a i, PDE6C 
and P, PDE6B) and inhibitory gamma subunits. PDE6A and PDE6B are found in rod 
membranes where they form heterotetramers with two inhibitory gamma subunits. 
PDE6C is found in cone outer segments (12). It is not known what the stoichiometry 
of this enzyme complex is.
Relative to the other PDE families, the physiological role of PDE6 is well 
understood (see review (149)). In visual excitation, absorption of a photon by the 
receptor rhodopsin, leads to dissociation of the a-G  subunit of the photoreceptor
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coupled heterotrimeric G-protein transducin. The a-G  subunit then relieves the 
inhibition of the PDE6 gamma subunit to liberate active PDE6. The effect of PDE6 
stimulation is to rapidly and transiently decrease cGMP levels which results in closure 
of a cGMP gated sodium channel which in turn causes a hyperpolarisation signal to 
occur. All PDE6 fonns contain a high affinity noncatalytic binding site for cGMP. It is 
thought that the cGMP binding sites in PDE6 allow modulation of the duration of 
PDE6 activation by transducin (12).
1.11 PDE7 IBMX INSENSITIVE PDE
Virtually all PDEs are sensitive to the non-specific phosphodiesterase 
inhibitor, isobutylmethylxanthine (IBMX). However, IBMX-insensitive, cAMP- 
specific phosphodiesterase species have been identified in both hepatocyte and liver 
preparations (150). More recently cDNAs have been identified which encode PDEs 
which show just such an insensitivity to IBMX (151,152). These cDNAs most likely 
reflect splice variants of the one which has been identified as PDE7A. Of the 
other members of the PDE gene superfamily, the PDE7 gene is most closely related to 
the PDE4 genes (see figure 1.2). However, beyond their insensitivity to IBMX little is 
known about the PDE7 isoforms, which are widely expressed, with the highest 
expression being in skeletal muscle (151 ). The earlier report does suggest that PDE7 
may be insensitive to simulation by Mg^+ (150)
1.12 The polymerase chain reaction (PCR)
The polymerase chain reaction is a robust method for amplifying known or 
unknown sequence held between two known pieces of sequence from which template- 
specific amplification can be primed (X and Y in figure 1.13). This technique is used 
routinely in a variety of molecular biological protocols, which include analysis of RNA 
populations and design of recombinant constructs, which are both methods employed 
in this thesis.
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Figure 1.12 The polymerase chain reaction (PCR)
Repeated cycles of DNA polymerisation (lines with arrows) from opposed sense (X) and 
antisense (Y) primers results in a chain reaction amplification such that in only two cycles 
a single length of DNA is produced which accounts for half of tlie DNA molecules in the 
reaction mixture. After -30 cycles tliis DNA molecule is virtually the only amplification 
product and it is usually detectable following gel electrophoresis of the reaction products.
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1.12.1 Isolation of novel gene sequence by PCR: Rapid Amplification 
of cDNA ends (RACE)
Probing of cDNA libraries remains the major method for isolating new genes. 
However, cDNAs isolated from conventional dT primed libraries and even those 
primed with random hex amers are often incomplete. This promises to be a major 
bottleneck in projects that plan to sequence all human genes. As a result a number of 
PCR based methodologies have arisen to take over isolation of the remaining sequence 
following the initial cDNA library screen. Though standard RT-PCR is able readily to 
detect specific RNA transcripts in total RNA extracts, PCR based isolation of 
sequence beyond the known area of sequence is more problematic. Extra 3' sequence 
can be isolated by using a sequence specific sense primer with a poly dT primer which 
anneals to the poly A tracts commonly found at the 3' end of mature RNAs. This is 
not an option for isolation of extra 5' sequence and so this is even more challenging 
though the intrinsic topological problem remains identical: because of the uni­
directional processivity of DNA synthesis (5’ to 3’) there must be some known 
sequence either side of the unknown sequence before the PCR reaction can be used to 
isolate that unknown sequence. A large number of protocols have arisen, all 
attempting to tag some known sequence on to the 5' end of the unknown sequence 
(see below.) (153). Such an approach has been particularly attractive in tlie PDE4 field 
(78,90) because each gene is alternatively spliced at the 5' end of a fairly large gene.
Both these factors heighten the likelihood that only partial clones will be isolated from 
cDNA libraries as has repeatedly happened (66-68,74,75,79-81). In chapter 6 of this 
thesis I have attempted to use such RACE protocols to complete just such a truncated 
open reading frame.
TdT (terminal deoxynucleotide transferase) RACE and RLM (RNA-ligase 
mediated) RACE adopt an identical rationale of tagging the end of first strand cDNA 
and then amplifying the end of the cDNA by PCR with a tag-specific primer and a 
gene specific primer. The relative merits of these techniques are discussed in more 
detail in chapter 6. Other methods have arisen for PCR of double stranded DNA where 
the upstream sequence is unknown (154).
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Inverse PCR can also be used to PCR amplify upstream sequence (155,156). 
The same topological problem as above is here answered by circularising the DNA. 
This can be efficiently achieved by the action of T4 RNA ligase on single stranded 
DNA or the action of T4 DNA ligase on double stranded DNA. This DNA circle is 
then amplified by primers designed to process away from each other on the known 
piece of sequence into the unknown piece in both dhections.
In chapter 6 of this thesis I have tested a variety of PCR based methods for 
isolating upstream cDNA sequence. I then go on to test a new method that I devised 
for cloning upstream sequence. This novel method will be applicable to many other 
kinds of sequencing projects .
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2. MATERIALS AND METHODS: BIOCHEMICAL METHODS
Except where mentioned, biochemicals were obtained from Fisons and were 
of analytical grade.
2.1. STANDARD POLYACRYLAMIDE GEL ELECTROPHORESIS
2.1.1. Buffers
2.1.1.1. Resolving gel buffer (Buffer A):
2M Tris/HCl, pH 8.8
0.4% (w/v) SDS
2.1.1.2. Stacking gel buffer (Buffer B);
0.5M Tris/HCl, pH 6.8 
0.4% (w/v) SDS
2.1.1.3. Acrylamide mix:
30% (w/v)acrylamide N,N'methylenebisacrylamide 
29:1 (3.3% cross-linking, Bio-Rad)
2.1.1.4. Resolving gel (8%):
13.9ml distilled water
7.8ml Buffer A
8ml acrylamide mix (BioRad)
300pl 10% ammonium persulphate
18|il N,N,N',N'-tetramethylethylenediamine (TEMED) (Sigma)
2.1.1.5. Stacking gel:
6.8ml distilled water 
1.35ml Buffer B
1.7ml acrylamide mix (BioRad) 
lOOpl 10%) ammonium persulphate 
lOpl TEMED (Sigma)
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2.1.1.6 Laemmli buffer (2x):
2.5ml IM Tris/HCl, pH 6.8
5ml glycerol
8ml 10%(w/v) SDS
3.5ml distilled water
0.007% (w/v) bromophenol blue
1ml p-mercaptoethanol (added prior to use)
2.1.1.7. Electrode buffer:
192mM Glycine 
25mM Tris 
0. 15% (w/v) SDS
2.1.2. Preparation of Samples
Samples containing no more than 400pg of protein were added to an equal 
volume of 2x Laemmli buffer (157) and boiled for five minutes.
2.1.3. Protein Molecular Weight Markers
Prestained protein molecular weight markers (Bio-Rad) contain the following 
proteins: myosin H chain (200kDa); phosphorylase B (97.4kDa); BSA (68kDa); 
ovalbumin (43kDa); carbonic anhydrase (29kDa); B-lactaibumin (18.4kDa) and 
lysozyme (14.3kDa). The apparent molecular weights varied from batch to batch and 
the precise sizes of the proteins are indicated on figures.
2.1.4. Casting and Running of the Gel
Following assembly of the gel apparatus, the resolving gel was poured
When'
between the plates and 2ml of water was layered on top. t  the gel set, the water was 
removed, a comb inserted and the stacking gel poured. When the stacking gel set, the 
comb was removed and the gel placed in a tank containing electrode buffer. The
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samples were loaded into the wells and the gels were run at 60mA per gel until the 
bromophenol blue (in the loading buffer) reached the bottom of the gel.
2.2. POLYACRYLAMIDE GEL ELECTROPHORESIS FOR LOW 
MOLECULAR WEIGHT PROTEINS
2.2.1. Buffers
Component Separating gel Spacer gel Stacking gel
acrylamide solution 5ml 1.25 ml 1ml
(49.5%)
gel buffer 5ml 2ml 3.1ml
water 2.5ml 2.75ml 8.4ml
glycerol 80% 2.5ml
10% APS 75|LLl 30^ 11 lOOpl
TEMED (Sigma) 7.5pl 3pl lOpl
2.2.2. Protein Low Molecular Weight Markers
Pre-stained low molecular weight markers (Sigma) contained
differently coloured ovalbumin (yellow, 45kD), carbonic anhydrase (orange, 29kD), 
trypsin inhibitor (green, 20kD), a-Lactalbumin (purple, 14kD), aprotinin (blue, 
6.5kD)
2.2.3. Casting and Running of the Minigel
Following assembly of the gel apparatus (BIO-RAD), the separating gel was 
poured 4.2cm high and spacer gel was immediately poured on top 1cm high. Water 
was layered on top. When the gel set, the water was removed, a comb inserted and the 
stacking gel poured. When this set, the comb was removed and the gel placed in a tank 
containing electrode buffer. The samples (prepared using Laemmli's loading buffer 
(157)) were loaded into the wells and the gels were run at 100 volts per gel until the 
bromophenol blue reached the bottom of the gel.
Chaptcr2: M aterials and M ethods 63
2.3. WESTERN (IMMUNO) BLOTTING
2.3.1. Buffers
2.3.1.1. B lotting buffer:
192mM glycine
25mM Tris 20% (v/v) metlianol 80% (v/v) water
2.3.1.2. Tris buffered saline (TBS):
0.5M NaCl
20mM Tris/HCl, pH 7.4
2.3.2. Transfer to Nitrocellulose
The SDS polyacrylamide gel was placed in a cassette on top of a piece of 
nitrocellulose paper (Schleicher & Schuell), bound by two pieces of Whatman 3MM 
paper and two pieces of sponge. The cassette was assembled in a tray of blotting 
buffer, to exclude air bubbles. It was loaded into the transfer tank with the 
nitrocellulose side of the cassette towards the positive electrode. The tank was filled 
with blotting buffer and the proteins transferred for 2 hours at 1 A.
2.4 IMMUNO DETECTION USING ECL
The nitrocellulose was blocked using 5% dried skimmed milk (Marvel) in 
100ml of TBS for 2hrs with gentle shaking. It was then washed twice with TBS 
containing 0.1%; Nonidet P40 (NP40) (Calbiochem) for 5 minutes each. Next it was 
washed twice in TBS for 5 minutes each.
The primary antibody, namely that specific to the protein to be detected, was 
added in 10ml of TBS & 1% Marvel, sealed in a polythene bag and incubated at room 
temperature with vigorous shaking for 2hr.
After washing with TBS as described above, secondary antibody was added.
This antibody was horse radish peroxidase (HRP) conjugated, directed against the Ig 
first antibody added. Secondary antibody (SAPU) was added as 40|il in 100ml TBS
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plus 1% Marvel and incubated for 1 hour at room temperature with gentle shaking. 
The nitrocellulose was then washed four times with 100ml TBS for 5 minutes each
The membrane was incubated with ECL (Amersham) reagents as per 
manufacturers instructions. X-ray film (Fuji) was exposed to the nitrocellulose for 5 
seconds to 10 minutes depending on the intensity of the signal. The film was then 
developed using a Kodak X-omat.
2.5. TRANSFORMATION OF BACTERIA
2.5.1. Medium and buffers
2.5.1.1. LB-medium:
170mM NaCl
0.5% (w/v) Bacto-Yeast Extract 
1 % (w/v) Bacto-Tryptone pH 7.5
2.5.1.2. LB-Agar:
170mM NaCl
0.5% (w/v) Bacto-Yeast Extract 
1% (w/v) Bacto-Tryptone 
2%  (w/v) Agar
2.5.1.3. Transformation buffer 1: 
lOOmM RbCl
50mM MnC1.4H20
30mM Potassium acetate
lOmM CaCl2-2H20
15% (w/v) redistilled glycerol
pH 5.8, adjusted with 0.2M acetic acid.
Filter sterilise through a 0.22p filter.
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2.5.1.4.Tmnsfomnation buffer 2: 
lOmM RbCl
10mM3-(N-Moipholino)propane sulphonic acid (MOPS)
75mM CaCl2.2H20
15% (w/v) redistilled glycerol
pH 6.8, adjusted with 0.2M NaOH. Filter sterilise through a 0.22p filter.
2.5.2 Procedure: Preparation of Competent E. coli JM109
A 10ml culture of JM 109 E. coli in L-broth was inoculated from a glycerol 
stock and grown overnight at 37"C with constant shaking. The next day 3ml of this 
culture was used to seed a 500ml LB medium culture which was grown at 37°C in an 
orbital shaker (200rpm) until the optical density at 550nm was between 0.5 and 0.55.
The culture was divided equally between two sterile 250ml centrifuge bottles and 
cooled on ice for 30 minutes. They were then centrifuged at 2500rpm (950g) in a 
Beckman JA14 rotor for 15min and each pellet resuspended in 20ml of ice-cold 
transformation buffer 1. The cells were incubated on ice for a further 15min before 
centrifugation at 2500rpm for 10 minutes. The supernatant was removed and the cell 
pellets gently resuspended in 3.5ml of transformation buffer 2. The resuspended cells 
were pooled and incubated on ice for 15 minutes. The competent cells were snap- 
frozen in 250(il aliquots and stored at -80"C.
2.5.3. Transformation
An aliquot of frozen competent cells was thawed slowly on ice. For each 
transformation a 50pl aliquot of competent cells was transferred to a sterile 
microcentrifuge tube. To each 50pl, approximately lOOng of DNA was added and 
incubated on ice for 15mins. The cells were then 'heat shocked' for 60 seconds at 
42"C and incubated on ice for a further 1 minute. 1ml of L-broth was then added and 
the transformed cells incubated at 37"C for 30-60min with shaking. lOOpl of the 
culture was plated on a 10cm agar plate containing selection medium. Transformed 
colonies were picked and glycerol stocks made (section 2.5.4.)
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2.5.4 Glycerol stocks
Single colonies were used to seed a 10ml LB medium culture grown 
overnight at 37'C. To 750jil of the overnight culture, 250)il of 80% glycerol in L- 
broth was added and vortexed. Glycerol stock storage was at -80°C.
2.6. PHOSPHODIESTERASE ENZYME ASSAY
Phosphodiesterase activity was measured in a cAMP hydrolysis assay. This 
used a modification of the two step procedure of Thomson and Appleman (158) and 
Rutten et al (159), as described previously by Marchmont and Houslay (160). e n ­
cyclic nucleotide (8 position of the adenine or guanine ring) was hydrolysed to fomi 
labelled nucleotide mono-phosphate. The nucleotide mono-phosphate ring was 
converted to the corresponding labelled nucleoside by incubation with snake venom 
which has 5'-nucleotidase activity. The conditions were such that complete conversion 
takes place within the incubation time. Unhydrolysed cyclic nucleotide was separated 
from the nucleoside by batch binding of the mixture to Dowex-1 -chloride (Sigma).
This removes the charged nucleotides but not the uncharged nucleosides.
2.6.1. Buffers
2.6.1.1. Assay buffer: 
lOmM MgCl2
20mM Tris/HCl, pH 7.4
2.6.1.2 Dilution buffer
20mM Tris/HCl, pH7.4
2.6.2. Procedure
A 2x stock solution of cAMP was prepared by adding 30pl of ^H-cAMP 
(ImCi/ml, 41.7pM) to 10ml of 2pM cAMP in assay buffer. The assay volume was 
lOOpl consisting of 50pl 2x cAMP stock, 25pl for sample and 25fXl for effector, with 
sample and effector prepared in dilution buffer. All tubes were kept on ice prior to
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incubation at 30"C. The reaction was stopped after lOmin by boiling for 2min. The 
tubes were cooled on ice and 25pl of Img/ml snake venom (Sigma) was added and 
incubated for a further 10 min. After cooling, 400|il of Dowex (Sigma) resin was 
added and incubated on ice for 15 min. The Dowex was pelleted by centiifugation in a 
bench-top centrifuge for 3min and 150|il of the supernatant removed for scintillation 
counting in 2ml scintillation fluid.
2.6.3. Use of PDE assay to profile PDE families present in various 
tissues
To determine the contribution of various PDE families to the overall cyclic 
nucleotide phosphodiesterase content of a tissue the PDE assay reaction was 
supplemented with various specific inhibitors. These inhibitors exploit differences 
between PDE families whose regulatory properties and precise form of catalytic are 
often unique to a family (19).
2.6.3.1. PDE3 and PDE4
The PDE3 family is specifically inhibited by the drug cilostamide (161) and 
the PDE4 family by rolipram (162). PDE inhibitors were dissolved in 100% DM SO as 
lOmM stocks and diluted in PDE assay dilution buffer (see section 2.6.1.2) for use in 
assay. The residual levels of DMSO do not affect PDE activity at the concentrations 
used (163). Measurement of PDE activity with and without cilostamide (lOpM) and 
with and without rolipram (lOpM) present gave the contiibution of PDE3 and PDE4 
respectively.
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CELL CULTURE
2.7.1. Media
2.7.1.1. Foetal calf serum medium (FCSM)
The routine growth medium was Dulbecco's Modification of Eagle Medium 
(DMEM, Sigma D5671), This was supplemented with Penicillin/Streptomycin (100 
units/ml, Sigma), lOmM glutamine and 10% foetal calf serum (Sigma).
2.7.1.2. New born calf serum medium (NBCSM)
This medium was Dulbecco's Modification of Eagle Medium (DMEM, Sigma 
D5671), this was supplemented with Penicillin/Streptomycin (100 units/ml. Sigma), 
lOmM glutamine and 10%) new bom calf serum (Sigma).
2.7.1.3. Serum free medium (SFM)
For serum starvation of cells growth medium was replaced with serum free 
medium (SFM) consisting of Dulbecco's Modification of Eagle Medium (DMEM, 
Sigma D5671) supplemented with Penicillin/Streptomycin (100 units/ml. Sigma), 
lOmM glutamine (Sigma)
2.7.1.4. RPMI-1640 medium
RPMI medium consists of RPMI-1640 medium (Sigma 0883) supplemented with 
Penicillin/Streptomycin (100 units/ml, Sigma), lOmM glutamine and 10% foetal calf 
serum (Sigma).
2.8. COS-7 CELL LINE
COS-7 (ATCC Number: CRL-1651) cells are a fibroblast-like cell line 
derived from African green monkey kidney cells. These cells have been transformed 
by an origin defective mutant of SV40 which codes for wild type T-antigen. They are 
an excellent host for transfection with vectors requiring the expression of SV40 T- 
antigen. They permit replication of any plasmid containing an SV40 origin of 
replication, thus amplifying the expression of any genes encoded by the plasmid.
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2.8.1. Maintenance of COS-7 cells
Cells were grown in an atmosphere of 95% air and 5% CO2 at 37“C in 10ml 
DMEM +  10% FCSM (section 2.9.1.1.). When the cells reached about 90% 
confluency the cells were passaged 1:3 to fresh flasks and medium.
2.8.2. Passaging COS-7 cells
The cells were washed in 10ml of PBS (section 2.5.1.1.) pre-warmed to 
37“C and 3ml of trypsin were added. The cells were tlien returned to the incubator for 
2min or until they detached from the flask. Clumps were disrupted by pipetting the cell 
suspension up and down ten times in a 1ml pipette. This suspension was distributed 
evenly to three flasks each containing 9m 1 of FCSM
2.9. COS-7 CELL TRANSFECTION
2.9.1. Buffers
2.9.1.1. Transfection medium
Transfection medium was Dulbecco's Modification of Eagle Medium 
(DMEM, Sigma D5671). This was supplemented with Penicillin/Streptomycin (100 
units/ml. Sigma), lOmM glutamine, 10% new-born calf serum (Sigma) and lOOpM 
chloroquine. This was made fresh each time.
2.9.1.2. Tris EDTA buffer (TE):
ImM Ethylenediaminetetra-acetic acid (EDTA) 
lOmM Tris HCI, pH 7.5
2.9.2. Procedure
Cells were grown to about 50% confluency prior to transfection. lOpg of 
DNA was diluted to 250pl in TE and 200|il of DEAE Dextran (lOmg/ml in PBS, 
Sigma) were added. This was incubated for 15min at room temperature. COS-7 cell 
growth medium was aspirated from the cells and 5ml of transfection medium added.
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The DNA solution was added dropwise to the cells and mixed by swirling. The cells 
were returned to the incubator for 3-4h.
The cells were shocked by first aspirating tlie ti'ansfection medium and 5ml of 
10% DMSO in PBS were added for exactly 2 minutes. The DMSO was aspirated and 
the cells washed with 10ml of PBS. The cells were returned to normal growth 
medium, placed in the incubator for three days. Phosphodiesterase assays were then 
performed.
2.10 FRACTIONATION OF TRANSFECTED COS-7 CELLS: 
TRIETHANOLAMINE METHOD
2.10.1 Buffers
2.10.1.1 KHEM buffer 
50mM KCl
lOmM Ethyleneglycol“bis(P“aminoethylether)“N,N,N',N'“Tetra-acetic acid 
(EGTA)
50mM N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid (Hepes), 
pH 7.2
1.92mM MgCl2 
Added fresh:
ImM Dithiothreitol (DTT)
Protease inhibitors (These were added 1/1000 from a stock solution in 
DMSO. The final concentrations were 40pg/ml PMSF (Sigma), 156|ig/ml 
benzaraidine (Sigma), Ijig/ml each of aprotinin (Sigma), leupeptin (Peptide 
Research Foundation), pepstatin A (Sigma) and antipain (Sigma), added
fresh
Chapter2: M aterials and M ethods 7 1
2.10.1.2 TEA-KCl
lOmM Triethanolamine (TEA)
150mM KCl 
pH 7.2 with HCI
2.10.2 Procedure
Growth medium was removed from the cells and 2ml of KHEM added. The 
cells were incubated at 4“C for 45min with occasional swirling. The KHEM was 
removed and 5ml of TEA-KCl were added and incubated for lOmin at 4°C. The TEA- 
KCl was aspirated and the cells washed in 5ml KHEM. 1ml of KHEM was then 
added and the cells incubated for 2min at 4"C. The KHEM was aspirated, the cells 
scraped from the plate and homogenised with 20 strokes in a glass on glass dounce 
homogeniser. The homogenate was centrifuged at 650g for lOmin to pellet debris (PI 
fraction). P2 fractions were obtained by centrifugation at 75000rpm in a Beckman TL- 
100 ultracentrifuge. The supernatant was snap-frozen in liquid nitrogen in lOOpl 
aliquots and stored at -80“C.
2.11 FRACTIONATION OF TRANSFECTED COS CELLS WITHOUT 
TRIETHANOLAMINE
2.11.1 Homogenisation Buffer
20mM 50mM N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid 
(HEPES) pH7.5 
50mM NaCl
lOmM Ethyleneglycol-bis(P-aminoethylether)-N,N,N',N'-Tetra-acetic acid 
(EGTA)
Pro tease inhibitors (section 2.10.1.1) and ImM DTT added fresh 
When H89 (EC laboratories) was used (see chapter 3) it was incubated over 
the cells as discussed in the references within (63)
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2.11.2 Procedure
Growth medium was removed from the cells and the cells washed twice in 
homogenisation buffer. The buffer was aspirated (to leave -500|il of buffer on the 
plate) and the cells scraped from the plate and then homogenised with 20 strokes in a 
glass on glass dounce homogeniser. The homogenate was centrifuged at 650g for 
lOmin to pellet debris (PI fraction). P2 fractions were obtained by centrifugation at 
75000ipm in a Beckman TL-100 ultracentrifuge. These fractions were snap-frozen in 
liquid niti'ogen in lOOpl aliquots and stored at -80°C
2.12 OTHER CELL LINES
Information on these cell lines was routinely obtained from the American 
Type Culture Collection (ATCC) Catalogue of Cell Lines & Hybridomas (164).
2.12.1. CHO-Kl, stably transfected CHO cell lines
These cells are derived from Chinese hamster ovary (165). They are grown as 
a monolayer in Ham's F-12 medium supplemented with 10% Foetal calf serum 
(Sigma).
2.12.2. U-118 MG, U-87 MG and SK-N-SH cell lines
U-118 MG (ATCC Number: HTB-15) (166) and U-87 MG (ATCC Number: 
HTB-14) (166) cells are human glioblastoma cell lines. The SK-N-SH cell line is a 
human neuroblastoma. (ATCC Number: HTB-11) (167). Subculture is as shown for 
COS-7 cells (section 2.10) except that they were replated 1:5
2.12.3 U-937 cell line
U-937 cells are human monocyte-like cells derived from a lymphoma (ATCC 
Number: CRL-1593.2) (168). U937 cells are grown in suspension. Cultures were 
maintained by replacement of old medium with fresh medium. Cultures were 
maintained between 5 x 10  ^and 1 x !{/> cells/ml
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2.12.4. HeLa S3 cell line
HeLa S3 (ATCC Number: CCL-2.2) cells are derived from a human cervical 
carcinoma (169). Subculture is as for COS-7 (section 2.10) cells except that they are 
passaged 1:5
2.12.5. Jurkat J6 cell line
Jurkat J6 cells are human leukaemic T cells (170). They are grown as a 
suspension in continuous culture in FCSM
2.12.6. FTC133 and FTC236 cell lines
The human follicular thyroid carcinoma cell lines FTC133 and FTC236 (171) 
were cultured in RPMI growth medium
2.13 PROTEIN ASSAY
2.13.1. Bradford assay
A spectrophotometric standard curve of protein concentration was constmcted 
using 0-20|Lig bovine serum albumin (BSA, Sigma). These concentrations of protein 
were dissolved in SOOpl distilled water. To this, 200111 Bio-Rad reagent was added, 
the tubes were vortexed and the absorbance was read against a blank (as above but 
containing no protein), at a wavelength of 595nm. Protein concentrations of the 
samples were detenuined in a similar way, diluting 5|il of the sample in 800[il distilled 
water, adding Bio-Rad reagent and reading the absorbance in the spectrophotometer as 
before. All samples were assayed in duplicate. Protein concentrations were detenuined 
by plotting the standard curve and determining a line of best fit.
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GENERAL NUCLEIC ACID MANIPULATIONS
2.14. STERILISATIO N OF M ICRO -CENTRIFUG E TUBES, 
HOMOGENISERS, PIPETTE TIPS AND BUFFERS
All micro-centrifuge tubes tissue homogenisers, pipette tips and buffers used 
in nucleic acid manipulations were sterilised by autoclaving. Micro-centrifuge tubes 
and pipette tips were discarded after a single use.
2.15. CASTING AGAROSE MINIGELS
2.15.1. Buffer
2.15.1.1 Tris/Borate/EDTA (TBE) buffer lOX 
l.lM T ris  
0.9M boric acid 
24mM EDTA
2.15.1.2. Procedure: Casting a 2% gel
200 ml 0.5x TBE was prepared for each minigel. 17ml 2%  agarose in 0.5x 
TBE buffer was weighed in a small conical flask. This suspension was heated in 
microwave until the agarose dissolved. Once this occurred, the flask was reweighed 
and topped up with distilled water. The molten agar was poured into the gel apparatus 
and allowed to set. The rest of the TBE was then used to fill the tank. Samples were 
loaded after mixing with 6x loading dye (Promega). Ethidium Bromide (Sigma) was 
then added to final cone of 0.5 mg/1 (add 10 pi of 10 mg/ml stock, Sigma) and the gel 
was run at 75V
2% gels were typically run but occasionally different percentages were used 
when higher molecular weight samples were run:
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Range of Separation of linear DNA molecules according to agarose concentration. 
Percentage gel Size of fragment (kilobases)
0.9 0.5-7
1.2 0.4-6
1.5 0.2-3
2.0 0.1-2
2.16. EXTRACTION OF DNA FROM AGAROSE GELS WITH THE 
QIAEX II GEL EXTRACTION KIT
All DNA extracted from gels was purified using the QIAEX II DNA gel 
extraction kit according to the manufacturer's (Qiagen) instructions. Briefly, three 
volumes of 'QX-1' buffer and lOpl of QiaexII DNA binding beads were added to each 
gel plug. The plugs were dissolved by warming to 50"C during which time the beads 
were kept suspended by vortexing every 2min. After lOmin the beads were pelleted by 
a 20s centrifugation in a benchtop centrifuge. The supernatant was removed and the 
pellet washed in 500pl 'QX-1' buffer, resuspended, and then pelleted in the same 
manner as above. The pellet was then washed, resuspended and pelleted similarly in 
an ethanolic wash PE' buffer. The pellet was then allowed to dry for 10 min and then 
eluted in 20pl of water. This DNA was typically contaminated with ethanol and so 
was subsequently purified by ethanol precipitation.
2.17. RESTRICTION ENZYME DIGESTS
All restriction enzyme digestswere performed on pure plasmid DNA using 
restriction enzymes supplied by Promega or New England Biolabs. Incubation 
conditions were 37"C for a minimum of 1 hour using the appropriate buffer supplied 
by Promega. Following digestion DNA was run on an agarose gel and gel extracted 
using QiaexII gel extraction kit (Qiagen)
2.18. ETHANOL PRECIPITATION
To the volume of DNA to be ethanol precipitated, 0.1 volume 3M sodium
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acetate was added and 2 volumes of 100% ethanol. The vial was mixed and incubated 
at -80"C for 30 minutes. The precipitated suspension was centrifuged at 1 lOOOrpm in 
a Jouan (MR 1812) refrigerated centrifuge for lOmin to pellet the DNA. The 
supernatant was aspirated and 1ml of 70% ethanol added. The DNA was pelleted 
again by centrifugation at 1 lOOOrpm in the refrigerated centrifuge for 5min, the 
supernatant aspirated and the pellet allowed to air-diy for 5-10 minutes. The DNA was 
resuspended in TE buffer and the purity of the DNA checked by UV absorption at 
260nm and 280nm where A260/A280=1.8 for pure plasmid DNA.
2.19. PHENOL/ CHLOROFORM EXTRACTION OF DNA
The DNA solution had an equal volume of phenol:chloroform:isoamyl 
alcohol (25:24:1) added to it. It was then vortexed. The phases were separated by 
centrifugation for 15s at full speed in a benchtop microcentrifuge. The aqueous 
(upper) clear phase was transfened to a new microcentrifuge tube leaving behind the 
organic (lower) yellow phase and the interphase layer (with proteins). This phase 
separation was repeated until no protein was detectable at the interface
Next an equal volume of chloroform was added to the aqueous solution in a 
new microcentrifuge tube. This was vortexed into an emulsion. Phase separation was 
repeated by centrifugation in a benchtop centrifuge. The aqueous phase was the top 
layer again. This upper phase was transferred to a new microcentrifuge tube. 
Following phenol/ chlorofonn extraction the DNA was ethanol precipitated.
2.20. GENERATION OF PLASMID DNA
Plasmid DNA was prepared using maxiprep and miniprep kits (Promega). 
Cosmid DNA was isolated by similar means (Qiagen midiprep and maxiprep kits). A 
brief protocol for a Promega maxiprep kit is given below.
2.21.1 Promega maxi-prep
A culture was set up by stabbing a toothpick into frozen glycerol stocks and 
adding it to 400ml of ampicillin (50pg/ml, Sigma) LB medium. The culture was
Chapter2; M aterials and M ethods 77
incubated overnight at 37"C in a rotating incubator at 200ipm
2.21.2. Preparation of Cleared Lysate
The culture was then poured equally into 250ml Beckman centrifuge tubes 
and pelleted at 9500g for lOmin at room temperature in a JA-14 rotor. Each pellet was 
resuspended in 7.5ml 'Resuspension solution' using a heat-sealed 5ml pipette to 
manually disrupt the pellet. These suspensions were combined. To the combined 
15ml, 15ml 'Cell Lysis' solution was added and mixed by inversion. Lysis was 
allowed to complete (up to 20 min) and then 15ml of 'Neutralisation solution' was 
added and immediately mixed by inversion.
The suspension was centrifuged at 14,000g for 15min at room temperature.
The cleared supernatant was transfened to a new container
2.21.3. Plasmid DNA precipitation.
0.6 volumes of isopropanol was now added and mixed by inverting several 
times. The DNA was pelleted by centrifugation at 14,000g for 15 mins at room 
temperature. The supernatant was discarded and the DNA pellet resuspended in 2ml 
TE
2.21.4. Plasmid Purification
One Maxicolumn was inserted into a vacuum manifold. 10 ml of well-shaken 
pre-warmed 'DNA purification resin' was added to the DNA/TE solution and then this 
slurry was added to the maxicolumn. A vacuum was applied to draw the slurry 
through. The DNA/resin container was rinsed with 13ml of 'Column wash solution' 
and immediately added to the column under vacuum. A final wash of 12ml of 
'Column wash solution' was then added to the column. The resin was rinsed with 5ml 
of 80% isopropanol under vacuum.
The resin was dried by centrifuging the column in its 50ml conical tube in a 
bench-top clinical centrifuge at 2,500 rpm (1300 g) for 5min. It was then transfened 
to a new 50ml conical centrifuge tube. 1.5 ml pre-heated water (65-70"C) was applied
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to the tube. After 1 minute this water was centrifuged out of the column using the 
conditions above
DNA solution was stored-20"C
NUCLEIC ACID ISOLATION
2.22. ISOLATION OF RNA FROM TISSUE OR CELLS USING TRI­
REAGENT
Pre-weighed tissue was homogenised in Tri-Reagent (Sigma) (1ml per 50- 
100mg tissue) using a sterilised glass homogeniser (sample volume not to exceed 10% 
of vol of Tri-Reagent used). Alternatively one flask of a cell monolayer was scraped 
into 1ml of Tri-Reagent and resuspended with a pipette. Cells grown in suspension 
were lysed by addition to pelleted cells and resuspension with a pipette. The 
homogenate was stored at room temperature for 5 min. It was then transfeiTed, 1ml to 
each 1.5ml microcentrifuge tube. Cell membranes, polysaccharides and high 
molecular weight DNA were tlien pelleted out of the homogenate by centrifugation at 
11000 rpm for 10min at 4"C. The supernatant was transferred to another 
microcentrifuge tube. The RNA and DNA were now phase separated by addition of 
0.2ml RNAase-free chlorofonn per 1ml of Tri-Reagent. The solution was vortexed for 
15s then stored at room temp for 3min. Phase partition was brought about by 
centrifugation at 12 OOOg (11 000 rpm) for 15 min at 4"C. For DNA isolation the 
interphase and organic phase were taken (see 2.27). For RNA isolation the aqueous 
phase was transferred to a new microcentrifuge tube and the RNA precipitated by 
addition of isopropanol (propan-2-ol): 0.5ml per 1ml of T-R used initially. 
Precipitation was allowed to continue for 5-10 min at room temperature. RNA was 
then pelleted by centrifugation at 12 OOOg (11 000 rpm) for 10 min at 4“C. RNA 
forms a white pellet on the side and bottom of the tube. The supernatant was aspirated 
and the pellet washed in 1ml 75%; ethanol. In this state the RNA can be stored for up 
to a year at -20"C.
RNA was prepared for use by centrifugation at 7500g (9000 rpm) for 5min at 
4"C in a refrigerated Jouan (MR 1812) centrifuge. Most of the supernatant was
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aspirated and the RNA pellet dried under vacuum for 5-10 min (not to completion).
RNA was re-solubilised in di-ethyl pyrocarbonate (DEPC) treated water. Pellets which 
do not solubilise immediately were incubated at 55-60"C for 10 min. Typical yield 
was 6-10|ig RNA/mg liver
2.23. ISOLATION OF GENOMIC DNA FROM RAT LIVER USING 
TRI REAGENT
This used the interphase and organic phase of the Tri-reagent when it was 
partitioned by chloroform treatment (see previous section). The DNA in tliese fractions 
was then precipitated by addition of 300|al of ethanol per ml of Tri-reagent initially 
used. The samples were stored at room temperature for 3 min then the DNA 
sedimented by centrifugation at 4200rpm in a Jouan (MR1812) refrigerated centrifuge.
The supernatant was then removed and the DNA was washed twice in O.IM sodium 
citrate in 10% ethanol. 1ml was used per ml of Tri-reagent initially used. At each wash 
the DNA pellet was washed for 30min at room temperature with occasional mixing 
and then centrifuged as above. Following these two washes, the DNA pellet was 
suspended in 75% ethanol (1.5ml-2ml per 1ml of Tri-reagent used initially), stored at 
room temp for 20 min then centrifuged as above. Under ethanol the DNA could be
resuspended
S t o r e d  f o r  m o n t h s  at 4"C. DNA was dried f o r  5-10 m i n  i n  a vacuum t h e n  i n  8mMSi
sodium hydroxide by passing gently through a pipette. Insoluble material (cell 
membranes) was then removed by sedimentation at 1 lOOOrpm in a Jouan (MR1812) 
refrigerated centrifuge. DNA was quantitated by it absorbance at 260nm. Samples in 
8mM NaOH could be stored overnight.
2.24. SYNTHESIS OF FIRST-STRAND COMPLEMENTARY DNA 
(cDNA)
2.24.1. Procedure.
5 |ig of total RNA was made up to 20|il with DEPC H2O, heated to 65" C in 
a thermal cycler for lOmin then immediately chilled on ice
The "Bulk 1st strand cDNA mix" (Pharmacia) has its particulate matter gently
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suspended and then collected with a brief centrifugation. The cDNA synthesis reaction 
was prepared on ice and contains:
11 pi of "Bulk 1st strand cDNA mix"
1 pi of "DTT" solution
1 pi of a 1/25 dilution of "Notl-d(T)18" (0.2 pg/pl) primer 
20 pi heat-denatured RNA from 1st tube 
The cDNA synthesis reaction was incubated at 37° C for 1 hour
2.25. POLYMERASE CHAIN REACTION
2.25.1. PCR Reaction mix
50mM KCl (Supplied lOx in Tag polymerase buffer, Promega) 
lOmM Tris HCl (pH9) (Supplied lOx in Tag polymerase buffer)
200pM of each dNTP (Promega)
0.5pM of each primer (Genosys), (except for 1.5pM of OR 18 and GR19)
1.5mM MgCli (Promega)
3-5pl first strand cDNA mix
5U of Tag DNA polymerase (Promega)
2.25.1.1. 'Hot Start' PCR
Tag processes at 4°C albeit very slowly. This activity can reduce specificity 
of the PCR reaction. This is remedied by 'hot start' methodologies which reversibly 
inhibit Tag polymerase in a variety of ways. In cases where 'hot start' was used, Tag 
was first mixed with 'Tag Start' antibody (Clontech) for 'hot-start' PCR according to 
the manufacturer's instructions.
2.25.1.2. "Perfect Match" PCR additive
The PCR additive "Perfect Match" (Stratagene) is designed to increase 
specificity in complex backgrounds (such as cDNA derived from total RNA) by 
destabilising mismatch annealing. When it was used, the PCR additive "Perfect 
Match" was added last (0.5pl), to a total volume of 50|il
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2.25.2. Procedure
Amplification of sequence fragments was performed in Ix PCR buffer (see above). 
After amplification a 10|ll aliquot from each reaction was typically resolved by 
electrophoresis on a 2% agarose gel (section 2.20) and visualised with ethidium 
bromide under UV light.
2.25.2.1 Typical amplification protocol 
•Dénaturation for 60s at 94"C
•Annealing for 60s at a temperature 7"C below the melting temperature of the 
primer
•Extension for 60s at 72"C
METHODS USED IN PCR-BASED RAPID AMPLIFICATION OF 
cDNA ENDS (RACE) PROTOCOLS
2.26. REVERSE TRANSCRIPTION FOR RAPID AMPLIFICATION OF 
cDNA ENDS
First strand cDNA syhthesis of RNA for RACE used Superscript II enzyme 
(Gibco). This is the Moloney Murine Leukaemia Virus reverse transcriptase (MMuLY 
RTase) but it is a recombinant protein that has had its RNAse activity removed. As a 
result it synthesises more full length cDNAs than the wild type. It is also active at a 
higher temperature. Used at these higher temperatures less cDNA will be synthesised 
by mis-priming events.
5pg of RNA to be used in this protocol was diluted to lOpl using DEPC 
water. It was then denatured at 70"C for 5min in a thermal cycler which was 
programmed to heat the solution at the annealing temperature of the primer. Ipmol of a 
gene specific primer was now added along with lOx hybridisation buffer. For 
intramolecular ligation (circularisation) reactions a phosphorylated oligonucleotide was 
used. After this annealing step the reaction was heated at 42"C for 2nun before 
addition of ip l Siiperscriptll enzyme. The cDNA synthesis reaction was incubated at
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42"C for Ih. Then Ifil of RNAse H (Promega) was added and the reaction incubated 
at 55“C for 10 min.
ANCHORING REACTIONS IN RACE TECHNIQUES.
2.27. ANCHORING OF cDNA ENDS BY HOMOPOLYMERIC 
TAILING WITH TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE 
(TdT)
Homopolymeric tailing of cDNA ends was done using the '5' RACE System 
for Rapid Amplification of cDNA Ends' (GibcoBRL) kit.
First strand cDNA was separated from enzymes and buffer components by 
GLASSMAX spin cartridge (GibcoBRL). TdT tailing was then performed in the 
following reaction mix:
DEPC water 
lOX reaction buffer
(20mM Tris-HCl (pH 8.4), 50mM KCl)
25mM MgCU 
2mM dCTP 
cDNA sample
The mixture was incubated for 2min at 94"C then placed on ice. l |i l  TdT (10 units/|il) 
was added and incubated for 10 min at 37 "C. The TdT was now heat inactivated for 
10 min at 65" C
2.28. ANCHORING OF cDNA ENDS BY T4 RNA LIGASE  
MEDIATED (RLM) SINGLE STRANDED INTRAMOLECULAR OR 
IN TER M O LEC U LA R  LIG A TIO N  OF PH O SPH O RYLATED  
OLIGONUCLEOTIDES
First Strand cDNA was purified from primer by phenol/chloroform extraction 
followed by centricon 30 filtration (Amicon). Then Ipmol (Ipmol/fil) of 5'
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phosphorylated oligonucleotide was added to 16|il cDNA, 2p,l lOx buffer (50mM 
Tris-HCl, pH7.8, lOmM MgCU, lOmM p-mercaptoethanol) and Ifil T4 RNA ligase 
(New England Biolabs.). In cases where intramolecular ligations were attempted, the 
phosphorylated oligonucleotide was omitted. This ligation was incubated at 24°C 
overnight.
CLONING DNA 
2.29. PHOSPHATASE TREATMENT OF DNA
Prior to ligation of an insert into a vector, the plasmid DNA should be treated 
with calf intestinal alkaline phosphatase (CIAP, Promega) if the vector has been 
digested with a single restriction enzyme. The CIAP removes the 5' phosphate groups 
and thus prevents recircularization of the vector during ligation.
2.29.1 Reaction mix
Add the following in a microcentrifuge tube:
vector DNA
CIAP lOx buffer
CIAP
dH2()
Mix gently and incubate for 1 hour at 37"C. CIAP must be removed prior to ligation 
by phenol/chloroform extraction.
2.30. DOUBLE STRANDED DNA LIGATION
Double stranded DNA with cohesive ends was ligated into lOOng vector by 
adding lunit of T4 DNA ligase (Promega) to 1:1 and 1:3 ratios of vector and insert 
DNA in 19.5|il Ix Ligase buffer (lOX T4 DNA ligase buffer is 30mM Tris-HCl, 
pH7.8. lOOmM MgCH, lOOmM DTT, lOmM ATP). This reaction was incubated at 
14"C overnight. The ligase buffer was aliquoted to prevent degradation of ATP.
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2.31. TA CLONING
2.31.1 Sample preparation
PCR samples were used directly in ligations (see below). Cosmid digests 
were heated to 65"C for lOmin to inactivate the restriction enzyme, then concentrated 
by ethanol precipitation. The precipitates were then redissolved and incubated with 
Tag polymerase for lOmin to give 3' A-overhangs. The sample was collected again by 
ethanol precipitation. The precipitate was resuspended in a volume such that the ratio 
of concentration of the average sized insert to vector would be 3:1 in the ligation.
2.31.2, Ligation
TA cloning depends on a property which certain polymerases possess in 
transfeii'ing single adenines onto the 3' end of blunt-ended DNAs. Vectors carrying 
complementary T overhangs can ligate with these DNAs very efficiently because 
neither molecule can circularise thus promoting intermolecular reactions. TA cloning 
was performed using the Original TA cloning kit (Invitrogen) or the Eukaryotic TA 
cloning kit (Bidirectional) as required. The ligation reaction is earned out essentially as 
above, using the supplied precut vector containing the T overhang. The PCR reaction 
DNA was not quantified but instead Ijil of PCR reaction was added as advised in the 
manual notes.
2.31.3. TA cloning: transformation
An aliquot of frozen competent cells (The strain invaF was supplied with 
Original TA cloning kit. The strain TOPI OF was supplied with Eukaryotic 
Bidirectional TA cloning kit, both from Invitrogen) was thawed slowly on ice. 2|il of 
ligation reaction and 2ql of 0.5M(3-Mercaptoethanol was added to the tube, mixed 
with the pipette tip and incubated on ice for 30min. The cells were then heat shocked 
for 30s at 42"C and incubated on ice for a further 2min. 250jil of SOC broth was then 
added and the transformed cells incubated at 37"C for 60min with shaking (225rpm). 
lOOpI of the culture was plated on a 10cm agar plate containing 50pg/ml ampicillin. 
Transformed colonies were identifiable in the 'Original' TA cloning vector (pCR2.1)
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using blue/white colour selection because insertion was into the P-Galactosidase gene. 
Colour selection was not possible in the eukaryotic TA cloning expression vector 
(pCR3.1). In either case white colonies were picked, PCR screened C2.31.4) and 
glycerol stocks made of positive colonies (section 2.5.4.)
2.31.4. TA cloning: PCR screen
PCR screens were usually done with one vector primer and one insert 
specific primer used in the PCR, to select for recombinants. The template for PCR 
screens were colonies, which were picked onto a master plate before being placed into 
the reaction tube. In very large screens where very few positives were anticipated 
(such as the screens of cosmid digestion fragment subclones), the initial PCR screens 
were done with one tube for each row and column to reduce the number of tubes. The 
PCR mix was as normal (see section 2.29) except for Taq polymerase, where only 
lUnit was added per reaction. The final volume of each reaction was 30pl. The 
cycling times were:
Cycles (30) Dénaturation 96^C for 30s
Annealing* 47"C for 30s
Extension l l^ C  for Imin
Positive PCR reactions were detected by gel electrophoresis
2.32. DNA SEQUENCING WITH THE ABI SEQUENCER
2.32.1. Protocol for cycle sequencing
Samples for sequencing taken from maxi-preps or mini-preps were mixed 
with the Taq DyeDeoxy Terminator (ABI) reaction premix.
Reaction mix:
Reaction premix
(contains buffer, polymerase, dNTPs, magnesium) 8)il 
ds DNA template 400ng
primer (for ds DNA) 3.2pmol
H2O to 20|il
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Sequencing reactions so prepared were subjected to thermal cycling using the 
following conditions
Cycles (25) Dénaturation 96°C for 30s
Annealing* 47°C for 15s
Extension 60°C for 4min
* This segment temperature was variable according to the primer used. The 
temperature shown was that used for tlie T7 sequencing primer (taatacgactcactataggg) 
and the pCR2.1 upstream primer (agctatgaccatgattacg)
Reaction products were concentrated by ethanol precipitation and the pellets sent to the 
Glasgow University Molecular Biology Support Unit for gel electrophoresis.
2.33 SEQUENCE ANALYSIS
Routine DNA sequence handling and analysis was performed on the Gene 
Jockey II program (BIOSOFT), though some alignments (see figure legends) were 
then transferred to the DNA STAR program for presentation. Protein analysis was 
also done on DNA STAR. The GCG suite of software was used for similarity 
searching of the nucleotide and protein databases.
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3. STUDIES ON THE MEM BRANE ASSOCIATION AND 
REGULATION OF PDE3B.
3.1 INTRODUCTION: MEMBRANE ASSOCIATION OF PDE3B
The intracellular localisation of PDE3 derived from different sources varies 
(58). PDE3 activity in adipocytes, which is thought to be predominantly PDE3B (54), 
is almost exclusively particulate (56,172). A hydrophobic sequence between amino 
acid 73 and 251 of rat PDE3B has been proposed to confer membrane association 
upon the protein. This was suggested on the basis that this region displayed 
hydropathic periodicity which resembled that of integral trans-membrane helices (54). 
However, many soluble proteins have hydropathic periodicities which might 
otherwise be used to justify membrane association (173). Therefore this measure is in 
itself insufficient and, in any case, would not exclude other regions of the protein 
having membrane association determinants. To date, the most detailed studies 
characterising deletions of PDE3B have not addressed the issue of intracellular 
localisation (174,175), however a picture of the membrane association of PDE3 is 
beginning to emerge from other sources.
Membrane association of PDE3A has been studied, with targeting of both 
full-length and N-teiininal truncations of PDE3A being examined (52,56). It has been 
suggested, on the basis of sequence similarity (see figure 1.6.1.), that this work is 
also applicable to PDB3B (58). The susceptibility of full length PDE3B to 
solubilisation with high ionic strength or detergent has also been examined (56). All of 
this work is summarised below.
According to Leroy et al (56), in low ionic strength and the absence of 
detergent, full length recombinant PDE3B expressed in NIH3006 fibroblast is almost 
exclusively particulate, confirming data from adipocytes (172). Detergent was shown 
to be able to solubilise partially this enzyme, as was treatment witli high ionic strengtli. 
The combined effects of these treatments was at least additive, consistent with there 
being more than one means of membrane association. Similar results were obtained 
with full-length PDE3A expressed in Sf9 cells (52). In the absence of high ionic 
strength or detergent, N-terminally truncated forms, with deletion of either 483 amino
Chapter 3; Studies on PD E3B
acids (52) or 511 amino acids (56) of PDE3A, were found in both cytosolic and 
particulate fractions (52). In contrast, an N-terminally truncated construct with a 
deletion of 611 amino acids of PDE3A was entirely cytosolic (56). It therefore seems 
that the PDE3A membrane association determinants may be manifest in the first -600 
amino acids of the PDE. Taken together, these findings hint at a complexity of PDE3 
membrane association which is difficult to reconcile witli the single integral membrane 
binding domain originally proposed by Taira et al (54). Indeed there is a possibility 
that PDE3B may have more than one membrane association domain. Thus cytosolic 
localisation would only be confeiaed when all such binding detenninants are removed.
Wild-type rat PDE3B has two in-frame Sac II restriction digestion sites 
which, if digested (the short fragments removed) and religated, would delete 85% of 
the putative membrane association domain suggested by Taira et al (54). This 
construct, which is generated in this study and called PDE3BA1, might be considered 
an attractive first step to address the question of whether the membrane association 
domain proposed by Taira et al (54) does indeed harbour membrane binding 
determinants or not.
3.2 INTRODUCTION: INVESTIGATIONS INTO THE PATHWAY BY 
WHICH INSULIN SIGNALS TO PDE3B.
The evidence for insulin stimulation of PDE3B as a key step in insulin- 
mediated anti-lipolysis was discussed in the Introduction. The increase in activity of 
adipocyte PDE3B, due to either insulin or isoprenaline treatment, coincides with an 
increase in the level of phosphorylation of this enzyme (176), an effect which is also 
seen in cell free stimulation of PDE3B (49). Furtheiinore, okadaic acid, an inhibitor of 
protein phosphatases 1 and 2A, is able to block reversal of the insulin stimulation of 
PDE3B (177). Thus the stimulation of PDE3B by insulin is apparently due to a 
reversible phosphorylation of PDE3B.
The identity of the kinase (designated variously in the literature as 
cGIPDEISK for Cyclic GMP Inhibited PDE Insulin Stimulated Kinase or PDE3IK for 
PDE3 Insulin Stimulated Kinase (58)) responsible for this phosphorylation is still
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unknown. The PDE3ÏK activity appears to be located in the cytosolic fractions of 
liver, adipocytes and human platelets (178-180). The kinase is only insulin stimulated 
in the pH range 7-8 (178). PDE3IK activity is rapidly lost if cell lysis is not carried out 
in the presence of phosphatase inhibitors, consistent with the notion that the PDE3IK 
itself is also sensitive to phosphorylation (178-180). Since PDE3IK is not adsorbed 
by anti-tyrosine antibodies this suggests that PDE3IK is sensitive to serine/threonine 
phosphorylation (180). Insulin stimulation of PDE3B is resistant to tieatment with the 
PKC & PKA inhibitor H7 (177,178) and the protein kinase A inhibitory peptide 
(49,178), indicating that these kinases are not involved in insulin-mediated stimulation 
of PDE3 (177-179). To date, attempts to purify this protein to homogeneity have 
failed (63). However, inhibitor studies suggest that the kinase is not p70 S6 kinase, 
casein kinase II, PKA, PKC, Mn^+ specific protein kinase or protease-stimulated 
protein kinase (63,180). Despite contrary evidence from in vitro  studies (181) serine 
302 appears to be the sole site for physiological PDE3B phosphorylation following 
either insulin or isoprenaline treatment (182).
Insulin mediated activation of PDE3IK and the phosphorylation and 
activation of PDE3B are blocked by treatment with wortmannin at concentrations 
which inhibit phosphatidyl inositol-3 kinase (PI 3-kinase) (183). On this basis it has 
been postulated that the PDE3IK kinase lies downstream of PI 3-kinase (183). Three 
kinases, p70S6 kinase (p70 S6K) (184,185), glycogen synthase kinase-3 (GSK-3) 
(186) and protein kinase B (PKB, also known as RAC and akt, but not related to the 
small ras like GTPase rac) (187) are known to provide downstream effectors of PI 3- 
kinase. Of these kinases, two can most likely be discounted as putative PDE3B 
kinase. p70S6K is unlikely to be the PDE3B kinase since rapamycin, a specific 
inhibitor of p70S6K, has been reported to be ineffective at inhibiting insulin mediated 
PDE3B stimulation (63). Furthennore, GSK-3 is inactivated by insulin in tlie pathway 
downstream of PI3K (186). On this basis it is not possible that GSK-3 could mediate 
directly PDE3B phosphorylation and activation due to insulin. It thus seems likely that 
neither p70S6K or GSK-3 will participate in insulin signalling to PDE3B. In contrast 
there are two lines of circumstantial evidence that suggest that PKB might be involved
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in PDE3B stimulation due to insulin. First, the insulin mimetic pervanadate produces 
an insulin-like stimulation of PDE3 activity in adipocytes (61). This compound is also 
the most potent activator of recombinant PKB (186). Second, the observation that 
PKA and insulin synergistically activate PDE3B by phosphorylation on a single site 
(182) has led to postulation that PDE3IK might contain one PKA and one insulin 
mediated activation site, both of which would need to be activated for maximal activity 
(182). PKB is a candidate for this convergence of signals since it contains two 
phosphorylation sites, both of which need to be phosphorylated for maximum activity 
(188).
With these considerations in mind, co-transfection experiments were planned 
with kinase active and kinase dead forms of PKB. It was hypothesised that if PKB 
was able to signal to PDE3B, then following stimulation with pervanadate one would 
observe an increase in PDE3 activity in cell lysates. An important control would be 
that pervanadate was unable or at least significantly less able to have the same effect if 
kinase-active PKB was replaced with kinase-dead PKB since this would suggest that 
the pervanadate effect was due to a specific effect on PKB rather than a generalised 
effect on the cell or a specific effect on PDE3B itself (61).
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Figure 3.2 Schematic of planned experiment to test PKB signalling to 
PDE3B.
If PKB is capable of signalling to PDE3B in COS-7 cells, pervanadate treatment of 
cells should stimulate PKB which will then stimulate PDE3B. A negative control 
which should detect direct pervanadate stimulation of PDE3B is to repeat the 
cotransfection with kinase-dead PKB. PKA activity is acutely blocked with H89 
which does not effect insulin-mediated stimulation of PDE3B (63).
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RESULTS
3.3. SYNTHESIS OF PDE3B CONSTRUCTS
3.3.1. Construction of PDE3B/pSV SPORT
The cDNA for rat PDE3B (rcGIP-1) (54) was excised from the blue/white 
colour screen cloning vector pBluescript, where it was cloned into the Spe I site. For 
mammalian expression PDE3B was subcloned into the eukaryotic expression vector 
pSV SPORT on the basis that PDE3B liberated from pBluescript by Spe I digestion 
could be ligated directly into identically digested pSV SPORT. Greater than 50 
colonies were obtained in two ligations of PDE3B and pS V SPORT digested with Spe
I. Six colonies from each were mini-propped for further study. DNA was subjected to 
BamH I digestion. pSV SPORT containing PDE3B ligated in the correct orientation 
should give fragment sizes of 6, 0.9 and 0.6 Kb (see figure 4.3.1.a), whilst pSV 
SPORT with PDE3B in the wrong orientation and pBluescript with PDE3B in either 
orientation will give different banding patterns. 12/12 colonies gave a BamH I digest 
pattern corresponding to pSV SPORT containing PDE3B in the correct orientation 
except that the expected 0.9Kb band did not appear. This corresponds to the 3' 
untranslated region of PDE3B and was therefore confirmed by a new digestion where 
Spe I and Xba I co-digestion should give digestion fragments of 3.2, 2.6 and 1.8 Kb 
(see figure 4.3.l.b). The same 10/12 colonies contained these bands with the shared 
exception that the lightest band, which corresponds to the 3' untranslated region of 
PDE3B, was considerably shorter than expected (-0.9Kb versus 1.8Kb). Since this is 
in the area of the 3* end of the ORF sequencing of the plasmid was used to confiiin 
that the reading frame was intact. This showed that the Spe I site had in fact been 
engineered to cut out the 3' UTR (see figure 4.3.l.c) and this finding fully explains 
the abeiTant banding patterns observed.
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Figure 3.3.1.a,b Expected restriction digestion pattern of PDE3B/pSV 
SPORT following digestion with BamH I or Spe I and Xba I
Shown above is the plasmid map of PDE3B/pSV SPORT with PDE 3B cloned into 
the Spe I linker site in the correct orientation. The digestion pattern is that shown (a) 
when the plasmid is digested with BamH I, or (b) when it is digested with Spe I and 
Xba I. These patterns were different from those expected for pSV SPORT with 
PDE3B in the wrong orientation and for pBluescript in either orientation.
Chapter 3: Studies on PD E3B 94
3300 3310 3320 3330 3340
I I I I I
GGAACAAACTGCAGGTGGATAATGCCTCCTTACCTCAGGCAGATGAGATTCAGGT
GGAACAAACTGCAGGTGGATAATGCCTCCTTACCTCAGGCAGATGAGATTCAGGT 
I I I I I
10 20 30 40 50
3350 3360 3370 3380 STOP 3400
I I I I * * *  I
CATTGAAGAAGCAGATGAAGAGGAAGAACAAATGTTTGAATGAGAAGAAAACTCA
CATTGAAGAAGCAGATGAAGAGGAAGAACAAATGTTTGAATGAGGACTAGTCGGCI I I I *** I ****** I
60 70 80 90 STOP Spe I  110
3410 3420 3430 3440 3450
I I I I I
TGCTGAAGAAGCCTGGGGTGCTCTTCCCAGGGTCGTTACCTAGTGCTCACCGTAC 
• • •  • •  • • • • •  #
GGCCGCTCTAGAGGATCCAAGCTTACGTACGCGTGCATGCG 
I I I I
120 130 140 150
TGATTCTCAACTGACCATTCCCATGTGGACAGGCCTTAATACTGTGAGGGGATCC
TTGCTACCTTGGTAGTTCTCACTCCTAAGCACTTTGATTACAGACTAGAGACTGA
CCTTAGAGCTTTCTGCAGTTGAGT................ATTCTTGCTCAGGATACATAATT
TTAAACATTAATTATTATAAACGTGGCATAGATTTGCCAGAAAAAAAACATTGTC 
CTAATATTGATGTTACCTTTTATGAAATGAGCACCATTTTCTTTTAATTAAAGCC 
AAGAAAAAGGAGATGACTATCTTTTGCCTTAGTGGAAAATCAA 
I I I I I
4340 4350 4360 4370 4380
Figure 3.3.l.c  A Spe I site is found immediately following the stop 
codon in PDE3B/pSV SPORT construct
PDE3B/pSV SPORT construct was analysed by sequencing using the 3' T7 
sequencing primer (see methods). This DNA sequence was then compared to the 
published PDE3B ORF sequence (numbered as in (54)). The coding sequence is 
conserved but just downstream of the stop codon (STOP in diagram), a Spe I site is 
found. The sequence beyond this is vector sequence. That is, tlie remaining ~900bp of 
3' UTR was removed at some point in the cloning of PDE3B
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3.3.2. Construction of PDE3BA1: an internally deleted mutant of 
PDE3B/pSV SPORT which lacks 151 out of 178 amino acids of a 
putative membrane association domain.
PDE3B pSV/SPORT was digested with Sac II, to remove the putative 
membrane association domain of PDE3B (figure 3.3.2.a). Nar I, which digests one of 
the short deleted fragments at a unique site was also used to reduce the numbers of 
short fragments which would have double-ended Sac II sites and therefore be able to 
religate with the large linearised PDE3BAl/pSV SPORT. To reduce further the risks 
of intermolecular religation, the small digested fragments were removed by gel 
electrophoresis. The linearised PDE3BAl/pSV SPORT was then recircularised with 
T4 DNA ligase. Ten colonies were taken from the subsequent transformation and 
screened by cycle sequencing from an N-terminal primer used in the constmction of 
PDE3BA2 (see below). This primer gave reads long enough to deteiTnine whether the 
internal truncation had been made. All colonies for which sequence was obtained 
contained the PDE3B sequence with the membrane association domain removed. One 
of these colonies, (number 2) was taken for use in all further studies. Figure 3.3.2.C is 
a hydropathy plot of PDE3B which shows the hydrophobicity of the sequences 
deleted to make PDE3BA1.
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Sac II cut sites
303 426 797
Digestion, gel purification, re-ligation
PDE3B
PDE3BA1 
A 88-267
Figure 3.3.2.a Schematic of PDE3BA1 construction
PDE3B and PDE3BA1 are shown. The thick line represents the putative 
membrane association domain and the thin line represents the rest of PDE3B. PDE3B 
was subjected to Sac II digestion which cuts in PDE3B three times at the positions 
shown but not in the vector (not shown). Purification of this longest fragment by gel 
electrophoresis followed by recircularisation would yield a plasmid with an in frame 
deletion of nearly 500 nucleotides
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MRKDERERDTPAMRSPPPPPPPATATAASPPESLRNGYVKSCVSPLR
MRKDERERDTPAMRSPPFPPPP J^ J^^^SPPESlRHGYyKSCySPLR
I I
10 20
50 60 70 80 90
I I I I I
QDPPRSFFFHLCRFCNVEPPAASLRAGARLSLAALAAFVLAALLGAG
QDPPRSFFFHLCRFCNVEPPAASLRAGARLSLAALAAFVLAALLGAG
I I I I I
30 40 50 60 70
100 110 120 130 140
I I I I I
EERÏÏMMLG.LEILLSA.C5LSISPL.FSIACAFFELT(:FI.TRAQRGRQ
• • • • • • •
PERWAAA---------------------------------------------------------------------
I
80
150 160 170 180
I I I I
RGAGSWWLLALPACCYLGDFAAWOWWSWLRGEPAAAAAGRLCLVLSC
190 200 210 220 230
I I I I I
VGLLTLAPRVRLRHGVLVLLFAGLVWWVSFSGLGALPPALRPLLSCL
240 250 260 270 280
I I I I I
VGGAGCLLALGLDHFFHVRGASPPPRSASTADEKVPVIRPRRRSSCV
• • • • • • • • • • • • • • • •
------------------------------------------------------DEKVPVIRPRRRSSCV
I
90
Figure 3.3.2.b Sequencing analysis of the N-terminal of PDE3BA1.
A candidate PDE3BA1 clone (2) was sequenced using a primer designed to the 5' end 
of PDE3B. The inferred amino acid sequence (bottom; the sequencing primer starts at 
the ATG of PDE3B so the reads start further downstream, unread sequence is shown 
in italics) was aligned to the N-terminal region of PDE3B itself (top). The PDE3B 
putative membrane association domain (54) is underlined.
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Figure 3.3.2.c Kyte and Doolittle hydropathy plot of PDE3B. PDE3BA1 
lacks hydrophobic PDE3B sequences
The hydropathy of PDE3B is presented (189). The sequence marked delta 1 is that 
deleted in PDE3BA1
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3.3.3. Construction of PDE3BA2: The first 72 amino acids of PDE3B 
tagged to the vesicular stomatitis virus (VSV) epitope YTDIEMNRLGK
The construction of PDE3BA2 was done using a PCR based procedure. 
Three primers were designed for amplification of the N-teiminal 72 amino acids.
(1) A sense primer was designed to the N-terminal of PDE3B taking care to include 
the Kozak initiation sequence (190).
Sense PDE3B N-terminal + KOZAK sequence GCTATGAGGA AGGACGAGC 
(GR88)
(2) An antisense primer was designed to the vesicular stomatitis virus (VSV) epitope 
YTDIEMNRLGK (with codons selected for mammalian preference) and then 
continuing with tlie PDE3B region leading up to amino acid 72.
Antisense VSV tag fused to PDE3B sequence. CTACTTGCCC AGCCTGTTCA 
TCTCGATGTC GGTGTAGCGG AGCGAGGCCG CCGG (GR87)
(3) For amplification a second antisense primer was designed to the VSV epitope.
VSV amplification primer CTACTTGCCC AGCCTGTTC (GR89).
A PCR reaction was set up using a glycerol stab of PDE3B/pSV SPORT as
template (figure 3.3.3.a). The N-terminal of PDE3B is GC rich (PDE3BA2 sequence
is 76% G+C). Perhaps, because of this, a fragment of the coii'ect size (~256bp) was
obtained only when DMSO or a 96"C melting temperature was used. Cycling
conditions were 25 cycles of 96"C for 60s, 53"C for 60s (37"C in the first cycle) and
72“C for 60s. The PCR product was directly cloned into the bi-directional eukaryotic
expression TA cloning vector pCR 3.1. 60 clones were screened (as described in the
methods but again with a 96"C melt step) by a unidirectional PCR to identify clones
only if they are in the correct orientation. The screen used the T7 upstream (on the
vector) sequencing primer and the antisense primer used in the PCR. 9 positive clones
were cycle sequenced in both strands. All 9 sequences displayed the correct sequence
in every position in one or other read, but one colony, number 66, was taken for
further experiments because it reads perfectly on both strands (figure 3.3.3.b)
In figure 3.3.3.C, all tliree of the PDE3B constructs amino acid sequences are 
presented for comparison
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(a)
amino acid 1 amino acid 72
IQRB8: GCTATGAGGA AGGACGAGC- 1 PDE 3B n- terminal
QRBB QMCAGGCTQ QQCAAQTAQ
VSV TAG
TA CACCQACATC QAQATQAACA OQOTQQQCAAQTAQ
PDE 3B A2 
A 1-72VSV
(b)
10 20 30 40
I I I I
MRKDERERDTPAMRSPPPPPPPATATAASPPESLRNGYVKSCVSPLR
MRKDERERDTPAMRSPPPPPPPATATAASPPESLRNGYVKSCVSPLR t i l l  
10 20 30 40
50 60 70 80
I
QDPPRSFFFHLCRFCNVEPPAASLRYTDIEMNRLGK*
• • • • • • • • • • • • • • • • • • • • • • • • •
QDPPRSFFFHLCRFCNVEPPAASLRAGARLSLAALAAFVLAALLGAG 
I I I I I
50 60 70 80 90
Figure 3.3.3.a,b Construction of PDE3BA2.
(a) Schematic of the PCR mediated fusion of the N-terminal of PDE3B with 
the VSV epitope YTDIEMNRLGK. PCR was carried out using primers GR88 & 
GR89 with a lower concentration of primer GR87. (b) As PDE3BA2 was constructed 
by PCR based methodologies it was sequenced in both directions along its full length. 
The predicted amino acid sequence from clone 66 is shown (top) aligned with the first 
90 amino acids of PDE3B (bottom). The YTDIEMRNLGK motif is the VSV tag.
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10 20 30 40 50 60
I I I I I I
pde SB A2 MRKDERERDTPAMRSPPPPPPPATATAASPPESLRNGYVKSCVSPLRQDPPRSFFFHLCRFCNVEPPA
pde 38 M  MRKDERERDTPAMRSPPPPPPPATATAASPPESLRNGYVKSCVSPLRQDPPRSFFFHLCRFCNVEPPA
pde 38 MRKDERERDTPAMRSPPPPPPPATATAASPPESLRNGYVKSCVSPLRQDPPRSFFFHLCRFCNVEPPA
70 80 90 100 110 120 130
I I I I I I I
pde 38 A2 ASLR
pde 38 A1 ASLRAGARLSLAALAAFVLAALLGAGPERWAAA ....... ..........................
pde 38 ASLRAGARLSLAALAAFVLAAILGAGPERWAAAATGLRTLLSACSLSLSPLFSIACAFFFLTCFLTRA
140 150 160 170 180 190 200
I I I I I I I
pde 38 A1 ------------------------------------------------------------------------------
pde 38 QEGPDRGAGSWWLLALPACCYLGDFAAWQWWSWLRGEPAAAAAGRLCLVLSCVGLLTLAPRVRLRHGV
210 220 230 240 250 260 270
I I I I I I I
pde 38 A1 --------------------------------------------    -DEKVPV
pde 38 IVLLFAGLVWWVSFSGLGALPPALRPLLSCLVGGAGCLLALGLDHFFHVRGASPPPRSASTADEKVPV
280 290 300 310 320 330 340
I I I I I I I
pde 38 A1 IRPRRRSSCVSLGESAAGYYGSGKMFRRPSLPCISREQMILWDWDLKQWCKPHYQNSGGGNGVDLSVL
pde 38 IRPRRRSSCVSLGESAAGYYGSGKMFRRPSLPCISREQMILWDWDLKQWCKPHYQNSGGGNGVDLSVL
350 360 370 380 390 400
1 1 I I I I
pde 38 A1 NEARNMVSDLLIDPSLPPQVISSLR5ISSLMGAFSGSCRPKINSFTPFPGFYPCSEVEDPVEKGDRKL
pde 38 NEARNMVSDLLIDPSLPPQVISSLRSISSLMGAFSGSCRPKINSFTPFPGFYPCSEVEDPVEKGDRKL
410 420 430 440 450 460 470
I I I I I I I
pde 38 A1 HKGLSSKPSFPTAQLRRSSGASGLLTSEHHSRWDRSGGKRPYQELSVSSHGCHLNGPFSSNLMTIPKQ
pde 38 HKGLSSKP5FPTAQLRRSSGASGLLTSEHHSRWDRSGGKRPYQELSVSSHGCHLNGPFSSNLMTIPKQ
480 490 500 510 520 530 540
1 * 1  I I I I I
pde 38 A1 RSSSVSLTHHAGLRRAGALPSPSLLNSSSHVPVSAGCLTNRSPVGFLDTSDFLTKPSVTLHRSLGSVS
pde 38 RSSSVSLTHHAGLRRAGALPSPSLLNSSSHVPVSAGCLTNRSPVGFLDTSDFLTKPSVTLHRSLGSVS
550 560 570 580 590 600 610
I I I I I I I
pde 38 A1 SAADFHQYLRNSDSSLCSSCGHQILKYVSTCEPDGTDHHNEKSGEEDSTVFSKERLNIVETQEEETVK
pde 38 SAADFHQYLRNSDSSLCSSCGHQILKYVSTCEPDGTDHHNEKSGEEDSTVFSKERLNIVETQEEETVK
620 630 640 650 660 670 680
I I I I I I I
pde 38 A1 EDCRELFLEGDDHLMEEAQQPNIDQEVLLDPMLVEDYDSLIEKMSNWNFQIFELVEKMGEKSGRILSQ
pde 38 EDCRELFLEGDDHLMEEAQQPNIDQEVLLDPMLVEDYDSLIEKMSNWNFQIFELVEKMGEKSGRILSQ
690 700 710 720 730 740
I I I I I I
pde 38 A1 VMYTLFQDTGLLETFKIPTQEFMNYFRALENGYRDIPYHNRVHATDVLHAVWYLTTRPIPGLQQLHNN
pde 38 VMYTLFQDTGLLETFKIPTQEFMNYFRALENGYRDIPYHNRVHATDVLHAVWYLTTRPIPGLQQLHNN
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750 760 770 780 790 800 810
I I I I I I I
pde 3B A1 HETETKADSDARLSSGQIAYLSSKSCCIPDKSYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLV
pde 3B HETETKADSDARLSSGQIAYLSSKSCCIPDKSYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLV
820 830 840 850 860 870 880
I I I I I I I
pde 3B A1 ATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLNLDHMEFKRFRFLVIEAILATDLKKHFDFL
pde 3B ATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLNLDHMEFKRFRFLVIEAILATDLKKHFDFL
890 900 910 920 930 940 950
I I I I I I I
pde 3B A1 AEFNAKANDVNSNGIEWSSENDRLLVCQVCIKLADINGPAKDRDLHLRWTEGIVNEFYEQGDEEATLG
pde 38 AEFNAKANDVNSNGIEWSSENDRLLVCQVCIKLADINGPAKDRDLHLRWTEGIVNEFYEQGDEEATLG
960 970 980 990 1000 1010 1020
I I I I I I I
pde 38 A1 LPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWIEAEEGDDTESDDDDDDDDDDDDDD
pde 38 LPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWIEAEEGDDTESDDDDDDDDDDDDDD
1030 1040 1050 1060 1070 1080
I I I I I I
pde 38 A1 DEELDSDDEETEDNLNPKPQRRKGRRRIFCQLMHHLTENHKIWKEIIEEEEKCKAEGNKLQVDNASLP
pde 38 DEELDSDDEETEDNLNPKPQRRKGRRRIFCQLMHHLTENHKIWKEIIEEEEKCKAEGNKLQVDNASLP
1090 1100
I I
pde 38 A1 QADEIQVIEEADEEEEQMFE 
pde 38 QADEIQVIEEADEEEEQMFE
Figure 3.3.3.c Comparison of PDE3BA1 and PDE3BA2 sequence with 
PDE3B
PDE3BA1 and PDE3BA2 are shown compared to PDE3B. Note that PDE3BA2 also 
contains a VSV tag, but for simplicity the sequence is not shown here. The putative 
membrane association domain identified by Taira et al is underlined (54). The asterisk 
marks the start of a partially cytosolic construct made by Kasuya at al (52).
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3.4. USE OF PDE3B AND VSV-G SPECIFIC ANTIBODIES TO 
STUDY THE MEMBRANE ASSOCIATION OF PDE3B, PDE3BA1 AND 
PDE3BA2
Lysates of COS cells transfected with PDE3B/pSV SPORT subjected to 
Western blotting by two different antibodies revealed an immunoreactive band of the 
same weight (~135kD) in both PI and P2 fractions but not in the S2 fraction (figure
3.4.a.). There was no such immunoreactivity in lysates of mock transfected cells. 
Lysates of COS cells transfected with PDE3BA1 produced a -120 kD band when they 
were immunoblotted with the same antibody (figure 3.4.a.). This protein was also 
exclusively particulate. In order to determine the relative detergent solubilities of 
PDE3B and PDE3BA1, particulate fractions from transfected COS cell lysates were 
subject to washes in 1% triton X-100 (figure 3.4.b,c). For both PDE3B and 
PDE3BA1 the PI fraction could be partially solubilised (to about the same degree) but 
the P2 fraction was resistant to this. In contrast, PDE3B and PDE3BA1 particulate 
fractions from transfected COS cell lysates showed different sensitivity to washing 
with high ionic strength. Thus, PDE3B in either P2 or PI fractions appeared to be 
insensitive to washing with buffer containing 2M NaCl (figure 3.4.l.d). In contrast, 
PDE3BA1 in either P2 or PI fractions could be removed from particulate association 
by washing with high ionic strength (figure 3.4. Le).
Mock transfected and PDE3BA2 transfected COS cell lysates were 
immunoblotted with a VSV specific monoclonal antibody. This antibody detected an 
immunoreactive species of the correct size in transfected whole cell lysates. This 
species was not apparent in mock transfected lysates. Immunoblots performed on 
fractionated PDE3BA2 transfected COS cell lysates demonstrated that this construct 
was found exclusively in the cytosolic fraction (figure 3.4.1.f).
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Figure 3.4.a. PDE3B specific antibodies detect PDE3B and PDE3BA1 
in transfected COS cell lysis fractions.
82 (lanes 1-3) and P2 (lanes 4-6) fractions were prepared from various COS-7 cell 
lysates. These fractions, from COS-7 cells which were mock-transfected (lanes 1 and 
4), transfected with PDE3BAl/pSV SPORT (lanes 2 and 5), or transfected with 
PDE3B/pSV SPORT (lanes 3 and 6) were subject to immunoblotting with a PDE3B 
specific antibody. This was an IgG purified polyclonal antibody raised to the C- 
terminal of PDE3B. This antibody does not cross-detect PDE3A (56). Primary 
antibody was used at a concentration of 1/500. Secondary antibody was used at a 
concentration of 1/25(K). For each sample, the same amount of S2 protein was loaded 
and the proportionate amounts of P2 sample were loaded. The positions (from the top) 
of the 200kD, KKlkD, 75kD and 43kD markers are shown
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Buffer 1%
TRITON
NO
TRITON
1%
TRITON
NO
TRITON
Fraction S2 P2 WASH P2 WASH M PI WASH PI WASH
Figure 3.4.b. D etergent solubilisation of PDE3B from PI and P2 
particulate fractions of transfected COS cell lysates
Particulate fractions of lysates of COS cells transfected with PDE3B/pSV SPORT 
were washed with various buffers prior to immunoblotting with a PDE3B specific 
antibody. Lanes are labelled P I, P2 or S2 to denote the lysate fraction and the 
solubilisation treatment is also shown. PDE3B is marked with an arrow. 
Immunoblotting of PDE3B is with an N-terminal PDE3B specific polyclonal antibody. 
This antibody does not cross-detect PDE3A (56). Primary antibody was used at a 
concentration of 1/2()(K). Secondary antibody was used at a concentration of 1/2500. 
For each sample, equal amounts of S2, P2 and PI samples were loaded. M denotes a 
marker lane.
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Buffer 1%
TRITON
NO
TRITON
1%
TRITON
NO
TRITON
Fraction S2 P2 WASH P2 WASH M P1 WASH PI WASH
Figure 3.4.c. Detergent solubilisation of PDE3BA1 from PI and P2 
particulate fractions of transfected COS cell lysates
Particulate fractions of lysates of COS cells transfected with PDE3BAl/pSV SPORT 
were washed with various buffers then subject to immunoblotting with a PDE3B 
specific antibody as in figure 3.4.1. Lanes are labelled PI, P2 or S2 to denote the 
lysate fraction and the solubilisation treatment is also shown. PDE3BA1 is marked 
with an arrow. Immunoblotting of PDE3BA1 is with the C-terminal PDE3B specific 
antibody which was used as in figure 3.4.a. Primary antibody was used at a 
concentration of 1/5(K). Secondary antibody was used at a concentration of 1/2500. 
For each sample, equal amounts of S2, P2 and PI fraction were loaded. M denotes a 
marker lane.
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Buffer No Na 01 1M Na 01 No Na 01 1M Na 01
Fraction P2 WASH P2 WASH PI WASH P1 WASH
Figure 3.4.d. Treatment of particulate PDE3B with high ionic strength 
buffers: use on PI and P2 particulate fractions from transfected COS 
cell lysates
Particulate fractions of lysates of COS cells transfected with PDE3B/pSV SPORT 
were washed with various buffers then subject to immunoblotting with the C-terminal 
PDE3B specific antibody as in figure 3.4.1. Lanes are labelled PI, P2 or S2 to denote 
the lysate fraction and the solubilisation treatment is also shown. Immunoblotting of 
PDE3B is with the N-terminal PDE3B specific antibody which was used as in figure
3.4.b. Primary antibody was used at a concentration of 1/5(X). Secondary antibody 
was used at a concentration of 1/25(K). For each sample, equal amounts of P2 and PI 
fraction was loaded.
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Buffer No Na 01 1M NaCI No Na 01 1M Na 01
Fraction P2 WASH P2 WASH P1 WASH PI WASH
Figure 3.4.e. Treatm ent o f PI and P2 particulate fractions of  
transfected COS cell lysates with high ionic strength to evaluate the 
solubilisation of PDE3BA1.
Particulate fractions of lysates of COS cells transfected with PDE3BAl/pSV SPORT 
were washed with various buffers then subject to immunoblotting with a PDE3B 
specific antibody. Lanes are labelled PI, P2 or S2 to denote the lysate fraction and the 
solubilisation treatment is also shown. Immunoblotting of PDE3BA1 is with the C- 
terminal PDE3B specific antibody which was used as in figure 3.4.a. First antibody 
was used at a concentration of 1/5(K). Second antibody was used at a concentration of 
1/25(K). For each sample, equal protein concentrations of P2 were loaded. PI fraction 
was loaded at an amount 1:3 lower than the P2 fraction.
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SAMPLE:
WHOLE CELL S2 R1 P2
MOCK A2 MOCK A2 MOCK A2 MOCK A2
FRACTION:
Figure 3.4.f. PDE3BA2 localisation in fractions of transfected COS cell 
lysates
COS-7 cells were transfected with PDE3BA2/pCR3.1. Whole cell lysates and PI, P2 
and S2 fractions of lysates of these cells were immunoblotted with a VSV specific 
monoclonal antibody. Fractions from mock transfected cells were immunoblotted for 
comparison. First antibody was added at 1/250 dilution. Second antibody dilution was 
1/500. The small arrows on the left show the positions of the marker for 16kD (top 
arrow) and 6.5kD (bottom arrow). The larger arrows denote a band of the predicted 
size which is not found in untransfected COS-7 cells. For each sample, the same 
amount of PI protein was loaded and the proportionate amounts of P2 sample was 
loaded. Whole cell lysates and S2 fractions are 4 times more dilute than these 
fractions.
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3.5 STUDIES ON PDE3B ACTIVITY: A NOVEL, CILOSTIMIDE- 
INHIBITABLE PDE ACTIVITY OBSERVED IN COS-7 CELLS 
TRANSFECTED WITH PDE3B/pSV SPORT
Cilostamide inhibitable (PDE3) activity in untransfected COS cells is 18 ± 3 
pmol cAMP hydrolysed/min/mg of protein (n=3 separate transfections). All of this 
activity was restricted to the S2 fraction. When PDE3B/pSV SPORT was transfected 
into COS-7 cells a novel, cilostimide inhibitable PDE3 activity was observed. The 
amount of extra PDE3 activity observed varied between transfections and was 5-15 
fold greater than the endogenous PDE3 activity such that the observed cilostamide- 
inhibitable activity was 96-270 pmol cAMP hydrolysed/min/mg of protein (n=6 
separate transfections). Replicate transfections performed side by side had much less 
variation in the amount of PDE3 activity they exhibited. Transfection of PDE3B/pSV 
SPORT into COS-7 cells did not increase non-PDE3 activity.
3.5.1. Triethanolainine/KCl treatment partially solubilises PDE3B
COS cells transfected with PDE3B/pSV SPORT, were washed with 
triethanolamine/KCl buffer prior to homogenisation in KHEM buffer. The lysates 
were fractionated and the activity in high speed particulate (P2) and supernatant (S2) 
determined. It was found that approximately equal amounts of PDE3 activity was 
present in the S2 and the P2 fractions (The ratio of activities S2:P2 was 57:43). 
Furthermore, immunoreactivity was now detectable in soluble fractions, albeit less 
than that detected in the P2 fraction (figure 3.5.1.).
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Fraction P2 S2
Transfection Mock PDE3B Mock PDE3B
Figure 3.5.1. Solubility of PDE3B protein in lysates of COS-7 cells 
washed in TEA/KCl prior to homogenisation
COS-7 cells were incubated in TEA/KCl at 4"C for lOmin. They were then washed 
twice and fractionated. P2 and S2 fractions from these cells and from mock transfected 
cells were immunoblotted. Immunodetection was performed using PDE3B specific N- 
terminal antibody (see figure 3.4.b.) PDE3B is identified with an arrow
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3.5.2. The insulin mimetic pervanadate cannot stim ulate total 
phosphodiesterase activity in serum-starved TEA/KCl treated  
PDE3B/PKB cotransfection bulk fractions.
The effect of pervanadate was determined on the total PDE activity in SI 
fractions of COS-7 cells cotransfected with PDE3B/pSV SPORT and plasmids 
containing either kinase-active PKB (PKB+) or kinase-dead PKB (PKB-). The 
reaction and lysis buffers contained phosphatase inhibitors and cells were serum 
starved for 12 hours prior to treatment for 15 min with pervanadate and subsequent 
lysis. On five separate occasions no significant effect of pervanadate treatment on total 
PDE activity (figure 3.5.2.) was observed. However, the active PKB cotransfections 
had significantly more PDE activity than kinase dead PKB transfections (see figure
3.5.2.)
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n=2P D E 3  -
P V  P D E 3  -
n=4P K B -  P D E 3  -
n=5P V  P K B -  P D E 3  -
P K B +  P D E 3 n=5 *p-0.024
n=5 *p=0.012P V P K B + P D E 3  -
0 5 0 1 5 0100 200
% of unstimiilated PKB-/PDE3 activity
Figure 3.5.2. Effect of pervanadate treatment on total PDE activity of 
COS-7 cells.
COS-7 cells were transfected with PDE3B alone (PDE3) or co-transfected with 
PDE3B (PDE3) and kinase active PKB (PKB+ PDE3) or PDE3B with kinase dead 
PKB (PKB- PDE3). Cells were then treated with pervanadate (PV) prior to lysis. 
Total PDE activity of lysates was measured. Student's paired T-test was performed to 
assess significance of the increased activity in PKB+ co-transfections compared to 
PKB- co-transfections.
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3.5.3. Pervanadate up-regulates PDE3 phosphodiesterase in COS-7 
cells cotransfected with PDE3B and PKB+ but not in COS-7 cells 
cotransfected with PDE3B and PKB-
The protocol detailed in section 3.5.2. was now modified in a number of
ways.
1. Since PDE3B is found only in particulate fractions of adipocytes (172) and 
TEA/KCl apparently released PDE3B from COS-7 particulate fractions, the TEA/KCl 
step in cell lysis was omitted because this apparently resulted in non-physiological 
release of PDE3 protein. This may have effected its regulation (see below).
2. P2 fractions were taken for study instead of SI fractions. In adipocytes, the P2 
fraction is the only insulin sensitive subset of PDE3 activity (172). In addition, 
PDE3B western blots and activity data suggest that the P2 population of PDE3B is 
less active than the solubilised S2 population. This could be taken to imply, although it 
does not necessarily follow, that the membrane bound fraction has a greater capacity to 
be activated.
3. Based on the assumption that transfected PDE3B is active without any treatment, 
the PKA inhibitor H89 was added at concentrations which have been shown to block 
PKA mediated activation of PDE3B in other systems (63). This was done to prevent 
any unquantifiable PKA-mediated stimulation of PDE 3B occurring under basal 
conditions (see figure 3.2). For the same reason, phosphatase inhibitors were omitted 
from the reaction buffer, so as to heighten the threshold of kinase activation required 
to stimulate PDE 3B;
4. Cilostimide inhibitable activity was measured instead of total PDE activity. There is 
apparently no endogenous PDE3 activity expressed in P2 fractions. This suggests that 
all the cilostamide-inhibitable P2 PDE activity measured in COS-7 cells transfected 
with PDE3B/pSV SPORT is due to the recombinant PDE 3B. Any effects in this 
subset of PDE activity should thus become more obvious.
Using this protocol a -2-3 fold up-regulation of the P2 fraction of PDE3 
activity due to pervanadate was observed in co-transfections with kinase-active 
PDE3B. This did not occur in co-transfections with kinase-dead PKB (figure 3.5.3).
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P K B -  P D E 3  -
P V  P K B -  P D E 3
P K B +  P D E 3  -
P V  P K B +  P D E 3  - * p=0.0005
% of unstimulated PKB-/PDE3 activity
Figure 3.5.3. Pervanadate treatment of F2 fractions of mechanically 
lysed COS-7 cell transfections
Serum starved COS-7 cells were treated with pervanadate (PV) and the effect on 
cilostamide inhibitable activity measured in the P2 fraction. COS-7 cells were mock 
co-transfected with PDE3B (PDE3) and kinase active PKB (PKB+ PDE3) or PDE3B 
with kinase dead PKB (PKB- PDE3). Student's paired T-test was performed to assess 
significance.
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CONCLUSION
3.6. PARTICULATE FULL-LENGTH PDE3B CAN BE SOLUBILISED 
IN COS-7 CELLS
In this study I have characterised three constructs made from the rat PDE3B 
cDNA rcGIP-1. The complete cDNA was subcloned into the mammalian expression 
vector pSV SPORT and the integrity of the open reading frame verified. Two more 
constructs, PDE3BA1 and PDE3BA2, were made which lack certain regions of the 
reading frame. On transfection of these plasmids into COS-7 cells the proteins 
encoded by these plasmids can be detected by immunoblotting with specific 
antibodies. PDE3B has also been detected as PDE3 activity.
In conditions of low ionic strength and absence of detergent similar to those 
used here, others (56,172) have reported that PDE3B was exclusively particulate and 
the data presented here concurs with this. Thus I was unable to detect any soluble 
PDE3B under similar conditions.
Under conditions of high ionic strength or in the presence of non-ionic 
detergent, PDE3B activity has been shown to be solubilised from the particulate 
fractions, albeit to varying degrees depending on the cell type (56) (see table 3.6). 
Immunoblotting of two membrane fractions from COS-7 cells showed that the 
solubility of PDE3B within these fractions varied too. Thus particulate fractions which 
sediment at 3500g (PI, leaving a soluble SI fraction) contained PDE3B which could 
be readily solubilised by detergent but not by high ionic strength. This solubilisation 
probably does not reflect detergent-mediated release of soluble PDE3 from unbroken 
cells because, in the conditions used, there was little or no cytosolic PDE3B. On this 
basis it can be assumed that this PDE activity reflects a genuine release of full length 
PDE3B from the COS-7 cell low speed particulate fraction, rather than release of 
entrapped cytosolic enzyme.
A second particulate fraction was obtained by centrifugation of the SI fraction 
at lOOOOOg (P2). In contrast to the data obtained in the PI fraction, PDE3B in the P2 
fraction was not solubilised in detergent nor in high ionic strength. This is the first 
evidence that pools of PDE3B may associate differently with different membranes in
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the same cell. Thus the partial solubilities of whole cell particulate PDE3B (all the data 
from Leroy et al and Kasuya et al (52,56) in table 3.6 used single particulate fractions) 
may in part be due to them containing heterogeneous pools of particulate PDE3B 
which associate with the membrane in different ways, as has been proposed to explain 
the differences in PDE3B solubilities between cells (56). The differences in tlie PI and 
P2 PDE3B solubilisation are consistent with the notion that membrane bound PDE3 
exists in at least two states as has been suggested by others (52,56). Pertinent to this 
finding, adipocyte fractionation showed that adipocyte PDE3 is found in both the 
plasma membrane and in the endoplasmic reticulum (ratio 20:80) (191). It would be 
interesting to see whether the two states of membrane binding and of targeting (191) 
reflect the same division of PDE3B and if so, to pursue the mechanism by which 
alternative targeting of these conformers alters membrane association.
Data was also obtained which was consistent with the notion that extracellular 
addition of triethanolamine can partially solubilise PDE3B from membranes. Though 
there is evidence that triethanolamine can enter cells through channels (192) and that 
triethanolamine can alter cytoskeletal structure (193), the molecular bases of these 
phenomena are not yet well understood and therefore the solubilisation effect on 
PDE3B was not pursued.
The data presented in this chapter are the first presentation of immunoblots of 
solubilised full-length PDE3B because the two previous studies presented activity data 
only (52,56). The use of immunoblots is an important refinement, inspired by 
previous studies that were only able to establish the unequivocal membrane association 
of the PDE4A RDI by immunoblotting in place of activity measurements (110,112).
The previous works on PDE3 membrane association are open to two criticisms that 
solubilised PDE3 activity may not be due to solubilised full length PDE3. (1) The 
soluble activity may represent truncated forms of PDE3A or PDE3B which are known 
to exist in real cells by alternative splicing (174) and which are likely to be present also 
in recombinant systems due to aberrant translation initiation events at methionines 
downstream of the true initiator methionine (56). These forms are known to be 
partially particulate (52,56) but are more readily solubilised than the full length foims
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(56). By weight on the immunoblot, release of full-length PDE3B could be studied in 
isolation. The soluble activity measured could also be due to full-length or truncated 
PDE3A species but again, the immunoblot analyses employed in this study used 
antibodies specific for PDE3B (56) and thus PDE3B solubility was studied in 
isolation. (2) The release of activity from particulate fractions probably overestimates 
the amount of PDE3 mobilised because the activity data obtained here, and that 
presented in previous work (52,56), supports tire notion that solubilised PDE3 activity 
is ~2 times more active than when it is associated with the membrane and therefore a 
calculation of solubilisation due to activity release will overestimate the amount of 
PDE3 protein released.
Thus, by use of immunoblotting this work is the first unequivocally to 
demonstrate mobilisation of full-length PDE3B or indeed any full-length PDE3 from a 
particulate fraction. By finer fractionation of cells than previously, novel intracellular 
variations in the membrane association of PDE3B have been demonstrated. The 
significance of these findings is discussed below.
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Material
Source
Fraction
Examined
Solubility in 
detergent
Solubility in 
Na Br
Solubility in 
Detergent & 
Na Br
Reference
Adipocyte^ lOOOOOg PI 38% 16% 89% (56)
NIH3006
Fibroblast^
lOOOOOg PI 23% 10% 64% (56)
NIH3006
Fibroblast^
whole cell 71-87% 18-23% n.d. (56)
Sf9 cellsh2 whole cell n.d. n.d. 20-30% (52)
COS-7 3500g PI -50% none
detected^
n.d. This study
COS-7 lOOOOOg P2 <5% none
detected^
n.d. This study
1 These studies use activity measurements and so are only a guide to the true 
proportions of soluble PDE3B since soluble PDE3 is more active than particulate 
PDE3 (52,56) (see section 3.6)
2 These studies were on PDE3A but on the basis that regions of the N-terminal of 
PDE3A and PDE3B are conserved it has been suggested that these results may also 
apply to PDE3B
3 In the experiments in this chapter lOOOmM Na Cl was used in place of 500mM Na 
Br
n.d. = not detennined
Table 3.6. Summary of effects of detergent and high ionic strength on 
the membrane association of full length PDE3
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3.7. DELETION OF THE PUTATIVE INTEGRAL MEMBRANE 
BINDING DOMAIN EFFECTS SOLUBILITY OF PDE3B.
The particulate nature of full length PDE3B in conditions of low ionic 
strength and low detergent has already been discussed as has the fact of increasing 
solubility with greater N-terminal truncations of PDE3 (52,56). A new truncation 
construct, PDE3BA1, which removes 150 amino acids (amino acid residues 101 to 
266) of the hydrophobic putative N-terminal integral membrane binding domain, also 
altered some aspects of PDE3 solubility. Similarly to PDE3B all of the PDE3BA1 was 
particulate in low ionic strength and the absence of detergent. The PI and P2 fractions 
also showed the same differences in detergent solubility that were seen for the full 
length PDE3B. On this basis the truncation did not eliminate the triton soluble 
membrane-association domain. This could either be because PDE3BA1 has a large 
enough remnant of the putative domain's amino acids for an integral membrane helix 
(173) or because a triton soluble domain resides elsewhere in the N-terminal 600 
amino acids of PDE3B. Yet, despite these similarities between PDE3B and PDE3BA1, 
the latter was found to be soluble in high ionic strength, in contrast to the resilience of 
PDE3B to this treatment.
3.7.1. Central sequences of PDE3B harbour a membrane association 
domain which is sensitive to ionic strength.
As shown in figure 3.3.3.C, PDE3BA1 contains extra N-terminal sequences 
on either side of the putative membrane association domain when it is compared to the 
truncations used by Kasuya et al (52) or by Leroy et al (56) (the beginning of the 
largest of the largest construct used by Kasuya et al (52) or Leroy et al (56) is marked
express
with an asterisk in figure 3.3.3.C.) PDE3BA2 was designed to. the 73 amino acids 
preceding the putative membrane association domain (see figure 3.3.3.C.) to test 
whether this sequence could associate with the membrane. It was found that this 
sequence is entirely soluble.
These studies on PDE3B, PDE3BA1 and PDE3BA2 in COS-7 cells are 
consistent with the existence of a novel membrane association domain sensitive to
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ionic strength. This domain is located towards the middle of PDE3B, beyond the 
sequence already proposed and also outside of the first 73 residues of PDE3B. It is 
therefore likely to be present between residues 267 and around 600 (since 613 is the 
start point of the longest totally soluble PDE3 (56)). This triton insoluble domain is 
evident in all PDE3B association with the P2 fraction but not all association with the 
PI fraction PDE3B because a component of this fraction is triton soluble. Such a 
domain is implicit in previous data (52,56) and could explain why detergent treatment 
solubilises particulate PDE3 from different sources incompletely and variably (see 
table 3.6) (52,56). The ion-strength soluble domain at least does not coincide with tlie 
putative integral membrane binding domain (54) or with the extreme N-terminal of 
PDE3B. With the caveats given in the previous section (section 3.7) this may be true 
of the membrane association functioning through hydrophobic interactions ablated by 
triton. It is possible that the two putative domains are both found within residues 267- 
600. This region of PDE3B is in fact the next best conserved between PDE3A and 
PDE3B after their catalytic domains, with conservation exceeding that of Taira's 
putative membrane association domain (27% amino acid identity versus 22% for the 
Taira's putative membrane association domain and 8% for the extreme N-terminal 
sequence which contains all the sequence of PDE3BA2 (58), see figure 1.6.1). This 
conservation may be in part due to the existence of a conserved membrane binding 
detenninant.
3.7.2. Future work
This work was discontinued as a result of a collaboration breaking down. 
Future work to show the distribution of the ionic-strength sensitive domain should 
involve reassessment of the solubility of finer fractions of PDE3B activity in cell types 
already examined, NIH3006 and adipocytes. These studies should use immunoblots, 
not activity readings as a measure of the amount of PDE3B solubilised. Existing 
nested N-teirainal deletion constructs (174) could then be used to map more precisely 
the position of the domain in PDE3B. Once it is known which parts of the protein are 
responsible for which components of the membrane association, it should be easier to
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study these functions exhaustively. The figure (3.7.2) below summarises the effects 
of this work in this mapping.
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(a)
Ionic-strength sensitive  m em brane associa tion  dom ain
1 611 M  ►
P H F  3 B
1 73 251 1108M--------------------►
1 611
M-------- ►
267 611
Triton solub le m em brane associa tion  dom ain High Ionic
(b) D etergent strength
Localisation so lub le?  released ?
11-08- PDE SB
PDE 3BA1 
A 102-266
PDE SB A2 
A 73-1108
VSV
pi partial nop2 no no
partial yes
no yes
■ PDE3AA p l/s l n.d n.d.
A 1-483
. PDE3AA p1/s1 n.d n.d.
A 1-511
, PDE 3A A si - n.d.
A 1-611
Figure 3.7.2. Schematic summary of membrane binding determinants in 
PDE3
(a) Above full length PDE3, witli its putative membrane association domain shown in 
thick line (54), are the limits for the triton insoluble membrane association domain 
before (top) and after (bottom) the data presented in this chapter. Arrows beneath 
PDE3B show the same information for the triton soluble component of membrane 
association, (b) The schematic constructs summarise localisation and solubility 
information for PDE3,constructs; those for PDE3B are from this chapter, those from 
PDE3A are from (52,56).
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3.8 PERVANADATE TREATMENT ACUTELY ACTIVATES PDE3B 
ACTIVITY FOLLOWING COTRANSFECTION WITH PKB+
Following treatment of cells with pervanadate, PDE3B/PKB+ cotransfections 
show a 2-3 fold increase in PDE3 activity in the particulate fraction P2. This effect is 
apparently specifically due to PKB because identical cotransfections of PDE3B which 
replace PKB+ with PKB- did not show a similar increase in PDE3 activity. Previous 
studies on P2 fractions which have shown a similar up-regulation of PDE3B activity 
have claimed it as an activation. The increased total PDE activity in S 1 samples of 
kinase active PKB/PDE3B cotransfections versus kinase dead PKB/PDE3B 
cotransfections is certainly consistent with an overall up-regulation of PDE activity due 
to kinase active PKB transfections compared to kinase-dead. The activation in P2 
com pares favourably with other stim ulations of PDE3 (49,172,177- 
179,182,183,191,194). This preliminary result suggests that PKB is capable of 
activating PDE3B under the regulation of the insulin mimetic pervanadate. My finding 
is therefore consistent with the notion that insulin signals to PDE3B in a kinase 
cascade which includes PKB. Recent published data supports this finding. Thus, 
Wijkander et al (195) have shown that PKB and the PDE3IK, whose activity was 
measured by in v itro  assay, have the same chromatographic properties. It has also 
been shown that PKB and PDE3IK translocated to the membrane in response to 
pervanadate (195), this is the same stimulus as I used.
3.8.1 Future experiments
Now that PKB has been implicated in PDE3B signalling, it is important to 
reproduce these experiments in adipocytes or an adipocyte cell line. An additional tool 
which would be very useful for examining in vivo  PKB signalling would be a specific 
inhibitor for this kinase. Demonstration of this putative signalling pathway in the 
correct physiological context may allow other crucial questions to be answered.
First, the inhibitor H7 is a potent inhibitor of PKA and PKC but several 
papers purport that this is not the case for PDE3IK (177-179). PKB is most closely 
conserved with PKA and PKB amongst the kinases and thus it is probable that PKB is
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also a target for H7. Thus, if the data of Shibata et al (177-179) were true it would 
argue that PKB does not lie in the true physiological path of signalling from insulin to 
PDE3B. However, when Shibata et al used very high concentrations of H7 (178,179) 
they obtained it from Sigma and this supply was subsequently shown to be 
considerably less potent than advertised (196). It might therefore now be worthwhile 
reassessing the potency of H7 in inhibiting PDE3IK. The inhibitor H89 used in this 
study is more specific for PKA and thus it is less likely that this inhibitor will inhibit 
PKB
Second, the single site of activation and phosphorylation of PDE3B is at 
serine 302. This site is not likely to be a PKB site and thus there would have to be at 
least one other step between PKB and PDE3B in this scheme. Indeed, PKB appears 
not to phosphorylate PDE3B at serine 302 (195). The existence of a specific inhibitor 
for PKB might facilitate identification of this new PKB target.
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USE OF DEGENERATE REVERSE TRANSCRIPTION POLYMERASE 
CHAIN REACTION TO IDENTIFY A PROTEIN KINASE C-INDUCED 
C a 2  + / C a M  S T I M U L A T E D  C Y C L I C  N U C L E O T I D E  
PHOSPHODIESTERASE FOR WHICH NO SEQUENCE WAS 
AVAILABLE
INTRODUCTION
4.1. A PROTEIN KINASE C MEDIATED INDUCTION OF PDEl 
ACTIVITY
The cyclic AMP and lipid signalling patliways both provide major routes for 
controlling cellular function (20,197,198). Recently it has become established that 
interplay between these systems modulates the functioning of regulatory pathways, 
which has given rise to the notion of 'cross-talk' (10). Protein kinase C appears to 
play a key role in mediating such interactions between the lipid and cyclic AMP 
signalling system.
Protein Kinase C (PKC) activity is provided by a multi-gene family, the 
protein products of which are grouped on the basis of their distinct structural and 
biochemical properties (199,200). 'Conventional' PKCs (a , pi, pil and y) are 
calcium and diacylglycerol (DAG) sensitive whereas 'non-conventional' PKCs (e, 5,
0, jLL and T\) are calcium-insensitive. There are also atypical PKCs (C,X,x) which are 
structurally related to the other PKCs but whose activities are not regulated by either 
DAG or phorbol esters (201). There is evidence that particular PKC isoforms may 
have discrete functional roles, which is consistent with their exhibiting distinct 
biochemical characteristics and tissue distributions (199,200). This is seen in the 
various cell specific effects of PKC on cAMP signalling (10)
PKC regulates cAMP concentrations in many ways. It can modulate the 
functioning of stimulatory and inhibitory receptors (10), the inhibitory G protein Gi_2 
(5,10,202) and adenylate cyclase itself (10,203-205). An example of selectivity in 
such processes is that both PKCÇ and PKCa can selectively activate a specific 
adenylyl cyclase isofonn, namely adenylyl cyclase V (203). Additionally, tlie ability of
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PKC to attenuate the action of the inhibitory G-protein Gi appears to show cell 
specificity (5,10,202). There is also evidence that PKC may effect the activity of 
PDEs in certain cells (10,206).
The presented study originated from an observation made by Dr S. Spence in 
this laboratory, namely, that PMA and ligands able to activate lipid signalling 
processes can generate a rapid induction of calcium/calmodulin stimulated 
phosphodiesterase (PDEl) activity in Chinese hamster ovary cells. This appeared to be 
a novel PDE activity because wild-type Chinese hamster ovary cells (CHO-K) and 
Chinese hamster cells which had been stably transfected to overexpress the insulin 
receptor (CHO-T cells), demonstrated cAMP phosphodiesterase activity which was 
insensitive to Ca^+ZCaM (50|iM 20ngml-i), indicating an absence of PDEl activity 
(163). However, when CHO-K or CHO-T cells were challenged for 6h with the 
protein kinase C activator PMA (10 nM), the actinomycin D attenuable appearance of 
PDEl activity was detected (163). This is consistent with a novel PDEl activity being 
produced de novo by induced transcription. This novel PDEl activity was apparent 
within 25min, reached a maximum after a number of hours and then declined, thus 
being transient in nature. Additionally CHO-T cells stably expressing PKC a  or PKC 
e exhibited elevated PDE activity which is entirely attributable to Ca^+ZCaM- stimulated 
PDEl activity, whereas CHO-T cells stably transfected with PKC pi or PKC y  
exhibited PDE activity similar to untransfected CHO-T cells (163). This was taken to 
suggest that transcriptional control of this PDE gene may be regulated by specific PKC 
isoforms in CHO cells. Such an ability to induce novel PDEl enzyme is not restricted 
to PMA but could also be seen with occupancy of endogenous receptors which are 
known to be coupled to lipid-signalling processes which produce DAG. These include 
agonists for endogenous Pz-purinoreceptors, lysophosphatidic acid receptors and 
thrombin receptors (207).
4 .2 . D E S IG N  O F  M O L E C U L A R  P R O B E S  F O R  U SE  IN  
G EN ETICA LLY  U N DER-CHARACTERISED SYSTEM S
The identity of the PDEl isofonu involved in the PDEl induction in Chinese
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hamster ovary cells was not known. Therefore I set out to identify which of the three 
PDEl genes (see Introduction) was involved. As with any system which is not a 
major genetic model such as human and rat, the problem here is one of molecular 
probe design. Antisera able to detect PDEl in a species independent fashion are 
unavailable. Furthermore, when this work was initiated, there was no published PDEl 
sequence from Chinese hamsters. The absence of these data precluded analysis of 
protein by Western blotting or of transcripts by Northern blotting. By a rigorous 
rational application of information from the model species I was able to design low 
degeneracy PCR probes able to detect PDEl forms in a range of species.
It is usual to design primers for unknown genes to the sequences of known 
homologues, using conserved sequence containing several low redundancy codons, 
for example, those that code for phenylalanine. Then degeneracy can be minimised 
using codon usage tables for the particular organism. However, the final primer 
design is still often highly degenerate and the effectiveness of such primers in RT- 
PCR may be reduced because of this. This is presumably because of the dual effects 
of more non-specific reactions occurring and a lower effective concentration of 
cognate primer. Furthermore, low degeneracy codons on which this approach 
depends, code for rare amino acids such as tryptophan, histidine, cysteine and this,
fornecessarily, seriously restricts sequences which can be used.^such an approach (figure 
4.2).
To circumvent these problems I adopted a modified rationale in probe design. 
Selection of sequence conserved between two PDEl genes (PDEl A & PDEIB) from 
various species but differing from other closely related genes, aimed to identify very 
highly conserved regions of sequence since it is to be expected that sequences well 
conserved between genes will also be conserved between species. Having identified 
such sequences, probes for use in RT-PCR analyses could be designed to detect the 
lowest redundancy codons in this conserved gene sequence. Primers designed in this 
way would thus be far less degenerate. Using such an approach I was able to 
selectively detect PDEl transcripts in a range of species. This was despite die absence 
of enough published information to identify phylogenetically conserved PDEl A
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specific sequence.
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Figure 4.2. Amino acid usage increases as a function of the number of 
codons that code for the amino acid.
The graph shows the average number of times an amino acid is expressed per 
1000 residues (Y axis) against the number of codons that code for that amino acid (X 
axis). All but one of these values is the mean for all of the amino acids that have that 
number of codons. Thus: x=l is a mean of met and trp; x=2 a mean of phe, tyr, his, 
gin, asn, lys, asp, glu, cys; x=3 the value for ile; x=4 a mean of val, pro, thr, ala, gly 
and x=6 is a mean of leu, ser and arg. Raw data taken from a National Center for 
Biotechnology Information codon usage table derived from 1,697,109 mouse (mus 
musculus) codons.
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RESULTS
4.3. DESIGN OF PROBES TO PHYLOGENETICALLY STABLE 
SEQUENCES OF PDEl
4.3.1. Design of primers GR18 & GR19 to phylogeneticaily conserved 
PDEIA and PDEIB specific sequence.
Several sequences for PDEl forms were available at the start of this study. 
These sequences were (with GenBank accession numbers in brackets) for PDEIA 
from bovine (M90358) (32) and PDEIB from bovine (M94867) (34), rat (M94537)
(36), mouse (M94538) (36) and human (M94539) (36) sources. The existence of only 
one species' PDEIA sequence (accessions L34069 and M90358 (32)) made it 
impossible to identify phylogeneticaily conserved PDEIA specific sequences. The 
next best option was to identify phylogeneticaily conserved sequences in all PDEl 
forms. I thus set out to see if I could identify a stretch of sequence conserved between 
PDEl genes but which was not found in other PDE genes. The ability to locate such a 
region would enable primers to be designed which, when used in RT-PCR, would be 
expected to detect the presence of PDEl in a species-independent fashion. This would 
allow detection of the presence of transcripts for PDEl in RNA from CHO cells using 
RT-PCR.
To attempt this I first perfonned a multiple gap alignment of the complete and 
partial PDEl nucleic acid sequences listed above. This revealed substantial homology 
across the whole reading frame (52% identity among four complete sequences). I then 
analysed in detail a -1250 base pair stretch of sequence (nucleotides 440-1700 in 
mouse) which contains sequence encoding the putative catalytic domain (19) which 
showed >56% identity between the sequences. This region exhibited homology with 
the central domain of vaiious PDE types other than PDEl (including PDE2, PDE3 and 
PDE4). However, three stretches (figure 3.3.1.a; regions X, Y & Z) appeared to 
show high similarity between PDEl forms from various sources but were not present 
in other PDE subtypes. These were nucleotides 669-699 (region X; numbering for 
mouse PDEIB), which showed 77-96% identity, nucleotides 1243-1261 (region Y) 
which showed 88-100% identity and nucleotides 1330-1369 (region Z) which showed
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83-98% identity in pairwise alignments between different PDE Is. In contrast, for 
example, in alignment analyses done with four PDEs then region X showed only 3% 
identity, region Y 19% identity and region Z 49% identity. Similar results were 
evident for PDE2, PDE3 and PDE7. Therefore the alignments had exposed three 
phylogeneticaily stable sequences which appeared to be uniquely conserved in PDEl 
genes. In order to amplify a manageable fragment, degenerate primers (GR18 and 
GR19) were designed to regions X and Y. The sequences used for the primers were 
chosen so that degeneracy could be minimised. The primers were thus designed in the 
expectation tliat they would specifically amplify a 601 base pair fragment in PDEl in a 
range of species given the apparent phylogenetic stability of the sequences I identified.
The conserved sequences so identified were recently, subsequent to this 
study, shown to be conserved in a new PDEl gene. However the functional roles 
which presumably underlie this PDEl-specific conservation remain obscure. The 
sequences identified outside the catalytic domain do not converge with PDEl 
functional domains identified to date. These domains are a calmodulin binding 
domains and an inhibitory domain, both identified by Sonnenburg et al (33) (figure
4 .3 .l.b ).
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1252 bp
1243-1261 1330-1369
G CCTCATCAGCCGCTTTAAG ATTCC 
prim er 
GRIB
R YCT YATC AR C C G YTT YA AG ATTC
m ouse se q u e n c e  
G AACT OTTCC ATT AGG GCCTTGG 
prim er 
GR19
RAAYTCYTCCATKAGGGCCWTGG
1691
669-699
601 bp
Figure 4.3.1.a. Design of primers GR18 & GR19 to phylogeneticaily 
conserved PDEIA and PDEIB specific sequence.
As described in the text, pairwise alignments of PDEl cDNAs exposed 
> 1.2Kb of highly conserved sequence. Within this region, three shorter stretches were 
identified which were highly conserved between PDEl cDNAs but not other 
phosphodiesterases (hatched boxes X-Z). These were nucleotides 669-699 (region X; 
numbering for mouse PDEIB), which showed 77-96% identity, nucleotides 1243- 
1261 (region Y) which showed 88-100% identity and nucleotides 1330-1369 (region 
Z) which showed 83-98% identity in pairwise alignments between different PDE Is 
but negligible identity with other PDEs (163). Sequences were selected for primers in 
regions A and B (mouse sequence shown and actual primer sequence with degeneracy 
allowing perfect matching with every known PDEIA and PDEIB sequence). The 
predicted fragment size, 601 base pairs, is also shown.
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1 MGSSATEIEE LENTTFKYLT GEQTEKMWQR LKGILRCLVK QLERGDVNVV
51 DLKKNIEYAA SVLEAVYIDE TRRLLDTEDE LSDIQTDSVP..SEVRDmAST
101 FTRKMGMTKK KPEEKPKFRS IVHAVQAGIF VERMYRKTYH MVGLAYPAAV
151 IVTLKDVDKW SFDVFALNEA SGEHSLKFMI YELFTRYDLI NRFKIPVSCL
X
201 ITFAEALEVG YSKYKNPYHN LIHAADVTQT VHYIMLHTGI MHWLTELEIL
251 AMVFAAAIHD YEHTGTTNNF HIQTRSDVAI LYNDRSVLEN HHVSAAYRLM
301 QEEEMNILIN LSKDDWRDLR NLVIEMVLST DMSGHFQQIK NIRNSLQQPE
351 GIDRAKTMSL ILHAADISHP AKSWKLHYRW TMALMEEFFL QGDKEAELGL
Y
401 PFSPLCDRKS TMVAQSQIGF IDFIVEPTFS LLTDSTEKIV IPLIEEASKA 
Z
451 ETSSYVASSS TTIVGLHIAD ALRRSNTKGS MSDGSYSPDY SLAAVDLKSF
501 KNNLVDIIQQ NKERWKELAA QEARTSSQKC EFIHQ
Figure 4.3.1.b. The amino acid sequences of regions X, Y and Z do 
not coincide with PDEl specific conserved features with defined 
functions
The amino acid sequence of Human PDEIA (U40370) is shown. Regions X, 
Y and Z are shown double underlined. A conserved PDEl inhibitory domain is shown 
with a single dashed underline (33). The calmodulin binding domain of PDEl is 
shown with a single underline (33). Serine 120 (bold) can be phosphorylated by PKA 
and this alter the affinity of the PDE for calmodulin. Regions X-Z do not coincide with 
these motifs.
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4.3.2. Design of PCR primers GR45 and GR46 to a phylogeneticaily 
conserved PDEIC specific sequence.
A third PDEl gene, PDEIC, was described recently (29-31). This was 
reported subsequent to the design, use and publication of the PDEIA and PDEIB 
specific probe already discussed (163). Although the PDEl-specific sequences already 
identified are partially conserved in PDEIC, the changes in PDEIC are sufficient that 
probes GR18 & OR 19 will be unlikely to be able to detect transcripts from this gene. 
Therefore, in an attempt to design PDEIC specific probes, primers were designed to 
low-degeneracy codon, phylogeneticaily stable PDEIC specific sequence. This was 
done using the conventional method already described in section 3.1. Such an 
approach was possible here because, unlike PDEIA, PDEIC sequence was available 
from more than one species. By perfonning pairwise gap alignments of human and rat 
PDEIC sequences and other PDEl forms I could identify 500 base pairs of species- 
independent PDEIC specific sequence. This was located between the putative PDEIC 
catalytic domain and the 3' splice junction. Primers were designed to amplify this 
region (figure 3.3.2.).
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430bp PDE1C5
PDE1C2/3/4
PDE1C1
CM  A AG AG ATC  AGGTGTC A AG GTTRGAGTGATCCTTCTTGTCTG
GR45 PDEIC specific sense prim er GR46 PDE 1C specific antisense prim er
Figure 4.3.2. Design of PCR primers GR45 and GR46 to a 
phylogeneticaily conserved PDEIC specific sequence directly  
downstream of the PDEIC catalytic domain.
Schematic of PDEIC genes is shown. Thin solid line is splice variant specific 
sequence. Hatched line is catalytic domain and upstream sequence, which is 
homologous to sequence in other PDEl genes. The length of this sequence is larger 
than is shown in this schematic. 5' splicing of the PDEIC fonns is not shown. Thick 
line is PDEIC specific sequence found between the end of the catalytic domain and the 
3' end splice junctions. Primers GR45 and GR46 were designed to the PDEIC 
specific sequence between the catalytic domain and the splice junctions, as shown. 
The primer sequences and expected fragment size are shown.
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4.4. USE OF PROBES DESIGNED TO PHYLOGENETICALLY  
STABLE SEQUENCES OF PDEl
4.4.1. Use of PDEIA and PDEIB specific primers GR18 and GR19 and 
the PDEIC specific primers GR45 and GR46 in a range of genetic 
backgrounds
The primers GR18 and GR19 were first used in RT-PCR on RNA extracted 
from rat brain. This is known to provide a good source of PDEl mRNA (32,34,36). 
Subsequently RNA from cat brain was used. This allowed for fragment of the correct- 
size (-600 base pair) to be amplified, consistent with the notion that these primers 
could amplify PDEl sequences from more than one species (figure 4.4.1).
The primers GR45 & GR46 also allowed amplification, by RT-PCR of RNA 
from rat brain to identify a fragment of the expected size (-430 bp).
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1353
1078
872
603
310
281/
271
Marker Cat Rat Mock Marker Mock Rat
Figure 4.4.1. Detection of PDEIA, PDEIB and PDEIC specific RT- 
PCR primer pairs
Total RNA was first isolated from tissues and cells and then RT-PCR carried out as 
described in the Method chapter, (a) Using primers GR18 & GR19, designed to 
PDEIA both and PDEIB, I was able to amplify a 6(K)bp band from cat brain and rat 
brain, a tissue in which these forms are known to be expressed (32,34,36). No 
product was evident in a mock reaction with no cDNA. The PCR conditions were 40 
cycles of 94"C for 60s, 50"C for 80s and 72“C for 70s, with hot start' and PCR 
additive Perfect Match' added
Using primers GR45 and GR46 designed to detect PDEIC transcripts, I was able to 
amplify a band of the correct size in RNA from in rat brain cells, where PDEIC is 
expressed (31). No fragment was amplified in a mock reaction containing no cDNA. 
PCR conditions were 40 cycles of 94"C for 60s, 5TC for 70s and 72”C for 70s, with 
hot start' and PCR additive 'Perfect Match' added
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4.4.2. The PDEl specific primers GR18 & GR19 anticipate exactly the 
relevant sequence of human PDEIA
The sequence of a human PDEIA form has now been published (29) 
(GenBank accession U40370). The sequence homologous to that which primers 
GR18 & GR19 were designed to is contained within the modest degeneracy encoded 
widiiii these primers (36x per primer), with no mismatches in either primer. Given tlie 
fact that the only PDEIA sequence in the data set was the evolutionarily distant bovine 
form and given that this single sequence precluded identification of PDEIA specific 
phylogeneticaily conseiwed sequence, this adds further support to the contention that 
the primer sequences identified here using a deductive approach are capable of 
identifying PDEIA in RNA from a range of species.
4.4.3. Use of PDEl specific primers to monitor the induction of PDEl 
by PMA in Chinese hamster ovary (CHO) cells.
The PD El specific primers GR18 & GR19 were used to monitor the 
induction of PDEl in Chinese hamster ovary (CHO) cell lines. Attempts to amplify 
PDEl from RNA extracted from untreated wild type (CHO-K) or from Chinese 
hamster cells stably transfected to overexpress the insulin receptor (CHO-T), were 
unsuccessful. This is consistent with CHO-K and CHO-T PDE having activity 
profiles which suggest that there is no PDEl activity present (163). However, RT- 
PCR using primers GR18 & GR19 on RNA extracted from CHO-K or CHO-T cells 
that had been challenged with PMA (6h; lOnM) detected a single band of the 
anticipated size, consistent with there having been an induction of transcripts. This 
concurs with biochemical data which showed that when CHO-K or CHO-T cells were 
treated with PMA, an actinomycin D-inhibitable appearance of PDEl activity was 
detected (163).
Conversely, I was singularly unable to detect transcripts using PDEIC 
specific primers, consistent with the notion that PDEIC was not expressed in these 
cells even following PMA treatment.
Chapter 4: An induction o f  P D E IB  140
4.4.4. Use of PDEIA and PDEIB specific primers to monitor the effect 
of stable transfection of PKC isoforms on the presence of PDEl 
transcripts in Chinese hamster ovary cells.
When the presence of PDEl transcripts was determined in RNA taken from 
CHO-T cells stably transfected with PKC isofoiras it was found that ti'anscripts could 
be detected in RNA from cells expressing PKC a  or PKC e but not PKC pi or PKC 
y. This is consistent with the observed biochemical data where CHO-T cells stably 
expressing PKC a  or PKC e exhibited up-regulated PDEl activity compared to PKC 
pi or PKC Y which failed to exhibit such activity (163).
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Br c tr k t  e a [i\
k t ji\
Figure 4.4.3. RT-PCR analyses on PDEl transcripts in CHO cells.
This was done as described in Methods with precise conditions as described 
in figure 4.4.1. These experiments probed for PDEIA and PDEIB using primers 
GR18 and GR19. An aiTOw denotes a band of the correct size.
In (a) are shown analyses done on rat brain (Br), control blank (ct), CHO-k 
cells (k), CHO-t cells (t), CHO-e cells (e), CHO-a cells (a), CHO-pi cells (pi) and 
CHO-y cells (y).
In (b) are shown analyses done on cells which had been treated with PMA 
(lOnM) for 6h prior to harvesting. These are for CHO-k cells (k) CHO-t cells (t) and 
CHO-pI cells (pi). Data show typical experiments perfonned at least three times with 
different cell preparations.
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4.4.5. Use of PDEl specific primers to monitor the induction of PDEl 
transcripts in Chinese hamster ovary cells stimulated with ATP, a ligand 
for an endogenous lipid signalling receptor
CHO cells express endogenous P2-purinoceptors (208) which are able to 
stimulate inositol phospholipid metabolism and increase intracellular Ca^+ (209). Thus 
one might expect that the DAG produced would be able to activate endogenous PKC 
identified in these cells (199) and thence to activate PDEl. Employing a concentiation 
of ATP (lOOjiM) which has been shown to activate maximally inositol phospholipid 
metabolism in CHO cells (209), I identified a PDEl transcript by RT-PCR using 
primers GR18 and GR19 able to detect PDEIA and PDEIB (see figure 4.4.5.). This 
was consistent with the observed ability of ATP to cause an actinomycin D inhibitable 
up-regulation of PDEl activity (207).
As with the experiments on cells challenged with PMA, no transcripts for 
PDEIC were detected in the RNA from CHO cells either before or following 
stimulation willi ATP.
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Figure 4.4.5. RT-PCR analyses of PDEl transcripts in CHO cells
This was done as described in the methods with the conditions used as 
described in the legend to figure 4.4.1. An arrow denotes bands of the correct size. 
Lane 1-3 shows the result of PCR reactions using the primer pair GR18 & GR19 for 
detection of PDEIA or PDEIB transcripts. Lane 4 & 5 shows reactions using primer 
pair GR45 and GR46 for the detection of PDEIC transcripts. Shown are data using 
RNA from CHO cells treated with lOOjiM ATP (lanes 1&5), FTC-133 cells* (lanes 
2&4) and blank (track 3).
*These are a thyroid carcinoma cell line (115), see section 4.4.7.
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4.4.6. The Ca^*/CaM-stiniuIated PDEl enzyme in CHO cells is PDEIB
The RT-PCR analyses done on RNA from stimulated CHO cells supports the 
notion that either PDEIA or PDEIB but not PDEIC was induced by treatments which 
caused an increase in PKC activity (section 4.4.5). Since primers GR18 & GR19 
were designed to identify transcripts for PDEIA and PDEIB, it was necessary to 
clone and sequence bands from RT-PCR to discriminate between these two 
possibilities. Sequences of six separate clones of the 601 bp band amplified from 
PDEl induced CHO cells from either PMA or ATP treated cells were identical. Pair­
wise alignments found that the three existing PDEIB sequences shared 91-95% 
nucleotide identity with the Chinese hamster sequence whereas the PDEIA and PDEIC 
sequences were only 68-69% identical with the new sequence (figure 4.4.6.a). As 
might be expected, most of the mismatches occur at 'wobble' positions, such that the 
conservation between the Chinese hamster sequence and the homologous PDEIB 
sequences was even more marked at the amino acid level. Thus, the Chinese hamster 
sequence had 99% amino acid identity when compared to the other PDEIB sequences, 
but only 65-69% when compared to the non-homologous PDEIA and PDEIC 
sequences (figure 4.4.6.b.). I am thus able to assign my sequences as PDEIB forms 
(207) (figure 4.4.6.c).
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consensus.
C. Hamster I  B (1-602) 
human IB (1-554) 
human I  A (647-1248) 
human I  Cl (766-1370)
RCCTCATCAGCCGCTTYAAGATTCCCACWGTG 
"CTCATCAGCCGÛTTTAAGATTCCCACTGTG
CACTGTG
AÏÏCTMATCAScCGnTTCAAGATTCCiraT 
auctSatcagccguttcaagatScccaut
32 
32 
7
32 
TCT 32
consensus.
C. Hamster I  B (1-602) 
human IB (1-554) 
human I  A (647-1248) [jG 
human I  Cl (766-1370) GC
TTTYTGATGASTTTYCTGGAKGCCTTRGAGAC
tttctgatgagttttctggaggccStggagac
ttttSgatgagtttcctggatgccttggagac
64 
64 
39 
64 
GT 64
GT
consensus.
C. Hamster I  B (1-602) 
human IB (1-554) 
human I  A (647-1248) 
human I  Cl (766-1370)
consensus.
C. Hamster I  B (1-602) 
human IB (1-554) 
human I  A (647-1248) 
human I  Cl (766-1370)
consensus.
C. Hamster I  B (1-602) 
human IB (1-554) 
human I  A (647-1248) 
human I  Cl (766-1370)
GCTTCYTKCTCCGC
gcttHctgctccgc
TTGC
CTATAA
consensus.
C. Hamster I  B (1-602) 
human IB (1-554) 
human I  A (647-1248) 
human I  Cl (766-1370)
GCACTGCCTGTCRGAGATTGAGGTCYTGGCCA
GCACTGCCTGTCAGAGATTGAGGTCTTGGCCA
gcactgcctgtcggagattgagStcctggcca
G0ACTG5CTG0CGGAGiHfGAG0TCTT
192
192
167
192
192
consensus.
C. Hamster I  B (1-602) 
human IB (1-554) 
human I  A (647-1248) 
human I  Cl (766-1370) HA
TCATCTTYGCKGCAGCCATCCAYGACTATGAG
TCATCTTTGCTGCAGCCATCCATGACTATGAG
tcatctttgctgcagcQatccatgahtatgag
^TCTTTGCTGCHGCCATQCATGAUTATGAG
atcttcîîcSgcugccatccatgactaSgag
224
224
199
224
224
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consensus.
C. Hamster I  B (1 -602) 
human IB (1 -554) 
human I  A (647-1248) 
human I  Cl (766-1370)
consensus.
C. Hamster I  B (1 -602) 
human IB (1 -554) 
human I  A (647-1248) 
human I  Cl (766-1370)
consensus.
C. Hamster I  B (1 -602) 
human IB (1 -554) 
human I  A (647-1248) 
human I  Cl (766-1370)
consensus.
C. Hamster I  B (1 -602) 
human IB (1 -554) 
human I  A (647-1248) 
human I  Cl (766-1370)
AYCGMTCRGTGCTGGAGAATCACCACATCAGC
ATCGCTCGGTGCTGGAGAATCACCACATCAGC
atcgOtcagtgctggagaatcaccacatcagc
ATCGCTCÿGTScTÜGAGAATCACCACffiTgAG 
ACSGATCUGTlcTGGAGAATCACCAlilTWAG
320 
320 
295 
T 320 
T 320
GA 352
consensus.
C. Hamster I  B (1 -602) 
human IB (1 -554) 
human I  A (647-1248) 
human I  C l (766-1370)
consensus.
C. Hamster I  B (1 -602) 
human IB (1 -554) 
human I  A (647-1248) 
human I  Cl (766-1370)
consensus.
C. Hamster I  B (1 -602) 
human IB (1 -554) 
human I  A (647-1248) 
human I  Cl (766-1370)
ATGAACATYTTYATCAAYCTCACCAAGGATG
ATGAACATTTTTATCAATCTCACCAAGGATG
ATGAACATTTTCATCAACCTCACCAAGGATG
ATGAAnATCTTffAT0AATOTfflCCAA0GATG
atgaauattttBatuaacctcucPaaggatg
381
381
356
381
384
CYCTGGTY
ccQtggtt
CCCTGGTC
CCUTGGT0ATTG
ATGGTGTTRGCCACAGACATGTCCTGCCATTT
ATGGTGTTGGCCACAGACATGTCCTGCCATTT
ATGGTGTTGGCCACAGACATGTCCTGCCATTTATGGTQTTAQcQACAGACATGTCgGHCAgTT
atggtgBtggccacagaHatgtcutgucaBtt
445
445
420
445
448
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consensus.
C. Hamster I  B (1-602) 
human IB (1-554) 
human I  A (647-1248) 
human I  Cl (766-1370)
consensus.
C. Hamster I  B (1-602) 
human IB (1-554) 
human I  A (647-1248) 
human I  Cl (766-1370)
consensus.
C. Hamster I  B (1-602) 
human IB (1-554) 
human I  A (647-1248) 
human I  Cl (766-1370)
consensus.
C. Hamster I  B (1-602) 
human IB (1-554) 
human I  A (647-1248) 
human I  Cl (766-1370)
AGCAGYTKGARAGGATTGACAARTCCAAGGCC
AGCAGCTGGAAAGGATTGACAAGTCCAAGGCC
aEcagctggagaggattgacaagtccaaggcc
509
509
484
509
512
consensus.
C. Hamster I  B (1-602) A T ^ ^  
human IB (1-554) ~
human I  A (647-1248) 
human I  Cl (766-1370)
GCTGGACCAAGGCCCTMATGGARGARTTC 
GGACCAAGGCCCTCATGGAGGAGTT
GgTGGACCAllGGCCCTAATGGAGGAGTT 
GCTGGACfAUGUCPCTCSTGGAGGAGTTC
602
602
554
602
605
Figure 4.4.6.a Sequences of PDEl transcript PCR products.
Sequences of PCR products amplified using the PDE1A7B species- 
independent primers from PMA treated CHO cells and from human Jurkat T-cells 
(GenBank accession numbers U40585 & U40584 respectively) are shown compared 
with the equivalent region of human PDEIA and PDEIC sequences. Alignment 
mismatches (black on white) are shown with respect to a degenerate consensus of 
three PDE IB sequences: mouse, rat and bovine (GenBank accession M94538, 
M94537 & M94867 respectively). This shows that the novel sequences share a higher 
degree of homology with PDEIB forms than do PDEIA or PDEIC forms (human 
PDEIC and human PDEIA (GenBank accession U40370 and U40371 respectively) 
are shown in this alignment). Note that these PCR fragments were TA cloned by Dr 
Michael Sullivan
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mouse I  B pep 
Chinese hamster pep 
human I  B pep
mouse I  B pep 
Chinese hamster pep 
human I  B pep
mouse I  B pep 
Chinese hamster pep 
human I  B pep
mouse I  B pep 
Chinese hamster pep 
human I  B pep
mouse I  B pep 
Chinese hamster pep 
human I  B pep
LISRFKIPTVFLMSFLEALETGYGKYKNPYHNQIH
LISRFKIPTVFLMSFLEALETGYGKYKNPYHNQIH
tvfEmsflEaletgygkyknpyhnqih
AADVTQTVHCFLLRTGMVHCLSEIEVLAIIFAAAI
AADVTQTVHCFLLRTGMVHCLSEIEVLAIIFAAAI
aadvtqtvhcfllrtgmvhclseieI l a iif a a a i
HDYEHTGTTNSFHIQTKSECAILYNDRSVLENHHI 
HDYEHTGTTNSFHIQTKSECAILYNDRSVLENHHI 
HDYEHTGTTNSFHIQTKSEC AIÎÎYNDRSV L ENHHI
ssvfrmmqddemnifinltkdefSelralviemvl
SSVFRMMQDDEMNIFINLTKDEFVELRALVIEMVL
ssvfrI mqddemnifinltkdefvelralviemvl
ATDMSCHFQQVKTMKTALQQLERIDKSKALSLLLH
atdmschfqqvk| mktalqqleridkskalslllh
ATDMSCHFQQVKTMKTALQQLERIDKSKALSLLLH
mouse I  B pep ggg
Chinese hamster pep 
human I  B pep
ISHPT
ISHPT
35
35
27
70
70
62
105
105
97
140
140
132
175
175
167
200
200
184
Figure 4.4.6.b Amino acid sequence alignment of mouse PDEIB and 
novel Chinese hamster ovary PDEl forms from this study.
Amino acid sequences of PCR products amplified using the PDEIA/B 
species-independent primers from PMA treated CHO cells (GenBank accession 
number U40585) and from human Jurkat T-cells (GenBank accession number 
U40584) are shown aligned with mouse PDEIB (GenBank accession M94538). The 
large number of matches to the simple majority (white on black) demonstrate that these 
sequences are even more closely conserved at the amino acid level as would be 
expected in evolutionarily conserved sequences since many of the mutations in such 
proteins will occur at silent or wobble positions. Furthermore, the majority of 
substitutions are conservative (for example E to D, V to L, S to T)
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m ouse 1 C 
rat 1 C 
^  human 1 C 
human 1 A 
bovine 1 A 
““  Chinese hamster
— bovine 1 B
— m o u se  1 B
— rat 1 B
— human 1 B
— rat 4 A
Figure 4.4.6.C The novel PD El sequences cluster with PDEIB  
sequences on a phylogenetic tree of PDEl forms.
The sequences homologous to the 601 bp fragment were identified in all published 
PD El forms. These sequences then had their distances calculated and a tree 
constructed in the MegAlign program of the DNAstar suite of programs, using the 
default settings. This tree shows quite clearly that the Chinese hamster and human 
sequences isolated here are highly related to PDEIB sequences but not to either 
PDEIA or PDEIC sequences. The rat PDE4A sequence is included as a less related 
"control" sequence.
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4.4.7. The Ca^+/CaM-stimulated PD El enzyme in human thyroid 
carcinoma cell line FTC133 is a PDEIC form
The human thyroid carcinoma cell line FTC 133 (210-214) is known to contain PDEl 
activity which can be attenuated when the PDE4A form RNPDE4A1 (RDI) is stably 
transfected into them (115). Using primers GR18 and GR19 however, we were 
singularly unsuccessful in detecting transcripts for either PDEIA or PDEIB in RNA 
preparations made from native FTC133 cells, FTC133G cells and the R D I-expressing 
FTC 133A cells. However, when 1 used PDEIC specific primers GR45 and GR46 1 
was able to amplify a fragment (431 bp) of the expected size, indicating the presence 
of PDEIC in the native FTC 133 cell line. Whilst no attempt was made to perform 
quantitative studies, the magnitude of this signal was similar using identical amounts 
of RNA from both the native FTC 133 cells and the 'control' transfected FTC133G 
cells but was dramatically reduced in the R D I-expressing FTC 133A cell line (figure 
4.4.7). This trend is consistent with the decrease in PDEl activity observed in 
FTC133G cells and the lack of observable PDEl activity in RDI transfected FTC 133A 
cells (115).
4.4.8. The Ca^+ZCaM-stimulated PDEl enzyme in the mouse neuronal 
cell line AtT 20 cells is a PDEIC form.
The mouse neuronal cell line AtT 20 is known to contain PDEl activity (F. 
Antoni unpublished). Yet using GR18 and GR19, 1 was singularly unsuccessful in 
detecting transcripts for either PDEIA or PDEIB in RNA. However, when I used 
PDEIC specific primers GR45 and GR46 we were able to amplify a fragment (431 
bp) of the expected size, indicating that the PDE in AtT 20 cells is a PDEIC foim
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1 2 3 4 5 6 7
Figure 4.4.8. Detection of PDEl transcripts in human FTC133 cell 
lines and mouse AtT20 cell lines
RT-PCR was carried out using primer pairs GR18 & GR19 or GR45 & GR46 
to detect PDEIA/B and PDEIC, respectively. An arrow denotes a band of the correct 
size.
(a) Using primers GR45 & GR46, which are specific for PDEIC analyses were 
done on RNA (track number is in brackets) (1) rat brain; (2) FTC 133A cells; (3) 
FTC133G cells; (4) FTC133 wild-type cells; (5) no DNA control lane and (6) AtT20 
cells
(b) Using primers GR18 & GR19 to detect both PDEIA and PDEIB in RNA 
from (1) no DNA control; (2) rat brain; (3) rat brain; (4) FTC 133A cells; (5) FTC 133 
wild type cells; (6) FTC133G cells (7) AtT20 cells.
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4.5. CONCLUSION
4.5.1 Use of primers which are able to amplify select PDEl forms
RT-PCR was used to identify the nature of the PDEl isoform which was 
rapidly induced in CHO cells in response to a number of stimuli including PMA, PKC 
a  and e isoform overexpression and latterly exposure to ligands for endogenous 
receptors which stimulate lipid signalling processes. This was achieved even though 
there was no sequence information available for PDEl or indeed any PDE form, for 
Chinese hamster.
Probes for non-homologous systems are normally designed to conserved 
gene sequences containing several low redundancy codons. Then, in order to 
minimise degeneracy further, species specific codon usage tables are employed. 
However, the final primer design is often still highly degenerate and thus the 
effectiveness of such primers in RT-PCR can be reduced. The rationale adopted in this 
study for the design of PDEIA/B specific primers serves to ameliorate these problems 
and may be more generally applicable. Thus, by selecting sequence conserved 
between two genes, rather than just one, and between species but differing from other 
closely related genes, one can rigorously apply conservation information from genetic 
model systems such as rat and human to genetically uncharacterised systems. Here I 
have done this for the analysis of PDEl isoforms in Chinese hamster. Once such 
stretches of sequences are identified, then probes can be designed to them in the usual 
way, to amplify sections containing low redundancy codons. These primers will be far 
less degenerate whilst still able to selectively detect transcripts in a range of species.
As has been shown, the primer sequences chosen were published before and conectly 
anticipated the human PDE lA  (Gen Bank accession; U40371) sequence exactly (no 
mismatches in either primer). The primers were also able to amplify PDEl fonns from 
a variety of species and as such should provide an invaluable tool for the detection of 
transcripts for these isoforms.
4.5.2. Induction of PDEIB by PKC subtypes
By RT-PCR analyses I have been able to show amplification of a PDEIA/B,
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but not PDEIC fonn in CHO cells under conditions of PKC stimulation where novel 
PDEl activity has been shown to be induced (163,207). Sequencing of the PCR 
fragments revealed that the induced PDE was a PDEIB form (207). On the basis that 
induction of PDEIB could be elicited by the phorbol ester PMA it is reasonable to 
assume that protein kinase C provides the basis for induction by the endogenous 
receptor systems in CHO cells which are coupled to lipid signalling processes. That 
overexpression of PK C-a or PKC-e, but not overexpression of PKC-(3 or PKC-y, 
can also induce PD El activity and transcript production, suggests that the 
transcriptional regulation of the PDEIB gene may show a distinct specificity as 
regards the action of protein kinase C isoforms. Identification of the molecular basis of 
this remarkably rapid induction may shed light on the functional roles of protein kinase 
C isoforms and 'crosstalk' between the lipid and cyclic nucleotide signalling 
pathways.
Though this study was the first to show an induction of PDEIB, such an 
effect has now been reported by others (35) following mitogenic stimulation of several 
types of lymphoblastoid and leukaemic cells. It was suggested by Jiang et al (35) that 
the PDE activity might be contributing towards a 'survival' signal, since antisense and 
vinpocetine blocking of the PDEl activity led the lymphocytes to undergo apoptosis.
This is a very interesting result, although the mechanism for this 'survival' signal has 
still to be detennined.
4.5.3. Identification of two cell lines which express PDEIC
The PDEIA/B primers designed here were unable to identify PD El 
transcripts in FTC 133 and AtT20 cell lines which are known to express PDEl 
activity. I have now determined that the reason for this is that these express PDEIC 
forms which are not detectable with GR18 and GR19. These are the first cell lines 
shown to express PDEIC and in the case of FTC 133 cells, the first examination of 
PDEl forms in thyroid cell RNA. In FTC 133 cells the data reported (115) is 
consistent with the notion that the loss of PDEl activity in the RDI (PDE4A)- 
expressing transfected cell line FTC 133A, is likely to have been due to a marked
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reduction in the amount of PDEl enzyme protein. If this is the case, this cell line might 
be of use in determining the molecular mechanism of the inteiplay between expression 
of PDE4A and PDEIC forms. This may involve an effect at the level of the of the 
PDEIC form.
One possible explanation for why the PDEIC RT-PCR signal did not 
disappear completely is that PDEIC spliceforms might be alternatively regulated (Five 
PDEIC forms have been reported so far (29-31)). Some of these could be 
constitutively expressed in the FTC cell line, whilst others were regulated, similar to 
the differing regulation of PDE4D splice variants (84,119).
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5. USE OF LOW STRINGENCY REVERSE TRANSCRIPTION  
POLYMERASE CHAIN REACTION TO DEMONSTRATE UNIVERSAL 
EXPRESSION OF MAMMALIAN HOMOLOGUES OF THE RAT 
SHORT FORM PDE4A TRANSCRIPT RDI (RNPDE4A1)
INTRODUCTION
5.1. RAT SPLICE VARIANT RDI (RNPDE4A1)
The splice variant RD1 was the first mammalian dunce PDE homologue to be 
isolated, being identified in a rat brain cDNA library (65). Since this time, the 
biochemical characteristics endowed by RDl's unique N-terminal 21 amino acids have 
been the subject of intensive study (see introduction). However, parallel to this effort, 
little was known about expression of native RDI forms. Despite data which indicated 
the existence of endogenous RDI (76,102), the continuing lack of any data on RDI 
homologues in other species raised the possibility that RDI might be a rat specific 
splice variant and therefore a curiosity of little relevance to man. The molecular layout 
of RDI and the published literature of the time did nothing to dispel this notion: (1) the 
RDI, PDE4A 'short' form splice junction is apparently unique, being distinct from tlie 
'short' form splice junction which is conserved between the other mammalian PDE4 
genes and that found in drosophila (see introduction); (2) the other cDNAs reported 
alongside RDI and suggested to be splice variants, namely RD2 (RNPDE4A2) and 
RD3 (RNPDE4A3) have now convincingly been shown to be cloning errors 
(68,76,82). This accounts for the subsequent inability of various investigators to 
detect these species; (3) human homologues of RDI have not, to date, been identified, 
although human homologues have been identified for many of the other rat splice 
variants. These include human homologues of all three rat PDE4D splice variants, 
(RNPDE4D1-3) (86), the two rat PDE4B splice variants, (RNPDE4B1 and 
RNPDE4B2) (68) and the 'long' foim rat PDE4A splice variant RNPDE4A5 (68); (4) 
rat RDI RNA has never been shown to be expressed in a rat cell line or any rat tissue 
other than rat brain by any technique. Nevertheless, in rat brain it has been detected by 
RNAse protection assay (76) which is in accord with the isolation of RDI from a rat
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brain cDNA library in the original study of Davis et al (65). RDI protein has, to date, 
only been suggested to be expressed in rat brain (102).
In view of these difficulties, there is a pressing need to determine whether 
homologues of RDI occur in humans and other species and thus whether conservation 
of biochemically identified motifs within RDI occur. Additionally, given the brain 
specific expression of RDI and the wealth of human brain cell lines compared to the 
lack of rat brain cell lines, identification of a human homologue of RDI and a cell line 
which expresses RDI endogenously would be a powerful tool for studying regulatory 
processes controlled by tliis PDE4A isoform.
Given my success using RT-PCR, in identifying novel PDE species in 
mRNA from a Chinese hamster cell line using sequence information from other species 
(163,207), I decided to search for a human RDI homologue by RT-PCR. To do this I 
used primers designed to sequences found within known human PDE4A sequence and 
rat RDI sequence
5.2 THE PRIMARY STRUCTURE OF PDE4A LR2
The structure of the LR2 region of PDE4A is currently of intense interest 
given its apparent role in species specific differences in the biochemistry of PDE4A 
splice variants. These include proposals that it may contain conformational 'switches'
(see Introduction) (19). Alignment of human and rat PDE4A sequence using default 
settings in alignment programs including Gene Jockey 2 and GCG PILEUP produces 
an alignment such as that shown in figure 5.2. In this alignment, a proline rich putative 
SH3 binding domain appears to occur only in the human form of LR2 (19,79). This 
deletion represents the major primary structural difference between human and rat 
PDE4A. Sequence information from the LR2 region of other species, which is 
presented in this chapter, deepens this understanding of the sequence differences 
between human and rodent PDE4A LR2. The new data is consistent with an alternative 
alignment which suggests that a form of a pro line rich domain is retained in both 
human and rat PDE4A, although individual residue positions are not well conserved.
In this chapter I demonstrate the true identity of the deletion in rat PDE4A LR2 and the
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significance of this is discussed with respect to the altered biochemical properties of 
human and rat PDE4A splice variants.
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UCRZ
10 20 30 40 50
I I I I I
MPLVDFFCETCSKPWLVGWWDQFKRMLNRELTHLSEMSRSGNQVSEYISNTFLD 
•  • • • • • • • • • • • • • • • • • • • • • • • • • • •  # # # #
WCLEQLETMQTYRSVSEMASHKFKRMLNRELTHLSEMSRSGNQVSEYISTTFLD 
I I I I I I
240 250 260 270 280 290
UCR2 LR2 LR2 CATALYTIC
60 70 80 90 100
I I I  I I
KQNEVEIPSPTPRORAFQQPPPSVLRQS------------- OPMSQITGLKKLVHTGSL
• • • • • • • • • • •  •  • •  •  •  • • • • • • • • • • • •  # # #
KQNEVEIPSPTMKEREKQOAPRPRPSQPPPPPVPHLOPMSQITGLKKLMHSNSL 
I I I I I
300 310 320 330 340
110 120
I I
NTNV-PRFGVKTDQEDLLAQE 
# • • • • • • • • • •  • • • • •
NNSNIPRFGVKTDQEELLAQE 
I I
350 360
Figure 5.2. Typical peptide alignment of rat (top) and human (bottom) 
PDE4A.
This figure shows a typical alignment of rat (RNPDE4A1) and human (HSPDE4A4) 
PDE4A sequence around the RDI splice junction and LR2 (underlined) (after (79)). 
This alignment clearly indicates that a proline rich domain is deleted in rat PDE4A. The 
positions of UCR2, LR2 and the putative catalytic domain are shown for orientation.
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RESULTS
5.3. USE OF PRIMERS DESIGNED TO RAT RDI ON HUMAN CELL 
LINES 293, FTC133, HeLa, SK-N-SH, U-87, U-118
In order to amplify specifically a fragment of rat RDI, I designed one primer 
(GR73) to sequence found within the unique 5' region of RDI. The second primer 
was designed to a region of human PDE4A sequence common to all splice variants 
known to date and which would be expected to appear in a human homologue of RDI 
(see appendix). Thus only one primer contained sequence uncertainty with respect to 
human PDE4A, namely the rat 5' RDI sequence. These primers readily detected a 
product in rat brain RNA of the expected size (372 bp) despite the three mismatches in 
the antisense primer with respect to the rat sequence. A similarly sized product was 
seen in RNA from various human brain cell lines, namely U-118 cells, SK-N-SH 
cells and also the human thyroid cell line FTC 133 but not in cervical cell line HeLa, 
human brain cell line U-87 or human kidney cell line 293 (cell-line accession numbers 
are in the Materials and Methods chapter). TA cloning and sequencing of the 372 bp 
product from the rat brain RNA source showed that the sequence of the amplified 
species reflected that of RDI. However sequencing of clones from the human sources 
did not identify any R D I-like species; all of the colonies reflected single primer 
artefacts, with no homology to RDI. Indeed, a putative "human RDI" PCR fragment 
is expected to migrate more slowly because of a deletion of rat PDE4A in LR2 which 
is part of the region amplified by these primers (figure 5.4.1.). Later results concur 
with this prediction (section 5.4.1). This is highly persuasive that the band seen here 
is artefactual and therefore that none of these cell lines express an RNA homologous to 
RDI. This preliminary failure forced me to reconsider the strategy employed.
Given that RDI has not yet been detected in any cell line I decided to screen 
RNA directly extracted from brain tissue. Since I could not discriminate whether any 
potential lack of signal could be because there was no RDI expressed in these cell 
lines or because my probes were unable to amplify human RDI, in the first instance I 
elected to screen mouse brain because the mouse is more closely related to the rat.
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1 GGGACTCGGC CAAACCTACC TTACCTGTGC GCCAGCCCAG
CAGGCG
GR5'HRD1
AGCTAAGCTT
GGCTAAGTCT
51 CCATCATGCC TCTGGTTGAC TTCTTCTGCG AGACCTGCTC CAAGCCCTGG
CCAAG TTCTTCTGCG AGACCIGCIC.CAAG
GR73 GR73
101 CTGGTGGGCT GGTGGGACCA GTTCAAAAGG ATGCTGAACC GTGAGCTCAC
151 ACACCTGTCG GAAATGAGCA GGTCAGGAAA CCAGGTCTCA GAGTACATTT
201 CCAACACATT CCTGGACAAG CAGAATGAAG TGGAGATCCC CTCACCCACA
251 CCTCGGCAGA GAGCCTTCCA GCAGCCCCCG CCGTCAGTGC TGCGACAGTC
301 CCAGCCCATG TCTCAGATCA CAGGGCTGAA AAAGCTGGTA CACACTGGAA
351 GCTTGAACAC CAACGTCCCA CGGTTTGGAG TCAAGACAGA TCAAGAGGAC
401 CTCTTAGCAC AAGAACTGGA GAACTTGAGC AAATGGGGCC TGAACATCTT
CCT CTTGGACTTG TTCACCCCGG AC
GR36 GR36
451 TTGTGTGTCG GAGTACGCTG GAGGCCGCTC ACTCAGCTGT ATCATGTATA
501 CGATATTCCA GGAGCGGGAC CTACTGAAGA AATTCCACAT CCCTGTGGAC
551 ACCATGATGA TGTACATGCT GACCCTGGAG GACCACTACC ATGCCGACGT
601 GGCCTACCAC AACAGCCTGC ACGCAGCGGA TGTGCTGCAG TCCACACACG
651 TGCTGCTGGC CACGCCCGCA CTGGACGCTG TGTTCACAGA CCTGGAGATT
701 CTTGCTGCCC TCTTCGCTGC TGCCATCCAC GATGTGGACC ACCCTGGCGT
GGTG CTACACCTRG TGGGAC
GR29 GR29
Figure 5.3 Primers used in this chapter.
The sequence shown is that for RDI (M26715). The initiator methionine of RDI is 
underlined. Sense primers are underlined once, anti sense primers are double 
underlined. GR29 is designed to both rat and human sequence, GR36 is designed to 
human sequence, hence there are a few mismatches when aligned to the rat sequence. 
GR37 is designed to rat sequence. Primer GR5' liRDl is designed to the recently 
identified human RDI 5' exon (see section 5.7).
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5.4. RT-PCR USING PRIMERS DESIGNED TO RAT RDI ON MOUSE 
BRAIN IDENTIFIES A MURINE RDl-LIKE SPECIES: A NEW RAT 
AND MOUSE SPECIFIC DELETION IS REVEALED
111 order to examine whether the RDI transcript is unique to rat, low 
stringency RT-PCR was done on mouse RNA. By cloning and sequencing, partial 
sequence of a mouse homologue of RDI was obtained.
5.4.1. Alignment of mouse RDI to rat and human PDE4A LR2 indicates 
that a hydrophilic MKEREKQQA motif forms the major primary 
structure difference between human and rodent PDE4A LR2
The previous alignment of human and rat LR2 (figure 5.2) is not supported 
by the extra sequence infonnation derived from tlie partial sequence of mouse RDI. In 
a multiple alignment of the mouse, human and rat LR2 regions, the deletion of a 
hydrophilic motif from the two rodent PDE4As is indicated (figure 5.4.1).
This tentative new alignment prompted me to attempt to isolate R D I-like 
signals from brains of a range of species. It was anticipated that the sequence 
information so obtained would be useful in two ways. Firstly, one would be able to 
identify RDI specific sequence conservation, so that primers could be designed to 
phylogenetically stable sequences (as shown in chapter 3 (163,207)) and tested on 
human RNA. Secondly, one would accumulate more sequence information to test the 
proposed new alignment and at the same time the sequence infonnation would allow a 
preliminary survey of the evolutionaiy history of the newly identified rodent PDE4A 
deletion (see section 5.7.7.)
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UCRZ
Consensus I ! | • • • • • • • • • • • • • • • • • • • • • • • • • • •  ######|#
RNPDE4A1 PWLVGWWDQFKRMLNRELTHLSEMSRSGNQVSEYISNTFLDKQNE
MMPDE4A1 PWLVGWWDQFKRMLNRELTHLSEMSRSGNQVSEYISNTFLDKQHE
HSPDE4A4 SVSEMASHKFKRMLNRELTHLSEMSRSGNQVSEYISTTFLDKQNE
UCR2 LR2 LR2 CATALYTIC
Consensus • • • • • • •  • •  # | • • • • [  | | • • • • • • • • • • • •
RNPDE4A1 VEIPSPT---------------- PRQRAFQQPPPSVLRQSQPMSQITGLKKL
MMPDE4A1 VEIPSPT---------------- PRQRPFQQPPPAAVQQAQPMSQITGLKKL
HSPDE4A4 VEIPSPTMKEREKQQAPRPRP-SQPPPPPVPHLQPMSQITGLKKL
Consensus ! • !  • • •  • 1 |
RNPDE4A1 VHTGSLN-TNVPRFGVKTDQEDLLAQE
MMPDE4A1 VHTGSLN-INVPRFGVKTDQEDLLAQE
HSPDE4A4 MHSNSLNNSNIPRFGVKTDQEELLAQE
Figure 5.4.1. New alignment of PDE 4A LR2 when mouse PDE4A LR2 
is include in the alignment.
Sequences from PCR fragments of rat (RNPDE4A1) and mouse (MMPDE4A1) 
PDE4A are aligned with human PDE4A (HSPDE4A4) sequence. LR2 sequence is 
underlined. The mouse sequence information exposes an alternative alignment where 
the human PDE4A LR2 specific motif is MKEREKQQA. LR2 and other PDE4 
domains are marked to allow orientation.
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5.5. IDENTIFICATION OF RDl-LIKE TRANSCRIPTS IN BRAIN 
RNA FROM A RANGE OF MAMMALS: DEMONSTRATION THAT 
RDI IS HIGHLY CONSERVED
RT-PCR of RNA from the brains of various mammalian species detected 
RD 1-like transcripts. This was done in RNA of cat, pig, rabbit, guinea pig and 
human. No signal was obtained from chicken, though this may simply reflect the 
longer evolutionary distance rather than an absence of an R D I-like transcript. 
Concerning the accuracy of the PCR data, each sequence represents data from six 
PCR clones. In every species, bar pig, all six colonies had identical sequence. In pig 
there was a 2/6 'silent' substitution in the DNA region coding for UCR2. The rat and 
human sequence in this chapter could, in part, be tested against existing sequence from 
rat and human PDE4A splice variants. I found no mismatches in the sequences of any 
of the clones.
The extra sequence found in human, pig, cat, guinea-pig and rabbit makes 
their bands slightly greater in size (~400bp). This agrees with the contention, put 
forward above (section 5.2), that the ~370bp band observed in RT-PCR on human 
cell lines with RD 1 primers is an artefact. The sequences I have isolated are the first 
data which demonstrate that R D I-like species of RNA are conserved in mammals 
including human (human RDI is henceforward designated liRDl)
5.5.1. Alignment of mammalian RDI forms demonstrates that a 
hydrophilic MKEREKQQA motif forms the major primary structure 
difference between human and rodent PDE4A LR2
The extra DNA sequence and inferred peptide sequence confirms the new 
alignment suggested in the section 5.4.1. Thus, when all of the peptide sequences are 
aligned, the rat and mouse sequences skip tlie same sequences as was predicted by the 
mouse, rat and human alignment (compare figure 5.4.1. with 5.5.1.a). Furthermore, 
the DNA sequence alignments skip the same sequences (figure 5.5.l.b). Therefore, 
explicitly stated, the new alignment is favoured over the old one for two main reasons. 
Firstly, the alignment programs give the new alignment when as more sequence
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information is supplied to them. Thus, a multiple alignment of mouse, rat and human 
PDE4A gives the new alignment. In contrast, a pair-wise alignment of rat and human 
PDE4A gives the old alignment. Secondly, the DNA alignment concurs with the new 
peptide alignment, not the old peptide alignment.
The new alignment clearly demonstrates that it is the deletion of the 
hydrophilic sequence, MKEREKQQA, which forms the major difference in primary 
structure between the LR2 regions of human and rodent PDE4A. LR2 regions of 
PDE4A which contain these hydrophilic regions (cat, pig, human and guinea-pig), are 
henceforth designated LR2HP (linker region 2 containing hydrophilic and proline 
components) to discriminate them from rodent PDE4A LR2P (linker region 2 
containing proline component) regions which lack the hydrophilic domain. PDE4 LR2 
regions categorisation is outlined in table 5.5.1. It is argued below (section 5.6.3.) 
that the hydrophilic component of LR2HP is an (otherwise) anciently conserved 
sequence.
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* * * * * * * UCRZ
Rat PDE4A1 
Mouse PDE4A1 
R abb it PDE4A1 
Human PDE4A1 
Guinea-P ig PDE4A1 
Pig PDE4A1 
Cat PDE4A1
Rat PDE4A1 
Mouse PDE4A1 
R abbit PDE4A1 
Human PDE4A1 
Guinea-P ig PDE4A1 
Pig PDE4A1 
Cat PDE4A1
Rat PDE4A1 
Mouse PDE4A1 
R abb it PDE4A1 
Human PDE4A1 
Guinea-P ig PDE4A1 
P ig PDE4A1 
Cat PDE4A1
Rat PDE4A1 
Mouse PDE4A1 
R abb it PDE4A1 
Human PDE4A1 
Guinea-Pig PDE4A1 
Pig PDE4A1 
Cat PDE4A1
PWLVGWWDQFKRMLNRELTHLSEMSRSGNQVSEYIS
PWLVGWWDQFKRMLNRELTHLSEMSRSGNQVSEYIS
PWLVGWWDQFKRMLNRELTHLSEMSRSGNQVSEYIS
PWLVGWWDQFKRMLNRELTHLSEMSRSGNQVSEYIS
PWLVGWWDQFKRMLNRELTHLSEMSRSGNQVSEYI5
PWLVGWWDQFKRMLNRELTHLSEMSR5GNQVSEYIS
PWLVGWWDQFKRMLNRELTHLSEMSRSGNQVSEYIS
36
36
36
36
36
36
36
CATALYTIC
ED2211I S-D?:u
TDQEgLLAQE 
TDQEELLAQE 
TDQEELLAQE 
TDQEELLAQE 
TDQEELLAQE 
QEELLAQE
107
107
112
116
116
iiNi8BIW89 116
Figure 5.5.1.a. Peptide alignm ent of all seven m am m alian R D I like transcripts 
exposes the M KEREKQQA-like m otif as a rat and mouse specific deletion. One R D l- 
specific and two PDE4 modules are conserved to differing degrees 
All the mammalian RDI like peptide sequences were aligned using a GeneJockey2 
multiple alignment. Consensus matches are white on black, mismatches black on white. 
The MKEREKQQA-like motif is deleted in rat and mouse, with some disturbance also in 
the rabbit form, section (see 5.6.3.1.)
The RDI PWLVGWW putative membrane association motif is perfectly (asterisked) and 
the UCR2 domain almost perfectly conserved in all species (section 5.6.1 and 5.6.2.). In 
comparison the N-terminal oi the putative catalytic domain is poorly conserved with 
substitutions accepted at over 40% of the positions with one gap (section 5.6.3).
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Consensus 
Human PDE4A1 
Pig PDE4A1 
Cat PDE4A1 
Guinea-pig PDE4A1 
Rabbit PDE4A1 
Mouse PDE4A1 
Rat PDE4A1
10 20 30
I I I
CCGTGGCTGGTGGGCTGGTGGGACCAGTTCAAGAGGATG 
CCTTGGCTGGTGGGCTGGTGGGACCAGTTCAAAAGGATG 
CCGTGGCTGGTGGGCTGGTGGGACCAGTTCAAGAGGATG 
CCGTGGCTGGTGGGCTGGTGGGACCAGTTCAAGAGGATG 
CCGTGGCTGGTGGGCTGGTGGGACCAGTTCAAGAGGATG 
CCGTGGCTGGTGGGCTGGTGGGACCAGTTCAAGAGGATG 
CCCTGGCTGGTGGGCTGGTGGGACCAGTTTAAAAGGATG 
CCCTGGCTGGTGGGCTGGTGGGACCAGTTCAAAAGGATG
Consensus 
Human PDE4A1 
Pig PDE4A1 
Cat PDE4A1
40 50 60
I
70
CTGAACCGTGAGCTCACACACCTGTCAGAAATGAGCAGG 
TTGAACCGTGAGCTCACACACCTGTCAGAAATGAGCAGG 
CTAAACCGTGAACTCACACACCTGTCAGAGATGAGCAGG 
TTAAACCGTGAACTCACACACCTGTCAGAGATGAGCAGG 
Guinea-pig PDE4A1 CTAAACCGGGAGCTCACACACCTGTCAGAAATGAGCAGG 
Rabbit PDE4A1 CTGAACCGGGAGCTCACGCACCTGTCAGAAATGAGCAGA
Mouse PDE4A1 CTGAACCGGGAACTCACACACCTGTCGGAAATGAGCAGG
Rat PDE4A1 CTGAACCGTGAGCTCACACACCTGTCGGAAATGAGCAGG
80 90 100 110
Consensus 
Human PDE4A1 
Pig PDE4A1 
Cat PDE4A1 
Guinea-pig PDE4A1 
Rabbit PDE4A1 
Mouse PDE4A1 
Rat PDE4A1
TCAGGAAACCAGGTCTCAGAGTACATTTCCACCACATTC
TCCGGAAACCAGGTCTCAGAGTACATTTCCACAACATTC
TCAGGAAACCAGGTCTCTGAGTACATCTCCACTACATTC
TCAGGAAACCAGGTCTCTGAGTACATCTCCACCACATTC
TCGGGAAACCAGGTCTCAGAGTACATTTCCACGACATTC
TCAGGAAACCAAGTGTCAGAGTACATCTCCACCACGTTC
TCAGGAAACCAGGTCTCAGAGTACATTTCCAACACGTTC
TCAGGAAACCAGGTCTCAGAGTACATTTCCAACACATTC
Consensus 
Human PDE4A1 
Pig PDE4A1 
Cat PDE4A1 
Guinea-pig PDE4A1 
Rabbit PDE4A1 
Mouse PDE4A1 
Rat PDE4A1
120 130 140 150
I I I I
CTGGACAAGCAGAATGAAGTGGAGATCCCATCACCCACG 
CTGGACAAACAGAATGAAGTGGAGATCCCATCACCCACG 
CTGGATAAGCAGAATGAAGTGGACATCCCATCACCCACA 
CTGGACAAGCAGAATGAAGTGGAGATTCCATCACCCACG 
CTCGACAAACAGAATGAAGTGGAGATCCCGTCACCAACG 
CTGGACAAACAGAATGAAGTGGAGATCCCCTCACCCACG 
CTAGACAAGCAGCACGAAGTGGAGATCCCATCGCCCACG 
CTGGACAAGCAGAATGAAGTGGAGATCCCCTCACCCACA
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M K E R E K Q Q A  
160 170 180 190
I I I I
Consensus ATGAAGGANCGAGANAAACAGCAAGCNCCNCGVCAGAGA
Human PDE4A1 ATGAAGGAACGAGAAAAACAGCAAGCGCCGCGACCAAGA
Pi g PDE4A1 ATGAAGGATCATGAAAAACAGCAAGCACCACGGCAGAGA
Cat PDE4A1 ATGAAGGATCGAGAAAAACAGCCAGCTCCCCGCCAGAGA
Guinea-pig PDE4A1 ATGAAAGACCGAGAGCCCCAAGAAGCACCCCGACAAAGG
Rabbit PDE4A1 TCGAAGGAACGAGAG CAGACGCCACGGCAGAAA
Mouse PDE4A1 -----------------------------------------------CCGCGACAGAGA
Rat PDE4A1 —  — ---------------------------------------CCTCGGCAGAGA
200 210 220 230
I
Consensus 
Human PDE4A1 
Pig PDE4A1 
Cat PDE4A1 
Guinea-pig PDE4A1 
Rabbit PDE4A1 
Mouse PDE4A1 
Rat PDE4A1
CCCTCCCAGCAGCCCCCACCCCCDGTVNNNCCVCAGTTC 
CCCTCCCAGCCGCCCCCGCCCCCTGTA— CCACACTTA 
CCTTCCCAGCAGCCCCCACCCCCTGGA— CCACAGTTC 
CCTTCCCAGCAGCCCCCGCCCCCTGGG— CCGCAATTC 
CCCTGCCAGCAGCTTCCACCCCCAGTG-—CCGCATTTG 
CCCTCCCCGCAGCCCCCAGCCCCGGTC— CCCCCGTTC 
CCCTTCCAGCAGCCCCCACCAGCAGCAGTGCAGCAGGCC 
GCCTTCCAGCAGCCCCCGCCGTCAGTGCTGCGACAGTCC
240 250 260 270
Consensus 
Human PDE4A1 
Pig PDE4A1 
Cat PDE4A1 
Guinea-pig PDE4A1 
Rabbit PDE4A1 
Mouse PDE4A1 
Rat PDE4A1
CAGCCCATGTCTCAGATCACAGGGGTGAAAAAGCTGATG
CAGCCCATGTCCCAAATCACAGGGTTGAAAAAGTTGATG
CAGCCCATGTCACAGATCACCGGGGTGAAAAAGCTGATG
CAGCCCATGTCTCAGATCACGGGGGTGAAGAAGCTGATG
CAGCCCATGTCCCAGATCACGGGGGTGAAGAGGCTGTCG
CAGCCCATGGCTCAGATCACAGGGGTGAAAAGGCCCACA
CAGCCCATGTCTCAGATCACAGGGCTGAAAAAGCTGGTA
CAGCCCATGTCTCAGATCACAGGGCTGAAAAAGCTGGTA
Consensus 
Human PDE4A1 
Pig PDE4A1 
Cat PDE4A1 
Guinea-pig PDE4A1 
Rabbit PDE4A1 
Mouse PDE4A1 
Rat PDE4A1
280 290 300 310
I I I I
CACAGCAGCAGCCTGAACNNNNACTCCAGCATCCCCCGC 
CATAGTAACAGCCTGAAC-—AACTCTAACATTCCCCGA 
CATAGCAGCAGCCTGAATGAGGATTCCAGCATTCCCCGC 
CATAGCAGCAGCCTGAGT-- -GACTCCAGCATCCCCCGC 
CACAACAGCGGCCTGAAC-- -AACGCCAGCATCCCACGC
CACAGCCTCGGC--------------- GACTCTGGCATCCCCCGC
CACACCGGAAGCTTGAAC----------ATCAATGTCCCACGA
CACACTGGAAGCTTGAAC----------ACCAACGTCCCACGG
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Consensus 
Human PDE4A1 
Pig PDE4A1 
Cat PDE4A1 
Guinea-pig PDE4A1 
Rabbit PDE4A1 
Mouse PDE4A1 
Rat PDE4A1
320 330 340 350
I I I I
TTTGGGGTGAAGACCGATCAAGAGGAGCTCCTGGCCCAA 
TTTGGGGTGAAGACCGATCAAGAAGAGCTCCTGGCCCAA 
TTTGGGGTGAAGACCGATCAAGAGGAGCTCCTGGCCCAA 
TTTGGGGTGAAGACCAACCAAGAAGAGCTCCTGGCCCAA 
TTCGGGGTGAAGACGGATCAGGAGGAGCTCCTGGCCCAA 
TTTGGCGTGAAGACCGACCAGGAGGAGCTCCTGGCACAG 
TTTGGAGTCAAGACAGATCAGGAGGACCTCTTAGCACAA 
TTTGGAGTCAAGACAGATCAAGAGGACCTCTTAGCACAA
Consensus GAACT
Human PDE4A1 GAACT
Pig PDE4A1 GAACT
Cat PDE4A1 GAACT
Guinea-pig PDE4A1 GAGCT 
Rabbit PDE4A1 GAACT
Mouse PDE4A1 GAACT
Rat PDE4A1 GAACT
Figure 5.5.l.b  DNA alignment of mammalian RDI like transcripts
DNA sequence from PCR fragments of (Genbank accession numbers in brackets) cat 
(U97589), pig (U97587), human (U97584), guinea-pig, rabbit (U97585), mouse 
(U97586) and rat are aligned by clustal alignment on the Gene Jockey 2 program, 
using the default settings. The rat and mouse nucleotide sequence clearly skip exactly 
the nucleotides that code for MKEREKQQA (this peptide sequence is shown). Small 
adjustments were made to the short insertions at -220 and -290 in order that they 
would match the peptide alignment as well. PCR conditions used to isolate the RDI 
fragments: 34 cycles of 1 minute 94"C, 1 minute 49 'C, 1 minute 72"C
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SPECIES GENE HYDROPHILIC
DOMAIN
PROLINE-RICH
DOMAIN
RAT RNPDE4A none PRQRAFQQPPPSVLRQSQP LR2P
MOUSE MMPDE4A none PRQRPFQQPPPAAVQQAQP LR2P
RABBIT 0CPDE4A SKERQT PRQKPSPQPPAPV-PPFQP LR2P
HUMAN HSPDE4A MKEREKQQA PRPRPSQPPPPPV-PHLQP LR2HP
PIG SSPDE4A MKDHEKQQA PRQRPSQQPPPPG-PQFQP LR2HP
CAT FCPDE4A MKDREKQPA PRQRPSQQPPPPG-PQFQP LR2HP
GUINEA-
PIG
CPPDE4A MKDREPQEA PRQRPCQQLPPPV-PHLQP LR2HP
Table 5.5.1. Classification of PDE4A LR2 domain types
To facilitate discussion of the results of this chapter, two sub-classifications of PDE4A 
LR2 domain are designated as in the table above. SPECIES IDENTIFICATION KEY: 
CP cavia porcellus (guinea-pig), FC felis catus (cat), HS homo sapiens (human) MM 
mus musculus (mouse), OC oryctolagus cuniculus (rabbit), RN (rattus norvegicus), 
SS sus scrota (pig)
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5.6. ANALYSIS OF THE SEQUENCE CONSERVATION OF THE 
MODULES CONTAINED IN THE N-TERMINAL REGION OF SEVEN 
RDl-LIKE SPECIES
As anticipated, sequence analysis of the fragments of RDI homologues has 
provided infonnation on the conservation of the various modules included within the 
fragment, as well as allowing the evolutionary histoiy of the rodent specific deletion to 
be examined (section 5.8.5.).
5.6.1. Conservation of the RDI membrane association domain and 
PDE4A UCR2 in seven mammals
The most striking conservation of sequence is that of the R D I-specific, 
putative membrane-association determinant PWLVGWW (114) which is perfectly 
conserved with no residue mismatches between all species examined (figure 5.4.b). 
Indeed, the entire PWLVGWWDQFK (see section 1.7.4.1) putative membrane 
association helix is perfectly conserved between all seven RDI homologues. The C- 
terminal 43 amino acids of UCR2 contained within these R D I-like species is also very 
highly conserved. There is only one non-conservative substitution, where threonine- 
289 (numbering for HSPDE4A4) is switched to an asparagine in rat and mouse. There 
are two conservative substitutions: these are asparagine-296 to histidine in mouse and 
glutamate-299 to aspartate in pig (figure 5.5. La).
5.6.2. The hydrophilic component of PDE4A LR2HP domain is 
conserved in two other PDE4 genes, PDE4B and PDE4D
As has already been described, LR2 is the region of PDE4 which connects 
UCR2 to the catalytic domain. In rodents, the LR2 region of PDE4A consists of a 
unique PDE4A proline-rich domain, LR2P. In human, cat, pig and guinea-pig PDE4A 
this proline-rich domain is juxtaposed with a hydrophilic domain and this type of LR2 
region is termed LR2HP. These types of LR2 regions are thus very different from 
each other.
As well as being conserved between most PDE4A species, the hydrophilic
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component of PDE4A LR2HP region is more widely conserved, with homologous 
regions found in PDE4B and PDE4D genes (figure 5.6.2.) I have termed these 
domains LR2H (Linker region 2 containing a hydrophilic component) regions. The 
PDE4B and PDE4D LR2H region is laiger than the hydrophilic component of PDE4A 
LR2HP but there is charge conservation in the shared regions (figure 5.6.2). Thus 
there is a reversal of the normal situation where sequences are typically better 
conserved between species' homologues of a gene than between different genes. 
Deletion of this sequence correlates with a restructuring of the N-terminal of the 
catalytic domain, (see section 5.6.4.). Finally, not all PDE4s conform to the patterns 
so far described such that neither hydrophilic or proline-rich regions are found in 
PDE4C nor the dunce gene. I have teimed these regions LR2A (Linker region 2 with 
atypical sequence).
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UCRZ
Cons. .FKRmL NRElI HLSEm SRSGNOVSEy I S..n.IFLDkQnPDE4A TMOTYRSVSE MASHKFKRML NRELTHLSEM SRSGNOVSEY ISTTFLDKON
PDE4B TIOTYRSVSE MASNKFKRML NRELTHLSEM SRSGNOVSEY ISNTFLDKON
PDE4C T LQ IEH SVGE MA5HKF.KRI L  hlR E L IH LS.EI . SRSGNOVSEY I SRTFLDQQTPDE4D TLOTRHSVSE MASNKFKRML NRELTHLSEM SRSGNQVSEF ISNTFLDKON
301 C a ta ly tic  350
Cons. eVEiPspTqk erekkk.p................................... qpMsqIs G.kkLmHSsS
PDE4A EVEIPSPTMK EREKQOAP R P  RPSQ PPPPPV PHLOm S O l T  GLKKLMHSNS
PDE4B DVEIPSPTQK DREKKKKQ...................................QLMTOIS GVKKLMHSSS
PDE4C EVELPKVTAE EAP............................................. OPMSRIS GLHGLCHSAS
PDE4D EVEIPSPTQK EKEKKKRP....................................... MSQIS GVKKLMHSSS
351 400
Cons LnnssipRFG VkT.qE..LA kE
PDE4A LNNSNIPRFG VKTDQEELLA OELENLNKWG LNIFCVSDYA GGRSLTCIMY
PDE4B LNNTSISRFG VNTENEDHLA KELEDLNKWG LNIFNVAGYS HNRPLTCIMY
PDE4C LSSATVPRFG VOTDQEEQLA KELEDTNKWG LDVFKVADVS GNRPLTAIIF
PDE4D LTNSSIPRFG VKTEOEDVLA KELEDVNKWG LHVFRIAELS GNRPLTVIMH
Figure 5.6.2. The hydrophilic component of the PDE4A LR2HP domain 
is conserved in other PDE4 genes
Alignment of partial sequences of PDE4 genes (human PDE4A, 4B, 4C & 4D are 
shown, there are similar sequences in rat PDE4B and 4D). The C-terminal of UCR2 
and the N-teiininal of the putative catalytic domain are underlined. The intervening 
section is the LR2 region. In the text the PDE4A LR2 regions which contain a 
hydrophilic motif (human, cat, pig and guinea-pig) are designated LR2HP regions and 
this sequence is in italics. The hydrophilic component of LR2HP which is conserved 
between PDE 4A, 4B and 4D (double underline) is shown within this sequence. This 
is a reversal of the nonnal situation as these sequences are not conserved between PDE 
4A from different species, as has already been shown (rat, mouse vs human, rabbit, 
cat and pig; figures 5.5.1.a).
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GENE HYDROPHILIC 
LR2 REGION
PROLINE-RICH LR2 
REGION
HSPDE4A MKEREKQQA PRPRPSQPPPPPV-PHLQP LR2HP
RNPDE4A none PRQRAFQQPPPSVLRQSQP LR2P
HSPDE4B QKDREKKKKQQL none LR2H
RNPDE4B QKDREKKKKQQL none LR2H
HSPDE4D QKEKEKKKRP none LR2H
RNPDE4D QKEKEKKKRP none LR2H
HSPDE4C none none LR2A
RNPDE4C none none LR2A
DMPDE none none LR2A
Table 5.6.2. Classification of PDE4 LR2 domain types compared with 
the two PDE4A LR2 subtypes.
To facilitate understanding of the results of this chapter, PDE4B, PDE4D and PDE4C 
and dunce PDE LR2 regions are classified based on Üieir similarity to the hydrophilic 
component of the PDE4A LR2HP domain. SPECIES IDENTIFICATION KEY: CP 
cavia porcellus (guinea-pig), DM drosophila melanogaster (fruit fly), FC felis catus 
(cat), HS homo sapiens (human) MM mus musculus (mouse), OC oryctolagus 
cuniculus (rabbit), RN (rattus norvegicus), SS sus scrofa (pig)
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5.6.3. Secondary structure analysis of LR2HP compared with LR2P
The hydrophilic sequences in the LR2HP and LR2H regions are exceptional 
in that they are the most hydrophilic sequence found in PDE4A outside of the putative 
catalytic domain. LR2HP is one of two hydrophilic proline-rich motifs found within 
HPDE46/RPDE6. The other hydrophilic-proline motif (UHP in figure 5.6.4.a) found 
in these splice variants is in their unique N-terminal (figure 5.6.4.a) (116). The 
functional significance, if any, of these hydrophilic proline motifs remains to be 
identified. So far, most of the allowed PDE 4A substitutions of LR2HP regions 
(excluding the rodent lineage-specific transition to LR2P) conserve charge, consistent 
with there being a functional role for this sequence. As a preliminai’y examination of 
the possible role of LR2HP/LR2P regions I have performed secondary structure 
analyses on all of the known LR2HP and LR2P sequences. Doing this I obtained three 
broad patterns from the data set of seven LR2 regions. For the LR2HP, as seen in 
human, pig, cat, and guinea-pig then using two secondary structure algorithms and a 
surface probability plot all suggest that MKEREKQQA like motif forms a surface 
alpha helix (figure 5.6.4.b). The rabbit form is intermediate between this form and 
LR2P forms (mouse and rat) where no secondary structure is predicted in the area of 
the deletion and the LR2 is much less hydrophilic (figure 5.6.4.c). A similar profile of 
secondary structure to that seen for the LR2HP (figure 5.5.4.2.b.) is seen in a UHP 
(data not shown) but there is not the same degree of charge conservation between the 
hydrophilic regions of the two sites as tliere is between different examples of the same 
site. Thus, the current consensus for the hydrophilic sections in all PDE4A UHP & 
LR2HP is (D/E) rE (k / r ) q, (where capitals represent the only residues found at that 
position and non-capitals represent residues where there is 1/6 substitution). Yet there 
is a higher degree of consensus between genes for the LR2HP when it is compared to 
the homologous LR2H regions in PDE4B and PDE4D. Here the consensus is 
K(D/E) (K/R)EK(K/Q) (k/q) (where non-capitals represent residues where there 
is a 1/9 substitution).
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(a) HUMAN
HydrophiUcity value 
(Hopp-Woods, 1981) 
4.00
L R 2 H P3.00 _
1 .00  _
2.00  _
CATALYTICUCRl UCR2
3.00 _
4 0 0  5 0 0
residue number
(b) RAT
HydrophiUcity value 
(Hopp-Woods, 1981) 4.00
3.00 _ UHP LR2P
1.00 _
CATALYTICUCRl UCR23.00 _
4.00
4 0 0 ^ 0 0  
residue number
Figure 5.6.4.a Hopp-Woods hydrophilicity plots of HSPDE4A4 and 
RNPDE4A5: Missing hydrophilic MKEREKQQA section of LR2HP in 
the rat LR2P
MKEREKQQA corresponds to the asterisked 'spike' in HSPDB4A4 (HUMAN) 
which is missing from the otherwise identical plot of RNPDE4A5 (RAT) 
hydrophilicity. This domain forms part of a PDE4A hydrophilic-proline LR2 
(LR2HP), as shown, which is therefore missing in rat (LR2P). There is another 
hydrophilic-proline rich domain which is shared between PDE46 and rPDE6 (UHP). 
UCRl, UCR2, LRl, LR2 and the catalytic domain are shown to allow orientation
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Figure 5.6.4.b Predictive Peptide Analysis of LR2HP Region
The partial peptide sequences (-1 It) amino acids) of PDE4A that I have obtained (see 
figure 5.5. La) were analysed using a number of predictive algorithms. This plot is 
typical of those when human, guinea-pig, cat or in tliis case pig are subjected to Hopp- 
Woods hydrophilicity, Emini surface probability and Chou & Fasman and Gamier & 
Robson secondary structure analyses. These species' PDE4A contain the LR2HP type 
of LR2 domains. The position of the hydrophilic component of LR2HP is marked on 
the first line. The two secondary structure algorithms agree and are consistent with 
LR2HP regions forming a surface alpha helix in PDE4A. The sequence in the region 
of the deletion in rat and mouse PDE4A is not predictive of alpha helix, is much less 
hydrophilic and is less likely to he present at the surface (compare with figure 5.6.4.c)
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Figure 5.6.4.C Predictive Peptide Analysis of LR2P Region
The complete partial peptide sequences (-110 amino acids) of PDE4A that I have 
obtained (see figure 5.5. La) were analysed using a number of predictive algorithms. 
This plot is typical of those when mouse or in this case rat are subjected to Hopp- 
Woods hydrophilicity, Emini surface probability and Chou & Fasman and Gamier & 
Robson secondary structure analyses. These species' PDE4A do not contain the 
hydrophilic component of LR2HP and are termed LR2P. The deletion relative to 
LR2HP is marked in the first line above. In contrast to LRHP2, in LR2P the two 
secondary structure algorithms predict random coil structure in the region around the 
deletion and this sequence is less likely to be presented at the surface.
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5.6.5. Conservation of the N-terminal of the putative catalytic domain: 
conservation of an octapeptide occurs only in PDE genes with LR2H or 
LR2HP regions
The PDE4A sequences I have obtained extend into the catalytic domain. The 
maximum N-terminal extent of the putative catalytic domain is marked in figure 5.6.2. 
This N-terminal catalytic sequence was not as well conserved as UCR2 in the RDI 
homologues I isolated. Nearly 40% of the positions are substituted and one gap is 
inserted (figure 5.5,1.a). I have found that the lack of conservation is concentrated in 
an octapeptide following the well conserved putative start of the PDE4 catalytic 
domain (see Introduction). Thus, the region between 332 and 344 (numbering for 
HSPDE4A4, as in figure 5.6.2.) is highly conserved between all PDE4 genes with a 
consensus of MsQITGvKklmHs (where capitals represent invariant residues and 
non-capitals residues with an absolute majority at that position). In contrast, the next 
eight residues, between positions 345 and 352, are found conserved only in a subset 
of PDE4 sequences. Thus, this octapeptide has a consensus of ssLnnssI (case 
significance as above) in PDE4 genes which contain LR2HP or LR2H but is 
unconserved in PDE4 genes which lack a hydrophilic domain in LR2 (see figure
5.6.5.a and 5.6.5.b). As a control, I compared LRl sequences from PDE4 fonus and 
found that conservation of LRl sequence was not linked to any particular LR2 
subtype. Instead LRl sequences are most closely conserved between homologues of 
the same gene from different genes, as would be expected.
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Percent Similarity
1 ; 2 3 4 S 6 7 8 9 10 11 12 13 14
1 33.3 11.1 11.1 0.0 0.0 11.1 11.1 11.1 11.1 11.1 11.1 0.0 11.1 1 DMPDE
2 75.0 4 4 .< 22.2 22.2 22.2 4 4 .4 44 4 44.4 44.4 44.4 44.4 33.3 44.4 2 RNPDE4C
3 100.0 62.5 11.1 33.3 22.2 33.3 33.3 33.3 33.3 33.3 44.4 22.2 33.3 3 HSP0E4C
A 100.0 83.3 100.0 0.0 0.0 33.3 33.3 22.2 22.2 33.3 44.4 33.3 33.3 4 0CPDE4A
3 100.0 66.7 50.0 100.0'm
28.6
77.8 33.3 33.3 44.4 44.4 33.3 22.2 33.3 44.4 5 MVIPDE4A
6 100.0 66.7 66.7 100.0 33.3 44.4 44.4 3 ^ ^ J i l l 44.4 6 RNPDE4A
7 100.0 62.5 75.0 66.7 50.0 1 0 T ^ B s8.9 66.7 66.7 55.6 66.7 55.6 66.7 7 RNPDE4D
8 100.0 62.5 75.0 66.7 50.0 50.0 12.5 ■ ■ 77.8 77.8 66.7 77.8 66.7 66.7 8 HSP0E4D
9 100.0 62.5 75.0 83.3 33.3 33.3 37.5 25.0 Mmliooo
l 0 : 0 j l ü
77.8 66.7 66.7 66.7 9 RNPDE4B
10 100.0 62.5 75.0 83.3 33.3 33.3 37.5 25.0 77.8 66.7 66.7 66.7 10 HSPDE4B
11 100.0 62.5 75.0 66.7 50.0 50.0 50.0 37.5 25.0 25.0 55.6 55.6 55.6 11 CPPDE4A
12 100.0 62.5 62.5 50.0 66.7 66.7 37.5 25.0 37.5 37.5 50.0 77.8 55.6 12 FCPDE4A
13 100.0 62.5 75.0 50.0 57.1 57.1 37.5 25.0 25.0 25.0 37.5 12.5 ■ 1 155.6 13 SSPDE4A
14 100.0 62.5 75.0 66.7 33.3 33.3 37.5 37.5 37.5 37.5 50.0 50.0 37.5 HSPDE4A
1 2 3 4 5 6 7 8 9 10 11 12 13
Figure 5.6.5.a Conservation of an octapeptide of sequence within the 
catalytic domain correlates with conservation of the hydrophilic domain 
of LR2 in PDE4 forms.
The matrix above shows the similarity of sequences in the octapeptide towards the 
beginning of the putative start of the catalytic domain. The octapeptide follows on 
from the start of the putative PDE4 consensus from (numbering for HSPDE4A4) 
amino acids 332 and 344 MsqIsGvkklmHs which is at the beginning of the putative 
catalytic domain (19) (see Introduction), Thirteen PDE4 sequences and dunce were 
compared in this region using the default settings on the DNAstar program. Percentage 
similarity is shown in the top right half, dissimilarity in the bottom left half. The 
diagram is quartered with two bold lines. The 'south-east' quadrant shows that this 
octapeptide is conserved between PDE4s which contain LR2HP or LR2P. These 
sequences are cat, guinea-pig, pig and human PDE4A, human and rat PDE4B and 
human and rat PDE4D. Sequences which lack hydrophilic LR2 regions (dunce, rat 
and human PDE4C rabbit, rat and mouse PDE4A) do not conserve their own separate 
sequence in this region, 'north-west', yet neither are their sequences in this part of the 
catalytic domain similar to those conserved between PDEs that contain the hydrophilic 
domain in LR2, ('north-east' & 'south-west' )
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( i )  LR2H: PDE4B& PDE4D
306 312 332 344 345 352KDREKKK MSQISGVKKLMHS SSLtNSSI
Catalytic
(11) LR2HP: PDE4A except rat, mouse and rabbit 
306 331 332 344 345 352
MKEREKQQAPRPRPSQPPPPPVPHLQP MSQITGLKKLMHS nSLNNSnl
HYDROPHILIC PROLINE-RICH Catalytic
LR2HP
(iii) LR2P: rat, mouse and rabbit PDE4A
315 331 332 344 345 352
PRQRAFQQPPPSVLRQSQP MSQITGLKKLVHT gSLtNv
PROLINE-RICH Catalytic 
LR2P
(iv) LR2A: PDE4C, d u n c e
non 332 344 345 352
HYDROPHILIC
Catalytic
UCR2 Catalytic
5.6.5.b. Schematic of LR2/cataIytic conservation for PDE4 genes
The conservation data of 5.6.5.a is summarised in the schematic above. Tlie LR2 domain 
and the furthest extent of the putative catalytic domain (19), are shown respectively with 
tliin and thick line. Numbering of residues is for HSPDE4A4. Sequences are human 
PDE4A for (i), human PDE4D for (ii), rat PDE4A for (iii) and human PDE4C for (iv). A 
schematic PDE4 gene structure is added to allow orientation.
(i) Conservation of a hydropliilic domain in LR2 (LR2H) correlates with conservation of 
tlie SSLNNSSI (matches to this consensus are shown in capitals) domain winch lies just 
witliin tlie putative catalytic domain. The intervening sequence is conserved in all PDE4 
forms, as shown, (ii) The hydropliilic domain and SSLNNSSI conservation correlation is 
also seen in PDE4A LR2HP domains (LR2 region which contains hydrophilic and 
proline motifs.), (iii) In rat, mouse and rabbit PDE4A the hydrophilic LR2 sequence is 
deleted. The 8mer whose conservation is linked with LR2H and LR2P is similarly 
unconserved, (iv) In LR2A subtypes there is no LR2 hydrophilic sequence with less 
hydropliilic sequences substituted. Again, tlie SSLNNSSI-like motifs are not conserved.
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Pereent Simil&iity
1 2 3 4 5 6 7 S 9
1 16.0 16,0 32.0 32.0 36.0 32.0 20.0 20.0 1 DMPDE
2 71.4 32.0 4.0 0.0 4.0 4.0 12.0 12.0 2 HSPDE4C
3 90.5 65.2 16.0 12.0 12.0 12.0 16.0 16.0 3 RNPDE4C
4 57.1 80.0 93.8 40.0 32.0 40.0 40.0 4 RNPDE4A
5 57.1 80.0 37.5 13.0 40.0 36.0 32.0 32.0 5 HSPDE4A
t 66.7 73.3 93.8 65.2 65.2 72.0 32.0 32.0 6 HSPDE4B
\ 7 68.2 80.0 86.7 63.2 63.6 22.7 36.0 36.0 7 RNPDE4B8 77.3 75.0 100.0 60.9 69.6 69.6 65.2 100.0 8 HSPDE4Dg 77.3 75.0 100.0 60.9 69.6 69.6 65.2 0.0 9 RNPDE4D1 2 3 4 5 6 7 8 9
Figure 5.6.5.C Sequences are typically conserved better in homologues 
of the same gene than in different genes.
The matrix above shows the similarity of sequences in PDE4 LRl. Eight PDB4 LRl 
sequences and dunce were compared using the default settings on the DNAstar 
program. Percentage similarity is shown in the top right half, dissimilarity in the 
bottom left half. The diagram is quartered with two bold lines as in figure 5.6.5.a. The 
'south-east' quadrant shows the conservation of LRl in PDE4s which contain LR2HP 
or LR2P. These sequences are human PDE4A, human and rat PDE4B and human and 
rat PDE4D. In the 'north-west' quarter of the diagram the conservation of LRl 
sequence between PDE4 with LR2A regions which lack hydrophilic LR2 component 
(dunce, rat and human PDE4C rabbit, rat and mouse PDE4A) is shown. The 'north­
east' and 'south-west' quarters of the diagram compare LR l sequences from PDE4 
which contain LR2A with LRl sequences from PDE4 which contain LR2H and 
LR2HP.
Unlike figure 5.6.5.a, no clear pattern emerges in the quadrants described. This 
indicates that LRl conservation is not linked with conservation of the hydrophilic 
domain of LR2. Instead, LRl sequences are most closely related to the homologue of 
the same gene (bold bordered boxes.)
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SPECIES GENE LR2 TYPE LINKED
CATALYTIC
SEQUENCE
HUMAN HSPDE4A LR2HP nSLN-NSnl
PIG SSPDE4A LR2HP SSLNedSSI
CAT FCPDE4A LR2HP SSLs-dSSI
GUINEA
PIG
CPPDE4A LR2HP SgLN-NaSI
HUMAN HSPDE4B LR2H SSLN-NtSI
RAT RNPDE4B LR2H SSLN-NtSI
HUMAN HSPDE4D LR2H SSLt-NSSI
RAT RNPDE4D LR2H SSLt-NScI
RAT RNPDE4A LR2P gSLNtN"-n
MOUSE MMPDE4A LR2P gSLNiN--v
RABBIT 0CPDE4A LR2P Ig — dSgl
HUMAN HSPDE4C LR2A aSLs-satv
RAT RNPDE4C LR2A tS L p -ta a l
DROSOPHILA DMPDE LR2A tn S f- tg e r
Table 5.6.5. Conservation of an octapeptide of sequence within the 
catalytic domain is linked with conservation of LR2H and LR2HP 
regions
This table recapitulates the information in figure 5.6.5.a-c. An octapeptide of putative 
catalytic sequence is apparently only conserved in PDE forms which conserve a 
hydrophilic domain in LR2. The type of LR2 for each PDE is listed (LR2HP, LR2H, 
LR2P and LR2A) and the conservation of the SSLNNSSI motif in the putative 
catalytic domain (matches are in upper case, mismatches in lower case. LR2H and 
LR2HP domains are linked with conservation of SSLNNSSI, these PDE forms are 
highlighted in bold. SPECIES IDENTIFICATION KEY: CP cavia porcellus (guinea- 
pig), DM drosophila melanogaster (fruit fly), EC felis catus (cat), HS homo sapiens 
(human) MM mus musculus (mouse), OC oryctolagus cuniculus (rabbit), RN (rattus 
norvegicus), SS sus scrofa (pig)
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5.7. Human RDI RNA shares homology with rat RDI upstream of the 
putative initiator methionine.
The full length sequence of hRDl has now been deduced from cosmid clones 
of human genomic DNA (82). It is homologous to the rat form RDI over the coding 
sequence for its unique 5' alternative splice region and also further upstream than the 
initiator ATG. RT-PCR of primers designed to this sequence were able to amplify a 
fragment from human brain. TA cloning and sequencing demonstrated that this 
sequence was the result of amplification of the hRDl transcript. This result confirms 
that the initiator methionine is present in the hRDl like transcript, along with 
conserved sequence further upstream.
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10 20 30 40 50
I I I I I
CAGGCGGGCTAAGTCTCCAAGATGCCCTTGGTGGATTTCTTCTGCGAGACCTG
ATGCCCTTGGTGGATTTCTTCTGCGAGACCTG 
I I I
10 20 30
60 70 80 90 100
I I I I I
CTCTAAGCCTTGGCTGGTGGGCTGGTGGGACCAGTTCAAAAGGATGTTGAACC
CTCTAAGCCTTGGCTGGTGGGCTGGTGGGACCAGTTCAAAAGGATGTTGAACC 
I I I I I
40 50 60 70 80
110 120 130 140 150
I I I I I
GTGAGCTCACACACCTGTCAGAAATGAGCAGGTCCGGAAACCAGGTCTCAGAG
GTGAGCTCACACACCTGTCAGAAATGAGCAGGTCCGGAAACCAGGTCTCAGAG 
I I I I I
90 100 110 120 130
160 170 180 190 200 210
I I I I I I
TACATTTCCACAACATTCCTGGACAAACAGAATGAAGTGGAGATCCCATCACC
TACATTTCCACAACATTCCTGGACAAACAGAATGAAGTGGAGATCCCATCACC 
I I I I I I
140 150 160 170 180 190
220 230 240 250 260
I I I I I
CACGATGAAGGAACGAGAAAAACAGCAAGCGCCGCGACCAAGACCCTCCCAGC
CACGATGAAGGAACGAGAAAAACAGCAAGCGCCGCGACCAAGACCCTCCCAGC 
I I I I I
200 210 220 230 240
270 280 290 300 310
I I I I I
CGCCCCCGCCCCCTGTACCACACTTACAGCCCATGTCCCAAATCACAGGGTTG
CGCCCCCGCCCCCTGTACCACACTTACAGCCCATGTCCCAAATCACAGGGTTG 
I I I I I
250 260 270 280 290
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320 330 340 350 360 370
I I I I I I
AAAAAGTTGATGCATAGTAACAGCCTGAACAACTCTAACATTCCCCGATTTGG
AAAAAGTTGATGCATAGTAACAGCCTGAACAACTCTAACATTCCCCGATTTGG 
I I I I I I
300 310 320 330 340 350
380 390 400 410 420
I I I I I
GGTGAAGACCGATCAAGAAGAGCTCCTGGCCCAAGAACTGGAGAACCTGAACA
GGTGAAGACCGATCAAGAAGAGCTCCTGGCCCAAGAACT 
I I I
360 370 380
Figure 5.7. RDl-like transcript in human brain RNA
Human brain RNA was probed for RD-1 like transcripts by RT-PCR using GR36 and 
a GR5'hRDl. Sequence of one of ten TA clones (clone h3) from this PCR reaction 
(bottom) is shown aligned to the expected transcript that would be produced if the RDI 
exon isolated from human genomic DNA was spliced in the same manner as rat RDI 
(82). This sequence starts at the conserved initiator methionine (underlined).
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5.8. CONCLUSION
5.8.1. RDl(RNPDE4Al)-like PDE4A splice variants transcripts are 
expressed in brains from various mammals.
In this chapter one of the longest standing questions of PDE molecular 
biology has been answered, namely: do homologues of RDI exist in other species?
By using primers designed to rat RD I, then using a low stringency RT-PCR 
procedure on brain RNA I have been able to demonstrate that RDl-like transcripts are 
expressed in a variety of mammals. Thus RDI has become only the second PDE4A 
splice variant, after HPDE46 (HSPDE4A4)/RPDE6 (RNPDE4A5) which has been 
unequivocally identified in more than one species. Since rat RD1 has been shown to 
date only to be expressed in the brain it is reasonable to anticipate that this may be the 
case in human. It will thus be of interest to see if a neuronal cell line can be found 
which expresses hRDl. The lack of availability of rat brain cell lines has meant that 
studies on RDI were hampered because the only sources from which RDI could be 
obtained were native brain tissue or recombinant protein. RT-PCR screening of the 
large number of human brain cell lines holds out the possibility that a cell line 
expressing hRDl may yet be found, which will make possible studies on regulation 
and targeting of endogenous protein.
5.8.2. The importance of functional domains identified in RDI and in 
other PDE4 species is underscored by their conservation in mammalian 
R Dl-like homologues.
My finding that the putative membrane association domain of RD I, 
PWLVGWW, is perfectly conserved in mammals emphasises the importance of a 
number of papers which have established this motif as a novel membrane association 
determinant which is primarily responsible for the membrane association of rat RDI 
(see Introduction) through a protein-protein hydrophobic interaction 
(102,110,111,113,114). The next residues are also perfectly conserved which is 
consistent with the notion that the DQFKR motif is needed to stabilise the 
PWLVGWW motif as was suggested by Smith et al (114). Given the conservation of
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the unique RDI motifs which is implied in the data presented here, it would seem 
likely that this region is conserved across all mammals, underscoring its importance. 
Further, the conservation of the N-terminus of RDI is certainly consistent with 
membrane association being due to a conserved molecular recognition involving the 
N-terminal of RDI (as proposed in (19)), rather than it being due to a less stringently 
conserved membrane insertion. This data makes it imperative that the molecular 
mechanism by which PWLVGWW attaches to membranes be elucidated and the 
physiological importance of tliis event defined.
The finding that the C-terminal of UCR2 is almost invariant between seven 
species of mammals (40/43 invariant residues) further confirms the conclusions drawn 
from the previous dunce/human/rat comparisons which first established the existence 
of UCR 2 conservation in PDE4 forms (68,81). The function of UCR2 remains 
poorly defined
5.8.3. Sequence conservation analyses of the mammalian PDE4 LR2 
regions and putative catalytic domain suggest two correlated variations 
of "ancient" PDE4 sequence in PDE4C, dunce,  and in rat, rabbit and 
mouse PDE4A
I have identified a short stretch of hydrophilic sequence which appears to be 
deleted from rat, mouse and rabbit PDE4A LR2P, which is not conserved in dunce 
and PDE4C LR2A but which is present in all other mammalian PDE4A, B and D 
forms. This deletion is predicted to alter radically the secondary structure of the LR2 
region. Comparison of my PDE4A partial clones with other PDE4 sequences also 
allowed identification of a second sequence which is apparently variable in a subset of 
PDE4. Interestingly, this variation correlates with deletion of the hydrophilic domain 
of LR2. Thus there is a reversal of the normal situation, where sequences are typically 
conserved more between homologues of a gene from various species than between 
different genes in the same species. I have shown, for example, that the latter is the 
case for conservation patterns in LRl.
Regardless of whether the LR2 hydrophilic motif and its linked octapeptide
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reflect 'ancient' mammalian sequence which has been duplicated in three of the four 
genes, or evolutionary molecular parallelism, a clear inference that can be drawn is that 
these sequences interact in some way because their conservation is linked.
Such sequence conservation analyses may now provide a means to derive the 
function of LR2HP. Whilst it is clear that the rat and mouse species are able to 
function without LR2HP and the linked 8mer within the putative catalytic domain, 
there may be nevertheless, alterations in function due to these changes. Thus mouse 
and rat PDE4A splice variants will provide null' controls against which putative 
functions of the domain can be tested. These may be powerful tools in experiments 
that aim to elucidate the role of LR2HP. Functional differences between rat PDE4A 
splice variants and their human homologues have already been observed. As discussed 
at length in the introduction, HPDE46 (HSPDE4A4) is able to switch between two 
states as sensed by rolipram, whereas the rat homologue of this isoform, RPDE6 
(RNPDE4A5), does not exhibit this ability (77,100). The unequivocal test of whether 
this property can be attributed to the newly identified sequences would thus be to 
engineer LR2HP and/or the linked catalytic 8 mer domains into the rat PDE4A in an 
attempt to recover a PDE with rolipram inhibition kinetics that resemble those of the 
human PDE4A. (figure 5.7.4). The converse approach would be to attempt to knock­
out conformation shifting in human PDE4A by deleting the hydrophilic domain in LR2 
and/or the linked octapeptide in the catalytic domain.
The interaction between LR2HP/LR2H and the linked 8mer, suggested 
above, could be regulated in PDE4A forms by binding to SH3 domains by virtue of 
the intervening sequence being proline rich. SH3 binding to the PDE4A specific LR2 
proline motif could sterically interfere with this interaction. This notion is consistent 
with functional differences between RPDE6 and HPDE46 which have been observed 
in COS cells. Thus, both RPDE6 and HPDE46 could bind to SH3 domains because 
their respective LR2 domains, LR2P and LR2HP, have proline-rich regions. 
Therefore, both HPDE46 and RPDE6 would bind to membranes. Only in HPDE46 
could this be expected to effect the interaction between LR2HP and the linked 8mer 
peptide in the catalytic domain, leading to conformational change. Evidence for such a
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mechanism could be obtained by trying to mimic the apparent effects of SH3 domain 
interaction on HPDE46 by saturating cell lysates with peptides designed to the 
hydrophilic section of LR2HP or the linked 8 mer peptide sequence. This would be 
expected to produce a conformer with a high affinity of rolipram binding in the 
absence of SH3 containing proteins.
Data is now also needed to define whether switches in other PDEs occur due 
to the sequence motifs identified here. Thus, based on tlie assumption that switching is 
caused by some interaction between LR2H/LR2HP and tlie linked Smer, it is predicted 
that isoforms which contain this sequence, PDE4A, B and D, will have multi-state 
conformations. To date, this switching has only been shown for PDE4A and PDE4D 
forms, as discussed in the introduction. PDE4B forms all show complex kinetics of 
rolipram inhibition (83,90). Although various IC50 (varying by up to 10 fold) values 
have been obtained for subcellular fractions of PDE4B, switching between these 
different kinetics of rolipram inhibition has not yet been observed.
Dunce PDE and PDE4C, which lack both LR2H/LR2HP and the linked 
8 mer, are predicted not to be able to exhibit switching between multi-state 
conformations. In this regard. Dunce PDE is not susceptible to inhibition by rolipram 
which in itself is consistent with the notion that LR2H and the linked 8 mer may have a 
role in rolipram binding. PDE4C does retain rolipram binding however. So, clearly, 
even if LR2H and the linked 8 mer play a role in rolipram binding, other conserved 
domains must exist in the rest of the protein. Intracellular switching of rolipram 
kinetics has not been observed in PDE4C. However, different patterns of rolipram 
inhibition have been detected for PDE4C from different sources. Rolipram inhibition 
which observed simple kinetics was detected in yeast whereas in COS-7 cells a 
complex inhibition was observed (78). Importantly however, these two PDEs showed 
a major (4-fold) alteration in the Ki„ for cAMP and thus are qualitatively different from 
the conformers sensed by rolipram in PDE4A, B and D where the for cAMP is 
always unchanged (90,100,137).
To recapitulate, the conformational shifts sensed by alterations of rolipram 
inhibition kinetics in PDE4C are also detected by an altered affinity of cAMP. Since
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the conformational shift detected in PDE4A, B and D is not sensed by cAMP, the 
underlying molecular basis for the alteration in PDE4C kinetics is probably not the 
same as that for PDE4A, B and D. Neither has PDE4C been shown to switch 
conformations in a single cell type, as is the case for PDE4A and PDE4D.
The form of the interaction that takes place between the LR2H/LR2HP and 
the linked 8mer peptide remains obscure. The LR2H/LR2HP hydrophilic sequence is, 
generally, positively charged but the linked catalytic octapeptide is uncharged. From 
the point of view of regulation one of the most attractive possibilities is that one or 
more of the four serines in the octapeptide could be phosphorylated and that this 
incorporation of negative charge would then allow a conditional charge interaction 
with the LR2 as has been suggested previously for UCRl association with UCR2 (19) 
but unlike the former case there are no obvious consensus sites for known kinases in 
this region (215).
5.8.4. Sequence variations in the N-terminal of the catalytic domain are 
consistent with the shortest previous estimation of the range of the 
catalytic domain
The finding here that the N-terminal of the putative catalytic domain is not 
very well conserved also concurs with the existing dunce/human/rat conservation data 
(see section 1.7.2.) but this appears to be accentuated in my data set. My data shows 
that the mammalian PDE4A putative catalytic domain is well conserved at its extreme 
N-terminal, starting at methionine 332 with a consensus of MsQITGvKklmHs, in 
good agreement with existing data (19). In the PDE4A sequences that I have isolated 
there is then the 8mer of sequence variation (residues 345-352) which was discussed 
above. Finally, there is a highly conserved sequence starting iPRFGVKT... This 
sequence, starting at position 352, is close to the starting positions of truncation 
mutants hybl (starts at 365) and AG212-P342 (which starts at 342) (19,129), which 
are the most radically truncated PDE constructs which still retain catalytic activity. The 
truncation data therefore indicates that the catalytic domain proper commences at the 
iPRFGVKT... motif (19). The lack of sequence conservation that I have identified in
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the 8mer linked peptide (345-352) concurs with this notion. Nevertheless, the position 
of the MsQITGvKklmHs motif and its conservation means that though it is 
unnecessary for PDE catalytic activity its position makes it highly likely that it will 
have some role in catalysis or catalytic regulation in native PDE4.
5.8.5. The PDE4A LR2 hydrophilic motif deletion may be suitable for 
delineating the true extent of the order rodentia.
Establishing ancestry by molecular means depends on finding genetic lesions 
which have occurred and been consolidated in a branch of evolution but not in others.
This allows closely related species to be assigned (or not) to this branch. The single 
most difficult problem in such analysis is deciding whether a shared taxonomic 
character is due to common ancestry or one that appeared independently due to 
convergence, parallelism or reversion to an ancestral state. Mitochondrial genomes are 
often used in these studies because of their maternal inheritance, lack of recombination 
and insulation from species-specific evolutionary constraints in preference to nuclear 
genes which are open to such variations. Recently, phylogenies have been constructed 
using mammalian LI retrotransposons which promise to revolutionise this field (216- 
218). These undergo periodic amplifications in which multiple copies of the elements 
are interspersed in the genome. Since these elements are transmitted only by 
inheritance and are retained in the genome, a shared LI amplification event can only be 
an inherited ancestral character. These two methods, combined with phylogenetic 
analyses on nuclear genes, do not agree with a number of phylogenetic orthodoxies 
regarding the validity of the taxonomic order Rodentia. First, they have challenged the 
validity of the proposed monophyletic superordinal grouping of Glires (219-221) 
which unites the orders lagomorpha (rabbits) and rodentia (rodents) (that is, these two 
orders were proposed to share a common ancestor which was not shared with any 
other order and this has now been challenged). Second, the monophyletic validity of 
the order rodentia itself has been questioned (220-224), with a proposal that the sub­
order hystricomorpha (guinea-pigs and porcupines) or at least the family caviomorpha 
(guinea-pigs) should be conferred an independent ordinal status, distinct from the
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other suborders, which include myomoipha (rats and mice.)
The radical restructuring of a conserved sequence of apparently ancient 
sequence that I have detected in the myomorphic PDE4A gene may yet be a useful 
taxonomic character in solving the refractory problems of rodent phylogenies 
discussed above. Once the extent of the LR2P motif amongst species assigned as 
rodents is known, it may be possible to address one or both of the above problems. 
This would be done by performing RT-PCR on brains from a range of rodent species 
to determine whether or not they contain the deletion in PDE4A. In principle tliis could 
be done without sequencing since the LR2P motif is distinguishable from LR2HP as 
altered mobility of DNA fragments on an agarose gel. Species containing the LR2P 
could then form a true monophyletic grouping of rodents. An important prerequisite 
for such a rationale would be to establish that the deletion seen is not more generally 
prevalent than my preliminary survey of five non-rodent species suggests (which 
would imply parallelism or convergence). This would be done by performing RT- 
PCR on brains from non-rodent species. For the deletion to be a reliable marker of 
rodent monophyly these fragments should not contain the LR2P region. Given the 
apparent ancient nature of the hydrophilic sequence in LR2HP, there is clearly a 
possibility that the LR2 deletion could be a reliable marker for a true monophyletic 
grouping based around rodents. This would be of considerable interest in the field of 
molecular taxonomy. In the meantime, based on the assumption that the deletion I 
have identified is rodent-specific, the preliminary data I have obtained certainly 
concurs with the notion that caviomorphs (guinea-pigs) and lagomorphs (rabbits) are 
not part of a monophyletic rodent grouping because neither of them share the deletion 
conserved in the myomorphs (rat and mouse).
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6. USE OF A NOVEL CLONING STRATEGY TO CLONE THE FULL 
OPEN READING FRAME OF A NOVEL HUMAN PDE4A SPLICE 
VARIANT, PDE4A10 
INTRODUCTION
6.1 PDE4A10, A NEW PDE4A SPLICE VARIANT.
This section of work follows on from the discovery of a rat cDNA library 
clone which apparently encodes partial sequence for a novel PDE4A splice variant 
(M.D. Houslay, unpublished) which I have designated PDE4A10. This cDNA has 
-90  base pairs of novel sequence upstream of the splice junction shared between all 
PDE4 'long' forms and the reading frame is open at the 5' end. It was decided to use 
the skills developed through the work of the two previous chapters to attempt to 
identify this partial clone in total RNA to confirm tliat it was not an artefact. Then PCR 
based methodologies would be employed to isolate the remaining sequences.
6.2. PCR BASED METHODOLOGIES FOR ISOLATING 5' END 
GENE FRAGMENTS: RAPID AMPLIFICATION OF cDNA ENDS 
(RACE).
Probing of cDNA libraries is still the major method for isolating new PDEs. 
However, PDE cDNAs isolated by such means are often incomplete (66-68,74,75,79- 
81). The robust nature of the PCR reaction makes it an obvious choice for isolating the 
remaining sequence but there are practical difficulties in applying PCR to cDNA end 
isolation. The abstract problem is that because of tlie uni-directional processivity of DNA 
polymerisation (5' to 3') there must be some known sequence on either side of the 
unknown sequence before the PCR reaction can be used to isolate that unknown 
sequence. A number of PCR based methodologies are now available to allow isolation of 
the remaining sequence. These methods are often termed RACE (for Rapid Amplification 
of cDNA Ends). RACE strategies are theoretically particularly attractive in tlie PDE4 field 
because each gene is alternatively spliced at the 5' end of a large G/C rich gene. This 
means that the splice variant specific sequence is not propitiously placed for identification 
in cDNA libraries as is manifest in the literature (see Introduction). The use of PCR
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based methods for isolating new PDE4 sequence has rarely been reported although it has 
been used successfully to generate new PDE4B and PDE4C forms (78,90). A reliable 
PCR-based method for isolating PDE4 5' ends was sought.
6.2.1.Terminal deoxyribonucleotidyl transferase (TdT) mediated 
RACE (see figure 6.2.1.)
This was the first protocol developed for PCR mediated isolation of 5' ends 
(225-227). cDNA is synthesised using a recombinant reverse transcriptase which 
lacks RNAse H activity. This is done in order to maximise synthesis of long cDNAs 
by eliminating reverse transcriptase mediated digestion of the template RNA. The 
cDNA primer is then removed to prevent competition for the tagging process, which 
uses the activity of terminal deoxynucleotidyl transferase to add a homopolymeric tail 
of nucleotides to the 3' end of first strand cDNA (see figure). An inosine containing 
primer designed to anneal specifically to this sequence is then used in PCR with a gene 
specific primer.
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Section 2 .2 6  RTasei
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Figure 6.2.1. Terminal deoxynucleotidyl Transferase (TdT) RACE
The figure above is a schematic of TdT RACE. cDNA is first transcribed from RNA 
by reverse transcriptase (RTase) (sections in figure relate to methods sections), using a 
gene specific primer (GSPl). Then TdT is used to 'tail' the 3' end of the first-strand 
cDNA with a homopolymeric stretch of nucleotides (CCCC). An inosine containing 
primer optimised for amplifying such homopolymers can then amplify the unknown 
sequence (hatched), in a PCR with a nested gene specific primer (GSP2)
PRIMER KEY: 5' end; Primers are unphosphorylated.
3' end: Primers unblocked at the 3' end have an arrow-head.
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6.2.2. T4 RNA ligase mediated (RLM) RACE (see figure 6.2.2.)
This protocol uses a different reaction for tagging the cDNA than TdT 
mediated RACE (above). Following cDNA synthesis the cDNA primer is removed. 
As in the TdT RACE protocol above this is to prevent competition for the subsequent 
tagging step. T4 RNA ligase which catalyses single stranded oligonucleotide ligations 
is used to ligate a phosphorylated oligonucleotide onto the cDNA 3' end (228-233). 
The concentration of primer added in this step is intentionally low so tliat PCR can be 
carried out directly on an aliquot of the ligation, using a primer complementary to the 
phosphorylated oligonucleotide and a primer complementary to the gene of interest.
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Figure 6.2.2. RNA Ligase Mediated (RLM) RACE.
The diagram above is a schematic of RLM RACE. cDNA was transcribed from RNA 
by reverse transcriptase (RTase) using a gene specific primer (GSPl). A single- 
stranded phosphorylated deoxyriboligonucleotide (•  -)  was then ligated to the 3' end 
of the first-strand cDNA. A complementary primer would then be able to amplify 
unknown sequence (hatched) as shown, in a PCR with a gene-specific primer 
(GSP2).
PRIMER KEY: 5' end; Primers phosphorylated at the 5' end are shown thus (•)  
whereas unphosphorylated primers are undecorated.
3' end: Primers unblocked at the 3' end have an arrow-head. Blocked primers are 
undecorated at this end of the primer
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6.2.3. Intramolecular RACE: T4 DNA ligase mediated isolation of gene 
fragments by inverse PCR (see figure 6.2.3.)
Intramolecular RACE is a variation on the theme of standard RLM RACE. 
This uses a phosphorylated oligonucleotide in the cDNA synthesis to create cDNAs 
with a phosphorylated 5' end. T4 RNA ligase was used to circularise these, a reaction 
which it carries out more efficiently than intermolecular ligations of standard RLM 
RACE (234,235). New sequence would then be isolated by inverse PCR (where 
primers polymerise away from each other on the known piece of DNA but because the 
cDNA is circularised, the unknown DNA is then PCR amplified, see figure
6.2.3.)( 156). This rationale has been used successfully with an RNA viral genome 
(236). However it has not been reported for cDNAs derived from complex RNA 
populations.
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Figure 6.2.3. Intramolecular RACE
The figure above is a schematic of intramolecular RACE. cDNA is transcribed from 
RNA by reverse transcriptase using a phosphorylated primer (GSPl). The cDNAs can 
then be circularised by T4 RNA ligase (234,235). The unknown sequence (hatched) 
can then be isolated by a standard inverse PCR (156) with a nested gene-specific 
primer (GSP2).
PRIMER KEY: 5' end; Primers phosphorylated at the 5' end are shown thus (•)  
whereas unphosphorylated primers are undecorated.
3' end: Primers unblocked at the 3' end have an arrow-head.
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6.3. SPLICE VARIANT ISOLATION FROM GENOMIC COSMID 
CLONES
PDE4 splice variants typically have only one 5' end exon alternatively 
spliced. Thus, each splice variant specific sequence will be found all together in one 
place in the genome. This makes genomic screening a realistic alternative, one where 
partial clones are not a problem. Indeed, with the recent mapping of a 210Kb contig of 
overlapping cosmid clones which covers all of the known PDE4A locus, screening of 
two or three of these -40Kb clones at the 5' end of the contig by PCR becomes a 
simple proposition (82), which allows probing of large amounts of sequence highly 
likely to harbour the splice variant specific sequence. The genomic organisation of 
PDE4s has allowed the use of a novel cloning technique that I have devised to isolate 
DNA sequence from large clones of DNA such as cosmids. This system has two 
major advantages over RACE: (1) The PCR reaction in the screen is a conventional 
one where the diagnostic band is of a known size; (2) Since there is no PCR step in 
the isolation itself, concerns regarding fidelity of thennal polymerases do not apply.
The major problem concerned with handling genomic DNA is processing the 
large amounts of DNA to get at the sequence of interest. The next sections outline a 
new method for production, alignment and restriction mapping of contiguous clones.
6.4. TA SHOTGUN CLONING: MORE EFFICIENT CLONING
Cutting a large DNA insert (such as cosmid or library inserts) sequence into 
smaller pieces (so called shotgun cloning) is a common procedure in molecular 
biology. The smaller insert is easily sequenced and more manageable for downstream 
cloning. This is typically done by digesting the DNA that is to be the insert with a 
frequent cutting enzyme such as Sau3 A I and digesting the vector with a rarer cutting 
enzyme which will give complementary ends to the frequent cutting enzyme. A 
suitable example in this case would be BamH I. Since Sau3A I fragments ligating into 
BamH I sites will mostly not regenerate the BamH I site (7/8 chance for all inserts), 
BamH I can be added to the ligation to prevent vector recircularisation. The small size 
of Sau3A I fragments sometimes makes the use of less frequently cutting enzymes
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such as Xho II more attractive for cloning into the BamH I site because this will 
produce larger inserts. However BamH I should not be added in ligations with Xho II 
because in this case half of all inserts will regenerate the BamH I insert at one or other 
end. Thus recircularisation of the vector will be promoted and ligation of Xho II 
fragments will be lower unless time consuming steps such as alkaline phosphatase 
treatment of vector or insert aie adopted in place of the use of BamH I in the ligation.
Regardless of the above considerations, 'classical' ligation efficiency is still 
reduced by circularisation of inserts. TA cloning is more efficient than this because 
neither insert nor vector can cii’cularise and thus intermolecular ligations are favoured. 
This is because TA cloning makes use of the property of certain DNA polymerases to 
add a single base overhang (usually an A) to DNA ends (237). This can then be ligated 
to a vector containing complementary single T overhangs and since neither vector nor 
insert have self-cohesive ends, intramolecular ligation is less probable. The efficiency 
of TA cloning was harnessed for subcloning. In principle the conventional 5' to 3' 
polymerase activity of Taq polymerase should be able to polymerise DNA digested by 
any enzyme which leaves recessed 3' ends (such as Xho II/ BamH V  Sau3A I). This 
DNA should then also have the non-template-directed A added onto its 3' end (237), 
allowing conventional TA cloning. I sought to establish whether this protocol would 
work by TA shotgun cloning cosmid DNA containing PDE4 unique exons.
6.5. OVERLAPPING TA SHOTGUN CLONING ALLOWS RAPID 
CONTIG ASSEMBLY AND SINGLE ENZYME RESTRICTION MAPS.
As a protocol for long distance sequencing classical shotgun cloning is not 
attractive (even as modified above) because the ends of the DNA fragments are 
identical and so it is not easily possible to order them without resorting to restriction 
mapping. This problem could be solved by making use of enzymes that cut away from 
their recognition sites. An example of such an enzyme is Hga I. If these digestion 
fragments are filled in as described above, then they could be formed into a contig 
without restriction digestion on the basis of the resulting unique overlaps (see figure
6.5.) As will be shown in this chapter, the ease of this approach could make it the
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method of choice for sequencing and/or restriction mapping projects using all but the 
largest pieces of DNA.
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I 1. Digest with Hga I: Recognition site GACGC
0—
2. Fiil in ends with 
Taq poiymerase
GACGCNNNNNagc^c
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Figure 6.5. Assembly of a contig by overlapping shotgun TA cloning
(1) The target DNA is digested with an enzyme wliich digests at a site beyond 
its recognition site (e.g. Hga I recognition site is shown in bold.) to give a unique 5' 
overhang (circles). (2) Tliis can be filled in by Taq polymerase to give two copies of tlie 
unique cut sequence, one in each of tlie restriction fragments. Taq polymerase also adds 
a non-template directed A. (3) The A overhang allows TA cloning and then the unique 
fragment ends (paired shapes) can be identified by sequencing. (4) Unique fragment 
ends (paired shapes) allow the fragments to be ordered into a contig and restriction map.
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RESULTS
6.6. IDENTIFICATION OF TRANSCRIPTS FOR RNPDE4A10 IN 
RNA EXTRACTED FROM THE OLFACTORY BULB OF RATS AND 
IN RAT GENOMIC DNA.
Piimers OR 10 and G R ll (see figure 6.6) were designed to the ends of the 86 
base pairs of unique RNPDE4A10 sequence in order to detect a band this size in RT- 
PCR on olfactory bulb RNA with reverse transcription primed by generic PDE4A 
primer GR29. Primer GR36, designed to sequence shared between all PDE4A>was 
also used in conjunction with GRIG (figure 6.6). When the two sets of PCR primers 
were used in RT-PCR both amplified bands of the expected size, consistent with the 
notion that rat olfactory bulb RNA does indeed express this RNA. PCR of genomic 
DNA using the same conditions with the two PDE4A10 specific primers GRIG and 
GRl 1 (the antisense primer GR36 could not be used here because that sequence is on 
a different exon) also produced a conect size band. This was further evidence that the 
clone was not an artefact. Thus it was decided to attempt to isolate the rest of the 
PDE4A1G open reading frame.
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1 CGCATTGCCC CTAGGACCAG AGTCACTGAC CCATTTCTCC TTCAGCGAGG 
GCATTGCCC CTAGGACCAG AGTC 
GR10 GR10
51 AGGACACTCT TCGACACCCT CCGGGCAGAT GTGTCAGCTT GGAGGCAGAA
GA GGCCCGTCTA CACAGTCGAA C
GRll GRll
101 AATGGGCCAA CGCCATCCCC TGGCCGCAGC CCCCTGGACT CGCAGGCGAG
151 CCCGGGGCTT GTGCTGCATC GTGGGGCCAC CACCAGCCAG CGCCGCGAGT
201 CCTTCCTCTA CCGCTCAGAC AGCGACTATG ACATGTCACC GAAGGCTGTG
GAAGGACAT GGCGAGTCTG TCGCT
GR84 GR84
251 TCCAGGAGCT CGTCTGTCGC CAGCGAAGCG CACGCTGAGG ACCTCATTGT
301 GACACCATTT GCCCAGGTGC TGGCCAGTCT CCGCAGCGTT CGAAGCAACT
351 TCTCACTCTT AACCAATGTG CCCATCCCCA GCAACAAGAG GTCTCCACTG
401 GGTGGCCCAC CCTCTGTCTG CAAGGCCACA CTGTCAGAGG AGACGTGCCA
451 GCAGCTGGCC CGGGAGACCC TGGAAGAGCT GGATTGGTGC CTGGAGCAGC
501 AGCTGGAGAC CATGCAGACC TACCGCTCTG TCAGCGAGAT GGCCTCACAC
551 AAGTTCAAAA GGATGCTGAA CCGTGAGCTC ACACACCTGT CGGAAATGAG
601 CAGGTCAGGA AACCAGGTCT CAGAGTACAT TTCCAACACA TTCCTGGACA
651 AGCAGAATGA AGTGGAGATC CCCTCACCCA CACCTCGGCA GAGAGCCTTC
701 CAGCAGCCCC CGCCGTCAGT GCTGCGACAG TCCCAGCCCA TGTCTCAGAT
751 CACAGGGCTG AAAAAGCTGG TACACACTGG AAGCTTGAAC ACCAACGTCC
801 CACGGTTTGG AGTCAAGACA GATCAAGAGG ACCTCTTAGC ACAAGAACTG
C
GR36
851 GAGAACTTGA GCAAATGGGG CCTGAACATC TTTTGTGTGT CGGAGTACGC 
CTCTTGAACT CGTTTACCCC GGAC
GR36
1151GCTGCCATCC ACGATGTGGA CCACCCTGGC GTCTCCAACC AGTTCCTAAT 
GG TGCTACACCT RGTGGGAC
GR29 GR29
Figure 6.6. Primers designed for RT-PCR of the 5' end of PDE4A10 
form s.
Above is shown the 5' sequence of the original cDNA clone of rat PDE4A10.
GR29 is designed to human and rat sequence. Primers were used in ligations and PCR 
as described in the text. Primer sequences are as presented, underline is sense, double 
underline is antisense.
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6.7. PCR-BASED ATTEMPTS TO ISOLATE THE 5' END OF 
PDE4A10
6.7.1. TdT RACE fails to produce any amplification products
PDE4A10 specific cDNA was primed with GR38. PCR with the gene 
specific primer GR39 and the anchor primer failed to produce a PCR band on three 
separate occasions.
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1 CGCATTGCCC CTAGGACCAG AGTCACTGAC CCATTTCTCC TTCAGCGAGG
GG AAGTCGCTCC
GR39
51 AGGACACTCT TCGACACCCT CCGGGCAGAT GTGTCAGCTT GGAGGCAGAA 
TCCTGTG CGTCTA CACAGTCGAA C
GR39 GR38 GR38
ADAPTORS
GR39 CAUCAUCAUCAUGTGTCCTCCTCGCTGAAGG
ANCHOR CUACUACUACUAGGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG
AMPLIFICATION CUACUACUACUAGGCCACGCGTCGACTAGTAC
Figure 6.7.1. Primers used in TdT mediated RACE
The diagram above shows the 5' end of rat PDE4A10 and the primers used in TdT 
RACE. Primer GR38 was used for reverse transcription. Anchor primer. 
Amplification primer and GR39 (the full sequence is shown beneath rat PDE4A10) 
were used in a PCR reaction to try to isolate new PDE sequence. The inosines in the 
anchor primer are designed to specifically bind to the polyC tail added to the cDNAs 
by TdT. The uracil containing 5' ends of the adaptors were to allow a ligase free 
ligation of any PCR products obtained
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6.7.2. RNA ligase mediated (RLM) RACE produces no PDE4A 
amplification products.
A series of experiments attempted to isolate upstream PDE4A10 sequence 
using RNA ligase mediated RACE (228). Though these experiments differed in fine 
detail, often simply modified PCR conditions, the results presented here are typical of 
those obtained.
6.7.2.1 Experimental outline
PDE4A10 specific cDNA was primed with GRl 1. This cDNA was ligated to 
the 5' end with one of two phosphorylated oligonucleotides, GR85 or GRIOO as 
shown in figure 6.2.2. GR85 and GRIOO are designed to reduce non-specific 
reactions. Thus, GR85 is truncated so that it is not an effective priming site for GR54 
amplification but gene specific polymerisation on the antisense strand then creates 
these sites. It is amine blocked at the 3' end so that if GR54 does bind to it, Taq 
cannot fill-in the overhang to create perfect competing GR54 binding sites. Amine 
blocking should also prevent intramoleeular or intemaolecular self-ligation reactions 
which would compete with intermolecular ligation to cDNAs. GRIOO is longer than 
GR85 which allows nested PCR of the anchor as well (see below). As with GR85, 
GRIOO was blocked at its 3' end to prevent self-ligation.
Both of the ligations were then subjected to two rounds of nested PCR. For 
the GR85 ligation, only the gene specific primer was nested, with the GR85 anchor- 
specific primer GR54 used in both PCR reactions. GRIOO is a longer anchor so in 
PCRs of this ligation nesting of anchor primers was possible too, thus the first PCR 
of this ligation used anchor-specific primer GR79 and the second PCR used anchor- 
specific primer GR54.
The gene-specific primer in the first PCR was always GR52. However, 
nested PCRs were done in parallel with different primers, GR51 & GR50. The 
different positions of these primers on PDE4A10 should cause authentic PDE4A10 
RACE amplifications to be differently sized in each reaction and for fragments up to 
~400 base pairs this would be readily observable on an agarose gel.
Chapter 6: Identification  o f  a new  P D E 4A  sp lice  variant 209
1 CGCATTGCCC CTAGGACCAG AGTCACTGAC CCATTTCTCC TTCAGCGAGG
GCATTGCCC CTAGGACCAG AGTC C g
GR10 GR10 GR52
CGTAACGGG GATCCTGGTCTCCAG GACTG GGTAAAGAGG AAGTCGCTCC
GR50 GR50 GR51 GR51
51 AGGACACTCT TCGACACCCT CCGGGCAGAT GTGTCAGCTT GGAGGCAGAA
TCCTGTGAGA AGCTGTGGGA G
GR52
GA GGCCCGTCTA CACAGTCGAA C 
GRll GRll
101 AATGGGCCAA CGCCATCCCC TGGCCGCAGC CCCCTGGACT CGCAGGCGAG
151 CCCGGGGCTT GTGCTGCATC GTGGGGCCAC CACCAGCCAG CGCCGCGAGT
201 CCTTCCTCTA CCGCTCAGAC AGCGACTATG ACATGTCACC GAAGGCTGTG
GAAGGACAT GGCGAGTCTG TCGCT
GR84 GR84
251 TCCAGGAGCT CGTCTGTCGC CAGCGAAGCG CACGCTGAGG ACCTCATTGT
1151GCTGCCATCC ACGATGTGGA CCACCCTGGC GTCTCCAACC AGTTCCTAAT
GG TGCTACACCT RGTGGGAC
GR29 GR29
Adaptors
GR54 GR54
GCATCGTCGACGTCATCTGCACG 
NH?-GCAGTAGACGTGC-P
GR85 GR85
GR79 GR79 GR54 GR54
GGAAGTCACAGCCTCGA CATCGTCGACGTCATCTGCACG 
NH?-CCTTCAGTGTCGGAGCTCGTAGCAGCTGCAGTAGACGTGC-P
GR100 GR100
Figure 6.7.2.I. Primers used in RLM RACE
Above is shown the 5' sequence of the original cDNA clone of rat PDE4A10.
GR84 is designed to the human sequence. Primers were used in ligations and PCR as 
described in the text. Primer sequences are as presented, underline is sense, double 
underline is antisense.
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6.7,2.2 Most bands obtained in the RACE reaction are RNA ligase specific but not 
gene-specific.
When T4 RNA ligase was omitted from the ligation reaction then subjected to 
two rounds of PCR as described above, very little amplification was detected. In 
contrast, when the same PCR was earned out on a ligation reaction which contains 
ligase, large amounts of amplification is detected in the nested PCR. However, there 
was little evidence of the expected shifting of band size in PCRs containing GR50 
against those containing GR51. Furthermore, most amplification was consistently 
seen in lanes where the second PCR only contained GR54 and no gene-specific 
primer. There were also discrete bands in PCR nested reactions which only contained 
gene specific primers GR50 or GR51. These could notionally be genuine PDE4A 
amplification products if they had been formed with miniscule amounts of primer 
carried over from the first nested reaction and indeed it has been suggested that use of 
such low concentrations can improve the specificity of RACE PCR (153). Therefore, 
a variety of the bands and whole PCR reactions which came from amplifications with 
GR51 were TA cloned. The resulting clones were screened with GR50 and a flanking 
TA vector primer. Very few TA clones were positive in this test and these clones were 
false positives in that they were not homologous to PDE4A10 when they were 
sequenced.
Chapter 6: Identification  o f  a new  P D E 4A  sp lice  variant 211
6.7.3. Intramolecular RACE produces artefacts apparently caused by 
intermolecular ligation of the phosphorylated cDNA primer
cDNA circularisation was attempted in the expectation that inverse PCR of 
these circles would yield upstream cDNA sequence. cDNA was synthesised with 
phosphorylated GR109 (figure 6.7.3.) This cDNA was then circularised by T4 RNA 
ligase. Nested inverse PCR was performed using GR51 and G R l08 followed by 
GR50 and GR107. When PCR products were TA cloned, most were sequences of 
varying lengths which resembled a number of G R l09 oligonucleotides joined 
together.
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1 CGCATTGCCC CTAGGACCAG AGTCACTGAC CCATTTCTCC TTCAGCGAGG 
CGTAACGGG GATCCTGGTCTCCAG GACTG GGTAAAGAGG AAGTCGCTCC
GR50 GR50 GR51 GR51
51 AGGACACTCT TCGACACCCT CCGGGCAGAT GTGTCAGCTT GGAGGCAGAA
CCT CCGGGCAGAT GTGTCAG 
GR107 GR107
AGGACACTCTTCGACACCCTC 
GR108 GR108
GGA GGCCCGTCTA CACAGTC-P
GR109 GR109
Figure 6.7.3. Inverse PCR RACE of rat PDE4A10
Above is shown the 5' sequence of the original cDNA clone of rat PDE4A10.
Primers were used in ligations and PCR as described in the text. Primer sequences are 
as presented, underline is sense, double underline is antisense.
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6.8 PCR SCREENS FOR HUMAN HOMOLOGUES OF RAT PDE4A 
SPLICE VARIANTS.
6.8.1. Identification of the human homologue of rat PDE4A10 hut not 
the putative human homologues of RPDE66 or rat PDE4A8 in human 
cell lines.
To attempt to isolate human sequence equivalent to the rat sequence for the 
unique exon of PDE4A10, PCR was attempted using the sense exon-specific primer 
successfully used on rat DNA and RNA (GRIO, see section 6.6) and also an 
alternative antisense primer designed to human sequence (GR84, see section 6.6) 
found in all 'long-form' PDE4A splice variants. The same approach was attempted for 
the other two rat PDE4A splice variants for which no human sequence has been 
isolated:
(1) RPDE66/ RNPDE4A9 (Graeme Bolger, unpublished) used unique exon specific 
primers
GR665 (sense ATGGAAGAGTGTTACCTTCAAGGAC;) and 
GR663 (antisense TCCAGTGGTCCATACTTCCAC;) or GR84;
(2) RNPDE4A8 (RPDE39) used exon specific primer
GR395 (sense ATGCCAAGTCGCAAGAGGCTGACAC; ) with GR84.
For PDE4A10, a correct size band was identified in U-118, SK-N-SH and 293 cells 
but not in U-87 or Jurkat cells (see figure 6.8.1.a). The band from RT-PCR on U-118 
cells was TA cloned. Sequence obtained from these clones revealed sequence highly 
homologous to that for the rat PDE4A10 sequence (See figure 6.8.l.b. The 5' extent 
of this sequence is marked in figure 6.10.d.). This short amount of sequence 
information is nevertheless important for a number of reasons. First, the sequence is 
conserved (and unlike the RDI conserved untranslated region (82), without 
frameshifts) which strongly suggests that it will code for protein (see figure 6.8.1b). 
Second, the human sequence crosses the exon boundary into PDE4A shared sequence 
(see figure 6.8.l.b), further confirming the notion that rat PDE4A10 is a genuine 
splicing variant. The alternative possibility, that the unique rat PDE4A10 sequence
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represents unspliced intronic sequence, is simultaneously undermined because such 
sequence would not be conserved between humans and rats. Third, the human 
PDE4A10 RNA has been shown to be expressed in human cells, only the third human 
splice variant for which this proof exists. The others being HSPDE4A4 (68) and 
HSPDE4A1 (chapter 5 and (82)).
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u-118 SK-N-SH 293 U-87
Figure 6.8.1.a. RT-PCR of human cell lines with PCR prohes designed 
to rat PDE4A10
RT-PCR was carried out on RNA from human cell lines using probes to rat 
PDE4A10. These different cell lines are labelled below the tracks.
The RT-PCR conditions used were 30 cycles of 96“C Imin, 55°C Imin, 72”C Imin. 
An arrow denotes fragments of the correct size (220bp). The fragment amplified from 
U-118 cells was cloned and sequenced (see section 6.8.l.b).
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RPDE4A10
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I I I I I
ACTGACCCATTTCTCCTTCAGCGAGGAGGACACTCTTCGACACCCTC
HPDE4A10
RT-PCR
CCTGACCCACTTCTCCTTCAGCGATGAGGACACCCGTCGGCACCCTC 
I I I I
1480 1490 1500 1510
HPDE4A10
RT-PCR
80
L E A E N G 
90 100
I I
110
RPDE4A10 CGGGCAGATGTGTCAGCTTGGAGGCAGAAAATGGGCCAACGCCATCC
AGGGCAGATCTGTCAGCTTCGAGGCAGAGAATGGGCCGACACCACCT 
I I I I I
1520 1530 1540 1550 1560
F E A E N G
RPDE4A10
120 130 140 150 160
I I I I I
CCTGGCCGCAGCCCCCTGGACTCGCAGGCGAGCCCGGGGCTTGTGCT
HPDE4A10
RT-PCR
CCCGGTCGCAGCCCCCTGGACTCGCAGGCGAGCCCAGGACTCGTGCT 
I I I I I
1570 1580 1590 1600 1610
170 180 190 200 210
I I I I I
RPDE4A10 GCATCGTGGGGCCACCACCAGCCAGCGCCGCGAGTCCTTCCTCTACC 
• • •  • • • •  • • • • • • • • • • • • • • • •  # # # # # # # # # # #  • • • •
HPDE4A10 ACATGCCGGGGTGGCCACCAGCCAGCGCCGGGAGTCCTTCCTGTACC 
RT-PCR I I I I I
1620 1630 1640 1650 1660
RPDE4A10
HPDE4A10
RT-PCR
220
I
GCTCAGACAGCGA
• • • • • • • • • • • • •
GCTCAGACAGCGA
I
1670
Figure 6.8.1.b. Identification of a fragment of human PDE4A10
The full extent of the RT-PCR fragment obtained from human U 118 cells is compaied 
with the 5' end of the incomplete rat PDE4A10 clone. Note that HPDE4A10 is 
numbered identically to figure 6. lO.d. The conserved peptide sequence which follows 
the long' fonn splice junction is shown. The human sequence crosses this boundary.
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6.8.2. Identification of the unique exon of rat PDE4A10 hut not the 
putative human homologue of rat PDE4A9 in three cosmids in the 
210Kh cosmid contig which contains the PDE4A locus
The identification and sequencing of a partial clone of human PDE4A10 
combined with the recent mapping of a 210Kb cosmid contig of PDE4A genomic 
sequence (82) allowed isolation of the remaining 5' sequence of PDE4A10 by a PCR 
screen of the cosmids. Thus three cosmids, R31069, R29158 and R27270, between 
them containing all the sequence from the 5' extreme of the PDE4A contig to the 5' 
end of the first commonly used PDE4A exon, were screened with the primers 
(brackets) specific to the rat forms of the unique PDE4A10 (GRIO & G R ll)  or 
PDE4A9 (GR665 & GR663) exon. The PDE4A10 primers readily detected a PCR 
fragment of the expected size (-90 base pairs) in all three cosmids whereas the primers 
designed to PDE4A9 did not amplify a PCR fragment from these cosmids. A human 
homologue for RPDE39 (RNPDE4A8) was not searched for by these means because 
the coding sequence for the unique exon of this splice variant is only 63 bp which is 
too small to be visualised on an agarose gel.
Attempted direct sequencing of the human PDE4A cosmids with the rat 
specific primers GRIO, G R ll, GR50, GR51 & GR52 or with a primer designed to 
the human specific sequence (primer GR HOLE was used which is a humanised 
version  of part of G R l l  (figu re  6 .7 .2 .1 ), w ith the sequence 
ACAGATCTGCCCTGAGG) was unsuccessful. Given that this may be due to the 
size of the cosmids (-50Kb per clone), it was decided to 'shotgun' clone a digestion 
of one cosmid and screen the subclone library for clones which contain the PDE4A10 
sequence.
6.9. SUBCLONING OF THE UNIQUE EXON OF HUMAN PDE4A10 
BY A NOVEL RAPID, EFFICIENT CLONING PROTOCOL.
The partial sequence of human PDE4A10 obtained by RT-PCR showed that 
there was a Xho II site at the 3' end of the PDE4A10 unique exon. This site is not 
found in the rat sequence. This enzyme will cut an unbiased, random sequence of
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DNA with an average frequency of 1/1024 which is a rare and useful property for 
subcloning. The average size of an insert from a digestion with a restriction enzyme 
with a six base pair identification sequence such as BamH I is 1/4096 and this presents 
difficulties in the efficient ligation of the insert, where efficiency decreases 
proportionally to insert size. Furthermore, sequencing reads are typically 400-600bp. 
This means that such large inserts have either to be 'walked' along with primers 
designed to the insert, or subjected to further subcloning. In contrast, the average size 
of an insert from a digestion with an enzyme with a four base pair identification 
sequence (such as Sau3A I) is 1/256 and this causes difficulties because the screens 
must be larger (-200 colonies assuming 100% ligation efficiency and equal ligation 
efficiency for all inserts) such that a straightforward PCR screen is no longer so 
attractive. Also, with such small inserts there is an increased possibility that not all of 
the exon sequence will be in a single digestion fragment. In such a case, where the 
sequence which was used in the PCR screen was dispersed amongst more than one 
subclone, then no single colony would show up positive, so an alternative screen 
would be required. Thus, the -1Kb average size of Xho II fragments is attractive 
because it is small enough to ligate efficiently and sequence rapidly yet it is large 
enough that one might reasonably expect to find all the sequence for an exon in one 
insert.
The positioning of the Xho II digestion site also facilitated subcloning. It is at 
the 3' end of the exon which meant that my existing PDE4A10-specific primers 
(GRIO &GR11) should identify the Xho II fragment in a PCR screen. Xho II 
digestion would place all PDE4A10 subclones at the ends of the inserts, thus 
eliminating completely the risk of subcloning the human PDE4A10 sequence in an 
inaccessible site placed in the middle of a large insert. To ensure a high efficiency of 
ligation of digestion fragments a novel subcloning strategy was used which harnesses 
the high efficiency TA ligation normally used for PCR products.
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6.9.1. TA cloning and PCR screening of Xho II fragments of cosmid 
R27270 for the human homologue of the unique exon of RNPDE4A10.
The Xho II digest of cosmid R27270 was TA cloned and 80 white colonies 
subject to PCR screen with GRIO and G R ll. This was performed in place of a PCR 
screen done with either GRIO or GRl 1 togetlier with a flanking vector primer because 
such a screen would be directional and this would have to be done twice; namely once 
in each direction. Since there was no PCR step in this cloning strategy, there was no 
risk of GRIO and G R ll amplifying contaminating, unrecombined template from a 
previous PCR. A single positive colony, 67, was obtained and taken for further study. 
PCR with GRIO and T7 or pCR2.1 reverse primer (see Methods section for vector 
primer sequences) revealed that the exon was ligated to the pCR2.1 reverse primer 
vector arm. The insert of colony 67 could not be sized by PCR with the two vector 
primers. Digestion with the EcoR I sites which flank the multiple cloning site excises a 
-2.5Kb fragment.
6.10. NOVEL TA CLONING STRATEGY PRODUCES OVERLAPPING 
FRAGMENTS OF THE 5' END OF PDE4A10 CLONE
Sequencing with the T7 sequencing primer of colony 67 reveals a reading 
frame still open at the 5’ end. The novel cloning strategy used in section 6.9. was 
repeated but this time a restriction enzyme was used which cuts away from its 
recognition site (see section 6.5) in order that clones with overlapping ends could be 
isolated. Using this protocol, fragments of the entire Xho II insert of clone 67 have 
now been sequenced and ordered into a contig. This contig order has been confii-med 
by two partial digests (see figure 6.10.b) and by PCR analysis (see figure 6.10.C.). 
Fragments 3 and 4 of this contig have now been sequenced fully and this sequence is 
presented in 6.10.d
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OVERLAP OF FRAGMENTS 1 AND 2 
.QAICTGAAGGGTTTT..0.4kb.. TCCCTGGTGTTTGTG
TTGTGGGGACGCGIC
OVERLAP OF FRAGMENTS 2 AND 3
..................................0 .4kb. . GACGCCTTCGGCTTC
I I I I I
GCTTCTCCGCAGCTG
OVERLAP OF FRAGMENTS 3 AND 4 
. .CTCTCCGGGTCTCTC
0 .9kb GGTCTCTCTCTCTGC
I I I I I
TCTGCGTCCTGCGIC.. 0. 7kb. .  CCCTCCGGGCA.G.AIC
Figure 6.10.a. Deduction of a Contig from Short Overlaps of DNA 
sequence.
The short unique overlaps (I) introduced into the PDE4A10 digestion fragments 
allowed the fragments to be correctly orientated and ordered. This in turn allowed 
immediate deduction of a contig equivalent to the original sequence digested (see 
figures 6.10.b and 6.10.c). Inspection of the sequence surrounding the overlaps 
identified Hga I recognition sites (underlined) consistent with these overlaps being due 
to filling-in of an Hga I digestion, as was intended. As discussed in section 6.10, the 
fragments at the junction between fragments 3 and 4 were more complex due to two 
Hga I recognition sites being close together in the DNA sequence. However, in such a 
situation, digestion at one site destroys the other, such that the overlap can still be 
identified in some clones. The dotted underlined GATC motif at the ends of fragments 
1 and 4 are the ends of the Xho II fragment following TA cloning (Recognition 
sequence RGATCY where R=G/A and Y= C/T)
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(i) CONTIG OF OVERLAPPING CLONES
Fragment 1
0.4kb 2
0.4kb . Fragment 3
0,9kb
COLONY 67 2.4kb
Fragment 4 
0.7kb
(ii) Hga I RESTRICTION MAP OF COLONY 67
m.
0.4kb 0.4kb 0.9kb 0.7 kb
(iii) COLONY 67 PARTIAL DIGESTS
11=2
<-
n=l
Figure 6.10.b. Analysis of Partial Digestion Fragments to Verify the 
Authenticity of a Contig deduced from Overlapping Sequence 
Information
(i) A schematic of a contig, deduced from introduced sequence overlaps, is shown.
(ii) Hga I restriction map based on the deduced contig.
(iii) Two kinds of partial digestion fragments were obtained from colony 67. Partial 
sequencing of these fragments (extent of sequencing depicted by the arrows) is 
consistent with tlie order and orientation of fragments 1-4 in the deduced contig.
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(i)
Fragment 1 
0.4kb Fragment 2 
0.4kb
GRl 18
GRl 27
COLONY 67 2.4kb
Fragment 3 
0.9kb Fragment 4 
0.7kb
GRl 25
G R ll5 GR110
CONTIG OF OVERLAPPING CLONES
(ii)
100bpladder GR118 GR127 QR125 G h iiè & primer
6R110 GR110 GR110 GR110 3' primer
Figure 6.10.C. PCR Analysis to Verify the Authenticity of a Contig 
deduced from Overlapping Sequence Information
(i) A schematic of a contig, deduced from introduced sequence overlaps, is shown. 
Primers were designed to these sequences in order to confirm this order and 
orientation by PCR. (ii) PCR analysis of colony 67 indicates that the orientation and 
order of the deduced contig are authentic. Thus, sense primers designed to fragments 
1-4 were able to amplify a fragment when PCR was performed with an antisense 
primer from fragment 4, indicating that the deduced fragment orientations are correct. 
Moreover, the sizes of the amplified fragments are consistent with the order of the 
fragments in the deduced contig. PCR conditions were 34 cycles of 98"C Imin, 47°C 
Imin and 72"C 2min.
PCR primer sequences: GR 118 GCATCTGGAGAGCTATG
GR127 TTGTGGGGACGCGTCCGG 
GR125 GCAGCTGCCAGGATTTGG 
GRl 15 ATCAGCGATCAGAGACCT 
GRl 10 GCAGGACCCCTGCAGG
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IGCTTCTCCGC AGCTGCCAGG ATTTGGGCCG CCAGGCTTGG GCTGGGGCTG
Spl Spl
51GGTAAGTGCA GCGCTGGTGG CCGTGGGTTC AAGTCGCCCC TGGCCACCTG
101GCGCACTCCA GGGTCTAGGG TTCGTGGCTC ACTCTCTCCA GCCTCACTTT
151CCTCTTCTGT CACATAGCAG CGATCAAAAT CATCCCTGAC CGCCAGGGTT
201GCCCTGGAGA CCTCTGATAG GGCATGCAGT AGACGTTTAA TAAATGTTGC
251ATCCTTCCCA CTTCCTGTGC AAACCTGAAG CTGCGGTCAC GCTTTGGAGG
301AGTGAGGGCG ACCTGCCATC CAGGTCATGT GTTCATCCTG GGGTATGTGT
351TCAGTTCTGT CAGCCTCAGT CTACTGGCCT GTGAAATGGG GCCAGTCATG
401CCTTCTGTGG GTGGCCTTGC GGTGAGGCTT GGTGTCACTC CTACTACCGG 
Spl Spl Spl Spl
451GCCACAGAGG GCAAATGGAA GTTCCCTTTC TGGCCAGACG GGGTGGGCTG
Spl
501CGGGGGCTTG AAGTCTGGGA GTGACAGGCC CCGAGGCCAC ATCCAGTCTG
Spl Spl
551GCTTTCTAAT GTCCTTATAT CCTGGAGGCA GAAGTTGGCA GCCCGGAGTT
601GGGCACTGGC TGGCCCTGGG GGCTTCTCCG GGTCCTCAGC CTCCCCCTCT
651TCCACCTACT TTCCACGTGC AATTGAGGCA CAGACTGAAG GAGGGCACGG
701CGGGGCAGGA CCGGGCCCAG CGACTGGCCC CAGGAACGAA ATGGGGCGGG
Spl
751GACAGAAGAG GAAGAGGGGC CAGGGCCTTT GGGAGCCCCG CGTGGGGTCC 
Spl
801GCAGGGTGTG TGTAGGGAAA TCGTTGCTTC TCTCCGGGTC TCTCTCTCTG 
Spl Spl
851CGTCCTGCGT CTCTGTCTCC ACTTCTGTCT CTTCTGTCTC TGTTTTGTTT
901CTCCTTCCCA CCGCTGAGCT GCAGCTTG.CC..(:TCC(:.CTGGG TTTATGICA.C
951.CCG.aCCC.CAC ACTCGAGTCC CGTTTCCCCG...aCG.aCGCACG GCGATCAGCG
1001ATCAGAGACC TCGAGCGGGC CCAGCTCGAC GTCAGGGCGG GGAGGGGGGA
CRE
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1051AA.GGCGGGGC .CGGAGGCGGT GGCAGGAGGG ■CGGGCCCG.GA...GCCG.GGAAA.C
Spl Spl Spl Spl
1101CGGAGG.CCCG..GGGCACG.CCA GAGGCCTAGG AGGGAGGAGA CGGGGGGGGG
1151GGGGGGGAAA TTGGTCCGAT TCCGCAGGAC CCCTGCAGGG GGAGGCAGAC
Spl Spl 
GCAGGAC CCCTGCAGG 
GR114 GR114
1201AGAGCGCCCG TGCGCTCCCT TCCCCCGTGC AGACCCGGGA ACGTT.CGA.CC
1251GCCCGGGGCI..GICCaGGGG..GGGIGACCAG..AGG.CGIGGAG..G.CGGJGG.CGG
1301CAGTGGAGGC CGCAGACACC TTGGG.CCTGG...CCAGCAGCG.C..G.CGCCACACC
Spl Spl
1351GCCCTGCCGC..CGTCCGCAIG.CGGGGCCCGA...CGACGG.CGCT tggctcccai
1401GCGTTCCGGT..GCAGCGCCCC..GGGCCCGGCC..CCGGCÇCCGT..GCCAISGCAA
*
G£AI
GR10
1451IGCCCCCCAC GGGCCCCGAG TCCCTGACCC ACTTCCCCTT CAGCGATGAG
§
TGCCCCT AGGACCAGAG TC
GR10
1501GACACCCGTC GGCACCCTCC GGGCAGATCT GTCAGCTTCG AGGCAGAGAA
GAGG CCCGTCTACA CAGTCGAAC
GRll F E A E N
Splice junction
1551TGGGCCGACA CCATCTCCTG GCCGCAGCCC CCTGGACTCG CAGGCGAGCC 
G
1601CAGGACTCGT GCTGCACGCC GGGGCGGCCA CCAGCCAGCG CCGGGAGTCC 
1651TTCCTGTACC GCTCAGACAG CGA
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Figure 6.10.d. Human Genomic Sequence Encompassing the 5' end of 
PDE4A10.
The sequence shown above encodes the 5' end of the PDE4A10 open reading frame 
including all of the unique splice variant specific sequence. The sequence is that of 
fragments 3 and 4 as depicted in figure 6.10.a, with extra 3' end sequence derived 
from RT-PCR. KEY:
TAG  The first in-frame stop codon in the PDE4A10 genomic clone 
§ The furthest 5' extent of sequence obtained by RT-PCR using primers designed to 
rat PDE4A10 ( primer GRIO was used, see section 6.8.1.) 
dotted.underline: GC rich regions
ATG: In frame putative initiator methionine (*=most likely initiator methionine, see 
next section)
Named sense primers are shown single underlined. Named antisense primers are 
shown double underlined.
Named putative promoter elements are shown double underlined. These are the 
putative cAMP response element (238) and putative Spl regulatory sites. (239).
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6.10.1. Expression of PDE4A10 as RNA in cells and identification of 
the initiator methionine of PDE4A10 by RT-PCR analyses.
There are four candidate initiator methionines (i~iv, figure 6.10.1.a) 
downstream of the first in-frame stop codon in the PDE4A10 genomic sequence. 
Authentic initiator methionines are found in the context of a Kozak consensus. The 
Kozak consensus sequence is CCIA /G ICCA TG G  (the methionine triplet is in 
bold)(190). Point mutations of this sequence indicated that the bases at +4 and -1 
(underlined) are the only bases that are essential if initiation is to be enabled at the site 
(190). Kozak showed that the critical positions in the consensus were -3 and +4 
(where the A of the ATG triplet is 1). The optimum sequence at these sites is a purine 
(A or G) at -3 and a G at -4. When these two requirements are met, Kozak showed that 
translational initiation is >15 fold more efficient from that ATG than an ATG which 
does not conform to the Kozak consensus (190). On these criteria, only sites (iii) and
(iv) are within a Kozak sequence and likely to be effective initiators of translation. This 
sequence information strongly indicates that translation will initiate at the first of these 
sites, which is site (iii). The lack of conservation of the site (iv) ATG in rat is also 
consistent with the notion that site (iii) is the initiator ATG because the PDE4 initiation 
sites are apparently always conserved between species (19). However, it remains to be 
seen whether sites (i)-(iii) are conserved.
Further experiments were carried out to provide further evidence that 
translation initiates at site (iii). Primer GRl 14 was designed to sequence upstream of 
sites (iii) and (iv) and primer GRIO is designed to sequence around sites (iii) and (iv) 
(see figure 6.10. l.b). RT-PCR was carried out on a number of human cell lines and rat 
and mouse brain using these primers with antisense primers GRIO and GR84 (see 
section 6.7.2.1). RT-PCR using primers designed to sites (iii) and (iv) produced 
correct-sized bands in RNA from mouse, rat and a range of human cell lines. In 
contrast, RT-PCR of sequence upstream of this position produces a signal in human 
U118 and SK-N-SH RNA samples but not in the rat or mouse RNA (figure 6.10.1.b 
and c).
The shorter band (A) is the same size as the human RT-PCR fragment already 
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sequenced. The longer RT-PCR band (C) obtained in U118 and SK-N-SH cells was 
now sequenced. Both these fragments were found to encode the expected segment of 
human PDE4A10 sequence (The sense primer in this reaction is G Rl 14. This fullest 
extent of human PDE4A10 RNA sequence is marked in both figure 6.10.d and
6.10.1.C). As I could only amplify this sequence from RNA from human cell lines, 
this result is consistent with the notion that sequence upstream of sites (iii) and (iv) is 
an unconserved UTR and that the ATG with suiTounding Kozak sequence is indeed the 
initiator methionine. The experiments of Kozak (190) showed that upstream sub- 
optimal Kozak sequences do not interfere with initiation from a downstream ATG 
which is in a Kozak consensus. This suggests that the presence of the site (ii) in the 
human PDE4A10 UTR should not perturb initiation from site (iii).
The DNA structure upstream of site (iii) contains a number of putative 
promoter elements, as reported below. These findings are consistent with the findings 
presented in this section. The full peptide sequence of the ORE of human PDE4A10 is 
shown in figure 6.10.1.d
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SITE CONTEXT OF PUTATIVE 
INITIATION CODON
POSITION OF ATG IN 
PDE4A10
KOZAK SITE 
CONSENSUS CCACC ATG G G -
C i) TTCTA ATG T 559
C i i) CTCCC ATG C 1398
C i i i ) GTGCC ATG G 1444
( iv ) TGGCA ATG C 1450
Figure 6.10.1.a In-frame putative initiator methionines for human 
PDE4A10
The putative initiator methionines for PDE4A10 are compared to the Kozak consensus 
(190). Underlines represent matches with the consensus at the crucial +4 and -3 
positions.
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(a)
JFi^gmen^
COLONY 67 2.4kb
0 4kb Fragment 2 
0.4kb Fragment 3
0.9kb
CONTIG OF OVERLAPPING CLONES
Fragment 4 
O.Zkb
(b)
< - r  ^ ' Unique S' exon of PDE4A10 /
PDE4A10 cDN/
850
PRIMERS FOR PDE4A10 RT-PCR
GR114 ------ >
1174
GRIG
1447
1537
GR11
1 ^ 9
PDE 4A10 COSMID SEQUENCE
GR84
}673
PCR REACTIONS USED TO SCREEN FOR PDE4A10
^ A ^
90bp
B SOObp 4 -----------------------------------------------------1^
C 370bp 4 -------------------------->
D 220bp <-
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M OU SE 293 U 87 SK-N -SH J u rk a t FTC133 U 118
A B A B A B A B A B A B A B
H eL a 293 olt R 27270 CONTROL R 31069
A B A B A B A D A D A D
Figure 6.10.1.b. RT-PCR screen for PDE4A10 expression
(i) and (ii) Orientation of primers for PDE4A10 PCR screen. RNA screens were 
performed with PCR reactions with GRIO and G R ll (Reaction A) or GR114 and 
GR84 (Reaction B). These primers are shown aligned to the PDE4A10 cDNA (the 
arrowhead indicates that there is more 3' sequence) and the PDE4A10 cosmid 
sequence. Since the PDE4A10 cosmid sequence is only the PDE4A10 specific exon, 
this could not be screened with GR84 which is designed to generic PDE4A sequence. 
For a PDE4A10 screen of cosmids, PCR reaction B was replaced with one using 
G R 114 and G R l l  (R eaction  C). Prim er G R 114 sequence  is 
GCAGGACCCCTGCAGG, the other primer sequences are listed in figure 6.7.2.1. 
Reaction D is that used in the initial RT-PCR analysis of human PDE4A10 (see figure 
6.8.1.a)
(iii) PCR screen of human cell lines, rat brain, mouse brain and cosmids. For reactions 
A, C and D, cycling conditions were 34 cycles of 96'C for Imin, 50“C (C) or 55“C (A 
and D) for Imin, 72”C for Imin. Reaction C was supplemented with 5% DMSO. For 
reaction B, cycling conditions were 34 cycles of 98“C for Imin, 50°C for Imin, 72"C 
for Imin. This was supplemented with 5% DMSO
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1 NSLYPGGRSW QPGVGHWLAL GASPGPQPPP LPPTFHVQLR HRLKEGTAGQ
51 DRAQRLAPGT KWGGDRRGRG ARAFGSPAWG PQGVCREIVA SLRVSLSASC
101 VSVSTSVSSV SVLFLLPTAE LHLPLPWVYV TRPHTRVPFP RGRTAISDQR
151 PRAGPARRQG GEGGKAGPEA VAGGRARSRE TGAPGHPRGL GGRRRGGGGG
II I I A
201 NWSDSAGPLQ GEADRAPVRS LPPCRPGNVR PPGAVPGGVT RGVEAVPAVE  >
1
251 AADTLGLASS ARHTALPPSP CAPRRRRLAP MRSGAAPRAR PRPRAMAMPP
301 TGPESLTHFP FSDEDTRRHP PGRSVSFEAE NG
Figure 6.10.1.c Candidate Initiator Methionines for PDE4A10
Putative peptide sequence is shown from the first in-frame methionine of the open 
reading frame of the PDE4A10 genomic sequence. Potential initiator methionines are 
underlined. Observations from experiments and sequence analysis which are relevant 
are mapped to their positions in this peptide sequence.
KEY:
I I I I : Position of the DNA encoding the putative CRE 
The 5' extent of PDE4A10/pSV SPORT construct (See next section).
 ^ : Furthest extent of human PDE4A10 detectable by RT-PCR (primer GRl 14,
see section 6.10)
9 : Furthest extent of rat or mouse PDE4A10 detectable by RT-PCR (primer 
GRIO, see section 6.10)
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1 MAMPPTGPES LTHFPFSDED TRRHPPGRSV SFEAENGPTP SPGRSPLDSQ
51 ASPGLVLHAG AATSQRRESF LYRSDSDYDM SPKTMSRNSS VTSEAHAEDL
101 IVTPFAQVLA SLRSVRSNFS LLTNVPVPSN KRSPLGGPTP VCKATLSEET
151 CQQLARETLE ELDWCLEQLE TMQTYRSVSE MASHKFKRML NRELTHLSEM
201 SRSGNQVSEY ISTTFLDKQN EVEIPSPTMK EREKQQAPRP RPSQPPPPPV
251 PHLQPMSQIT GLKKLMHSNS LNNSNIPRFG VKTDQEELLA QELENLNKWG
301 LNIFCVSDYA GGRSLTCIMY MIFQERDLLK KFRIPVDTMV TYMLTLEDHY
351 HADVAYHNSL HAADVLQSTH VLLATPALDA VFTDLEILAA LFAAAIHDVD
401 HPGVSNQFLI NTNSELALMY NDESVLENHH LAVGFKLLQE DNCDIFQNLS
451 KRQRQSLRKM VIDMVLATDM SKHMTLLADL KTMVETKKVT SSGVLLLDNY
501 SDRIQVLRNM VHCADLSNPT KPLELYRQWT DRIMAEFFQQ GDRERERGME
551 ISPMCDKHTA SVEKSQVGFI DYIVHPLWET WADLVHPDAQ EILDTLEDNR
601 DWYYSAIRQS PSPPPEEESR GPGHPPLPDK FQFELTLEEE EEEEISMAQI
651 PCTAQEALTA QGLSGVEEAL DATIAWEASP AQESLEVMAQ EASLEAELEA
701 VYLTQQAQST GSAPVAPDEF SSREEFVVAV SHSSPSALAL QSPLLPAWRT
751
801
LSVSEHAPGL
GGGGSGGDPT
PGLPSTAAEV EAQREHQAAK RACSACAGTF GEDTSALPAP
Figure 6.10.1.d The full peptide sequence of PDE4A10.
The sequence shown above is the full sequence of the most likely open reading frame 
ofPDE4A10.
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6.10.2. Analysis of the unique 5' exon of PDE4A10 and putative 
promoter sequence
The predicted amino acid sequence of PDE4A10 contains an N-terminal 
unique sequence of 30 amino acids. For comparison with other long' PDE4A forms, 
HPDE46 has 106 unique amino acids, RPDE66 has 65 amino acids and RPDE39 has 
20 amino acids. When compared in a FASTA similarity search the sequence shows no 
significant homology with any sequences in the Genbank nucleotide and EST 
databases. A second search, using the most N-terminal sequence conserved in 
PDE4As was similarly unable to identify a PDE4A 10-like sequence in the databases. 
This finding indicates that a novel splice variant has been identified. ~2.2kB of DNA 
has been isolated upstream of the putative initiator methionine of PDE4A10. There is 
no TATA box within this sequence but there are a number of GC rich stretches which 
are associated with promoter loci which lack a TATA box (240) (see figure 6.10.1). A 
number of putative Spl regulatory motifs (239), which promote tr anscription initiation 
from these GC boxes, are identified in the upstream sequence (figure 6.10.1). Most 
interesting however, is the near-perfect consensus cAMP response element sequence 
(238) upstream of the initiator methionine. This suggests that PDE4A10 expression 
could be dynamically regulated and may explain why, though it can be amplified at 
low levels in RNA from a range of cell-lines, PDE4A10 has not been identified 
previously by others.
6.11 CONSTRUCTION OF THE FULL CODING SEQUENCE OF 
PDE4A10 IN THE MAMMALIAN EXPRESSION VECTOR PSV SPORT
6.11.1. Construction of human PDE4A10 57pCR2.1
A human PDE4A10 5' end construct was made in pCR2.1 TA cloning 
vector. This construct represents the expected unique coding exon of PDE4A10. The 
construct was made from a Sau3A I fragment of the 5' exon of PDE4A10 from colony 
67. This was ligated to unphosphorylated adaptors. These adaptors extend the 
PDE4A10 sequence beyond the exon boundary into sequence conserved with 
HPDE46. The adaptor-ligated Sau3A I fragment was then TA cloned into pCR2.1 to
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produce PDE4A10 5'/pCR2.1. The adaptors incoiporate a BstB I site. Partial cleavage 
of this site enabled production of a cohesive end compatible with PDE46 digested with 
Taq I.
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Figure 6.11.1 Construction and plasmid map of PDE4A10 57pCR2.1
A Sau3A I fragment of colony 67 was TA cloned by ligation of an adaptor with a T 
overhang. This produces an insert with sequence which stretches beyond the 
alternative splicing junction of PDE4A10 into conserved PDE4A sequence. This exon 
can be fused to PDE46 to produce full-length PDE4A10 (see figure 6.11.2a, b)
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6.11.2. Construction of human PDE4A10/pSV SPORT
Construction of human PDE4A10/pSV SPORT incorporated a partial 
digestion. HPDE46/pSV SPORT was singly digested with Taq I. Singly cut plasmid 
was separated from uncut and multiply cut plasmid by gel electrophoresis. This 
product was then digested with Nar I and Kpn I, both of which digest HPDE46/pSV 
SPORT once (figure 6.11.2.a). The Kpn I digestion is to enable the human PDE4A10 
exon to be ligated in. The Nar I digestion site is in the 5* end of HPDE46. This 
digestion was performed to reduce the probability of recircularisation of HPDE46/pSV 
SPORT. PDE4A10 5' /pCR2.1 was digested with Kpn I and partially digested with 
BstB I and then ligated to the HPDE46/pSV SPORT construct which had been 
digested as already described (figure 6.11.2.b). The construct was analysed by PCR 
and restriction digestion (figure 6.11.2.C.)
Chapter 6: Identification  o f  a new  P D E 4A  sp lice  variant 237
PstI.KpnI.RsrII.EcoRI.Smal
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TaqISV40 ori/promoter
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poly A signal
Aatll.SphI.MIul.SnaBI.HindllTlBamHI.Xbal.NotI.SpeI.BamH
hPDE46
Figure 6.11.2.a. P lasm id m ap of hPDE46/pSV SPO RT
hPDE46/pSV SPORT was digested singly with each of Taq I (partial digest, but the 
intended insertion site is displayed), Kpn I and Nar I (see section 6.11.2.). 
Components of the plasmid are as labelled.
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KpnI.Sad.BamHI.Spel. BstXI.EcoRI. BstBi
PDE4A10 5' end BstB!
Pstl.Kpnl.
JaqISV40 ori/promoter
pSV.Sport PDE4A generic 
region
poly A sign^
Aatll.SphI.MIul.SnaBI.Hmdlll.BamHI.Xbat.NotI.SpeI.BamHT
Figure 6.11.2.b. Construction of PDE4A10/ pSV SPORT
The schematic above shows the Kpn I /BstB I fragment of PDE4A10 5' end. This was 
ligated into a Kpn 1/ Taq I PDE46/pSVSPORT digestion to produce PDE4A10/pSV 
SPORT
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Figure 6.11.2 c Plasmid map of PDE4A10/pSV SPORT
(i) A schematic map of the PDE4Al()/pSVSPORT construct, (ii) Evidence that the 
correct construct has been synthesised. As well as sequencing, the PDE4A10/pSV 
SPORT construct was subjected to restriction digestion with Sma I (left panel). This 
shows that the 5' end of PDE46, which is the 0.7kb band, is removed missing in 
PDE4A10. The smaller bands which then appear are because Sma I cuts several times 
in the PDE4A10 5' end. A PCR screen with PDE4A10 specific 5' primer GRl 14 and 
PDE4A specific primer GR84 (reaction D, see figure 6.10.1.b). produces a band of 
the correct size with the PDE4A10 construct but not PDE46 (right panel.)
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6.12 EXPRESSION OF PDE4A10/pSV SPO RT IN COS-7 CELLS
The new construct PDE4A10/pSV SPORT was transfected in COS-7 cells to 
allow over-expression of the PDE encoded by the plasmid. Cell lysates were then 
immunoblotted. Lysates of COS-7 cells transfected with PDE46/pcDNA3 were run 
alongside PDE4A10 lysates as a positive control for tlie PDE4A monoclonal antibody. 
These results clearly show a band migrating at tlie expected weight, which is markedly 
different to that of PDE46. PDE4A10/pSV SPORT apparently expresses as a doublet. 
This may be due to initiation occurring at the weak initiation ATG which is upstream 
of the correct ATG. As with other PDE4A forms HSPDE4A10 appears to run more 
slowly on an SDS-PAGE gel than one would expect from its calculated molecular 
weight of 90kD. Both of the PDE4AI0 expression products are entirely cytosolic.
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Figure 6.12 Over-expression of PDE4A10 in COS-7 ceils
COS-7 cells were transfected with PDE4A10/pSV SPORT. Cells were fractionated 
and the lysates were then immunoblotted with the PDE4A specific PDE4A monoclonal 
antibody. Lanes are labelled S2, for the high speed soluble fraction, P2 for the high 
speed particulate fraction and PI for the low speed particulate fraction. The molecular 
weight markers are shown. The apparent molecular weight of the PDE4A10 band is 
~95kD. Labels under the lanes show which fraction of each sample (P2, PI, S2) was 
run. PDE46, which migrates more slowly, is shown as a positive control for the 
antibody and for comparison with PDE4A10.
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CONCLUSION
6.13 FAILURE OF PCR-BASED METHODOLOGIES TO ISOLATE 
ANY EXTRA SEQUENCE OF RNPDE4A10
Four PCR based methodologies failed to isolate any further DNA sequence of 
PDE4A10, though the reasons for this remain obscure. The sequence, now identified 
by other means, shows that conditions were not propitious for PCR-based protocols. 
The sequence is GC rich, including one sequence of 25 consecutive G or C bases 
directly upstream of the known sequence. It is well established (228) that such regions 
provide a poor template for the PCR reaction. Knowledge of tlie sequence has allowed 
alteration of denaturing temperatures and DMSO concentrations in PCR reactions of 
the N-terminal of PDE4A10. This work has revealed that, for the human sequence at 
least, only at conditions more extreme than those in the RACE PCR is the coirect PCR 
band obtained. Therefore this is in itself reason enough why none of the PCR-based 
protocols worked. A further more basic problem is that in none of these protocols 
could the size of the PCR fragment be predicted and this thus removed a major way of 
discriminating artefactual amplification products. The use of two alternative gene 
specific primers (see section 6.7.2.) in parallel PCRs did not identify genuine PDE4A 
amplification products. These primers would have been better indicators of genuine 
amplification products if they had been placed further apart making the size differential 
of genuine amplification products larger between the two PCR reactions. Furthermore, 
given the likelihood that RNA Ligase Mediated (RLM) RACE will, in any case, 
produce a range of sizes of genuine amplification products (153), the chances of 
detecting the shifting of all these bands against the kind of background noise I have 
seen suggests that this innovation will be of limited value. A positive control 
sequence, which could have been RACE amplified alongside PDE4A10 could have 
shown that all the enzymes used in the RACE were active but this too would be of 
questionable value where sequence specific effects are so important on the outcome of 
an experiment (153).
There were further drawbacks specific to each protocol: (1) The ligase free 
cloning strategy which is integral to the Tenninal Deoxynucleotidyl Transferase (TdT)
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RACE kit meant that each primer in the PCR was greater than 30 base pairs long. 
This is considerably longer than is recommended in most RACE protocols (153). This 
may have been part of the reason why no amplification products were obtained with 
this system; (2) The inverse PCR of circularised single stranded cDNA protocol 
clearly suffered from insufficient removal of cDNA primer because these were seen 
ligated in polymers in PCR clones. The other 'tag' oligonucleotides were chemically 
modified at their 3' ends such that they would not be substrates for downstream 
ligations and it may be that this drawback is tlie reason why similar protocols have not 
previously been reported.
6.14 DISCOVERY OF A NEW PDE4A SPLICE VARIANT IN HUMAN 
AND RAT
This project began with an incomplete novel rat PDE4A clone, rat PDE4A10. 
By screening of PDE4A cosmid DNA with probes designed to the 5' end of this novel 
PDE4A cDNA, sequence has been isolated for the full open reading frame of a novel 
human PDE4A splice variant, HSPDE4A10. A 2.5 kb fragment of sequence which 
contains putative PDE4A10 promoter elements has also been isolated. The existence 
of HSPDE4A10 and RNPDE4A10 has been confirmed by RT-PCR in RNA from 
native tissues and for HSPDE4A10 in cell lines. Sequence infoimation was obtained 
from these RT-PCR fragments in order to validate the authenticity of the PDE4A10 
sequence that I had identified in human genomic DNA. This sequence information did 
indeed show that the extra PDE4A10 sequence identified by me in human genomic 
DNA is expressed in PDE4A10 RNA.
The failed attempts to obtain any evidence of the RPDE66 specific exon in 
genomic cosmids could be because a notional HPDE66 is not sufficiently homologous 
with RPDE66 or because such an exon is found beyond the 210Kb contig of PDE4A 
sequence so far isolated or because a homologue of RPDE66 is not found in human. 
Failure to identify RPDE66 species in RNA may additionally be due to the expected 
naiTow expression profiles of these two splice variants.
Chapter 6: Identification  o f  a new  P D E 4A  sp lice  variant 244
6.14.1 Identification of the initiator methionine of PDE4A10
The initiator methionine of human PDE4A10 has been identified on the basis 
of a number of criteria. Firstly, of the four in-frame methionines downstream of the 
first in-frame stop codon, only two (iii and iv) are contained within the context of a 
Kozak consensus. Site (iv) is not conserved in the rat sequence. Secondly, RT-PCR 
analyses show apparent lack of conservation of sequence further upstream between 
species, consistent with this upstream sequence being a UTR. Thirdly, the sequence 
upstream from site (iii) contains several sequence motifs which are commonly 
identified in promoters. These results are all consistent with the notion tliat site (iii) is 
the initiator methionine. These experiments represent a far more rigorous analysis of 
the initiation site than is normally carried out in the PDE field. The position of the 
human initiator methionine suggests that the original rat ORF is missing only one 
codon.
6.14.2. Primary structure and expression of human PDE4A10
As is the case with many other PDE4 forms there are a large number of 
prolines, serines and arginines in the N-terminal unique sequence of PDE4A10. 
Prolines and arginines often direct kinases to phosphorylate serines (215) and so it is 
clearly possible that kinases could phosphorylate PDE4A10. Possible phosphorylation 
sites are shown below the alignment of rat and human PDE4A10 sequence (figure
6.14.2). The predicted peptide sequence of the human and rat PDE4A10 forms (figure
6.14.2) is well conserved. This is expected to be due to some conserved functions. 
These still need to be identified but could include conserved regulatory phosphorylation 
sites. The level of conservation between human and rat PDE4A10 is similar to that of 
PDE46 and RPDE6 with -20% substitution in both cases. This contrasts sharply with 
the 100% conservation of unique exon sequence between human RDI, rat RDI and 
RDI homologues from a number of other species. This distinction further underlines 
the strict evolutionary constraints which the N-terminus of RDI seems to be under and 
which I argued in chapter 5 may be due to a conserved molecular recognition. As with 
RDI, it is anticipated that the human and rat PDE4A10 homologues will vary most at
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their LR2 domain, where human PDE4A10 will have LR2HP whereas rat PDE4A10 
will have an LR2P motif. Thus, rat and human PDE4A10 will be another pair of clones 
in which the function of LR2H can be studied.
The fullest extent of human PDE4A10 cDNA has been expressed in COS-7 
cells. This construct expresses protein which is readily detectable by a PDE4A 
antibody. The doublet produced may be due to aberrant initiation similar to that 
apparently observed in RDI PDE4A overexpression (114). Alternatively the doublet 
may be due to some as yet unidentified postranslational modification.
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Figure 6.14.a Peptide sequence conservation between the human and 
rat homologues of PDE4A10.
The unique splice variant specific sequence of human (TOP) and rat (BOTTOM) 
PDE4A10 are shown aligned together.
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Figure 6.14.b. Alignment of PDE4A splice variants
HSPDE4A10 is compared with the other known long' form PDE4A splice variants. 
These are, with the Genbank accession number in brackets, RNPDE4A5 (68) 
(L27057), RNPDE4A8 (77) (L36437). Each splice variant sequence diverges from the 
others at the same splice junction upstream of the conserved rat/human (F/L)EAENG 
motif.
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6.15  O V E R L A P P I N G  S H OT G U N  TA C L ON I N G:  A
STRAIGHTFORWARD, RELIABLE METHOD FOR CLONING, 
SEQUENCING OR RESTRICTION MAPPING PROJECTS.
A method has been described for producing overlapping clones for any 
shotgun cloning project. These clones could then be used to create a sequence contig 
or very long single enzyme restriction maps. Any enzyme which gives recessed 3' 
ends and which cuts away from the recognition sequence could be used in these 
projects, as presented in table 6.15. As can be seen they can be used to give a range of 
fragment sizes. A technical drawback is that if two restriction sites are very close 
together cutting of one may disrupt cutting of the other or both may cut to give a very 
small fragment which could be missed by downstream processing such as blue/white 
colour selection for recombinant clones. This is not a major difficulty however 
because, at worst, such sites will simply interrupt the contig; the size of the 
interruption may even be gauged by comparison of the length of the contigs with the 
length of the original DNA sequence
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Restriction
Enzyme
Recognition
Sequence
Frequency 
of cutting 
(bp)
Probability of 
chance overlap 
match 1 (bp)
Global
probability of 
match^
(Kb)
Alw261 
B bv l 
BsmA I 
BsmF I 
Bst71I 
Fok P  
SfaN I
GTCTC(N)l/5
GCAGC(N)8/12
GTCTC(N)l/5
GTCCC(N) 10/14
GCAGC(N)8/12
GGATG(N)9/13
GCATC(N)5/9
1/512 1/256 l/131Kb
H gal GACGC(N)5/10 1/512 1/1024 l/524Kb
E am ll04 I 
Ear I/Ksp632 I
CTCTTC(N)l/4 1/2048 1/64 l/131Kb
Bbs V B h v ie  II 
Bpi I/BpuA I 
BsaI/Eco311 
BsmB iyEsp3 I 
BspM I 
Gdi IP
GAAGAC(N)2/6
GGTCTC(N)l/5
CGTCTC(N)l/5
ACCTGC(N)4/8
CGGCCR(N)l/5
1/2048 1/256 l/524Kb
S ap l_ _  _ GCTCTTC(N)l/4 1/8192 1/64 l/524Kb
1 Probability of chance match between two unrelated overhangs.
2 Global probability of a random match between two unrelated overhangs. (Example 
calculation: Each Alw26 I end has will cut on average every 512 bp of DNA. Each of 
these overhangs has a 1/256 chance of matching. Thus the global probability of there 
being a random matching overlap is;
the probability of Alw261 cutting a piece of DNA x probability of an end matching
1/512 X 1/256= l/131Kb 
Therefore the global chance of a random overlap is 1 in 131Kb 
 ^Fok I possesses considerable 'star' activity (this is where the enzyme cuts at sites 
other than those it is supposed to digest). The effects that this might have on this 
cloning strategy are unknown.
Gdi II is not commercially available
Table 6.15. Restriction enzymes suitable for overlapping shotgun TA 
cloning.
All commercially available enzymes suitable for the novel cloning technique described 
herein are shown above (source: MB I Fermentas catalogue). These are all restriction 
enzymes that cut beyond the recognition sequence leaving a recessed 3' end.
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6.15.1 Overlapping TA shotgun cloning might be used for very large 
sequencing projects
Hga I is paiticularly attractive for overlapping TA shotgun cloning because it 
can be used to cut large amounts of DNA down to portions that can be sequenced. 
However, the probability of having ends matching by chance is extremely low, 
typically about 1 chance overlap per 0.5 Mb (see table 6.15). For comparison the 
typical bacterial genome is around 4Mb and the human genome is 3000Mb long. 
Furthermore, even if there are a few random overlaps some permutations could be 
discounted immediately, for example those that produce a circular contig for a DNA 
fragment that is clearly linear. Other pennutations could be discounted by looking for 
the permutation with the least number of contigs (see figure 6.15.1). For the 
production of very large scale contigs with the possibility of an increased number of 
chance matches this might become a difficult task. However this provides no obvious 
bar to automation of a 'least number of contigs permutation' search. Missing 
sequences disrupting the contig are unlikely to perturb these searches because any 
such gap would be present in both correct and incorrect contig permutations. It is 
difficult to determine how long sequences would have to be for use in this method 
before contig alignment becomes impossible. What is clear, from table 6.13, is that the 
technique described herein will be eminently suitable for contig creation for the many 
existing vectors designed to hold large amounts of DNA. For example, The Institute 
for Genome Research (TIGR) is currently engaged in 'end-sequencing' all of its 
Bacterial Artificial Chromosomes (BAG). This endeavour will provide some 
information to allow positioning and ordering of the sequence of these constructs 
within the human genome. If, instead, they were to employ my technique in 
sequencing their chromosomes, they could rapidly produce large contigs and 
restriction maps, as I have described, with very little more additional effort. These 
contigs and digestion maps would allow simpler isolation of new genes and more 
complete ordering of BAG contigs.
The application of this technique on small scale (gene/PGR products) 
sequencing projects contig construction will be straightforward because overlaps will
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generally either not occur or occur extremely rarely with around a 1/10 chance in a 
50kB cosmid cut with Hga I. The only drawback to gene sequencing by overlapping 
TA shotgun cloning is that the digestion sites may not be well placed to obtain all the 
sequence. However, as shown in figure 6.13, there are a number of enzymes with 
different specificities to choose from. In any case, use of my new protocol does not 
preclude the use of other protocols to fill in any gaps.
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Figure 6.15.1. Schematic of the simplest 'Least number of contigs 
permutation search'
Small numbers of random overlap matches can be resolved by finding the permutation 
which gives the least number of cosmids. In the example above the upright oval 
overlap matches the hexagon overlap, giving two possible permutations for the contig 
(1,2). The correct contig is the longer one (2).
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6.15.2 Overlapping TA shotgun cloning has practical advantages over 
existing methods of contig assembly.
Overlapping TA shotgun cloning offers considerable advantages over 
classical shotgun cloning in that much more information is obtained with very few 
extra experimental steps. The new method also has several practical advantages over 
the exonuclease/mung bean nuclease protocol which is currently the standard method 
for sequencing long pieces of DNA (241).
(1) Range. The exonuclease/mung bean nuclease protocol will only work if the 
restriction enzymes used are not present in the insert. For cosmids and other vectors 
which carry large inserts then most restriction enzymes will cut many times in the 
insert so that the exonuclease/mung bean protocol cannot be used (241).
(2) Reliability. The new technique I have described here uses the most robust DNA 
ligation reaction in TA cloning and only one other reaction, restriction digestion, 
which can be monitored by gel electrophoresis. Conversely, the full activity of 
exonuclease III and mung bean nuclease, as well as the proper specificity of the latter, 
depend on the efficient removal of small pieces of DNA and RNA and nicked DNA 
(241). SI nuclease, which has been used in place of mung bean nuclease is even more 
promiscuous (241).
(3) Ease. The need for pure DNA means that for the best chance of success the 
exo/mung bean nuclease protocol incorporates phenol chloroform extractions/ spin 
column extractions (241) whereas the new protocol will work with more 
straightforward gel purification and ethanol precipitation. Also, the exo/mung bean 
protocol becomes less attractive the larger the DNA insert gets. This is not only 
because of the extra risk of restriction digestion sites in the insert (see 1) but also 
because the positioning of the sequence of interest gets less certain so more time points 
have to be taken for the exonuclease digestion and these time points are longer. There 
are no time courses in the new protocol. Another practical difficulty with the exo/mung 
bean nuclease protocol is that there is no easy control for the second restriction 
digestion and yet the efficiency of this digestion is vital for the whole experiment's 
efficiency.
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6.15.3 Use of overlapping TA shotgun cloning in creating gel-free long 
restriction maps
Overlapping TA shotgun cloning could also be used to produce very long 
restriction maps. To date, these are typically constructed by logical deduction from 
double digests, or by consistency in the digestion patterns of overlapping clones. 
Technical difficulties of gel analysis of digests limit the lengths that such maps can be. 
As has already been discussed, the new metliod has more relaxed limitations and thus 
it should be possible to restriction map very large pieces of DNA. Drawbacks to the 
new approach are that this procedure requires sequencing data and can only use 
enzymes like those presented in table. Enzymes frequently used in restriction 
mapping, such as Eco RI or Not I cannot be used.
6.15 FUTURE PROSPECTS
There is now the prospect that this protocol may supersede others to allow 
identification of contiguous sequences (see figure) without recourse to time- 
consuming conventional restriction mapping or nuclease treatments. Continuing 
research into new restriction enzymes with longer overlaps and/or recognition 
sequences is the key to extending the already wide range of sequence lengths that can 
be used in this technique.
Chapter 6: Identification of a new  P D E 4A  sp lice variant 255
7. FINAL CONCLUSION
As was discussed in the Introduction, cAMP signals are produced as a result 
of many external stimuli and these cAMP signals are able to alter cell functioning in 
d istinct ways. This thesis details work towards an understanding of 
compartmentalisation of cAMP signals at the molecular level. Models for control of 
compartmentalisation of cAMP by PDEs were elaborated in the introduction. These 
depend on the existence of a large array of functionally different PDEs. The first two 
results chapters in this thesis concerned themselves with characterising these 
functional differences.
In chapter 3 of this thesis I examined the mechanism by which the insulin 
sensitive PDE3B associates with particulate cell fractions. To do this I made three 
constructs of various sections of PDE3B. Using these constructs I was able to 
solubilise full-length PDE3B by treatment with either non-ionic detergent or 
triethanolamine. The immunoblots of these solubilisations are the first to show 
solubilisation of full-length PDE3B. I have been able to map a new membrane 
association domain beyond that described by Taira et al (54) but which is implicit in 
other data (52,56).
In chapter 4 I examined a PKC-mediated induction of PDEl in Chinese 
hamster ovary cells in collaboration with co-worker Dr Sandra Spence (163,207). By 
use of RT-PCR I was able to show that there was an induction in the level of PDEl 
transcripts (163). I was further able to show that this induction was a selective 
induction of PDEIB (207). This is the first example of an induction of an identified 
PDE by PKC, My results are also the first identification of an induction of PDEl and 
similar results, implicating the same PDE in PKC-mediated stimulation, have since 
been reported by others (35). As such, the data from this chapter represent a 
significant contribution to understanding of PDEl regulation.
Chapters 5 and 6 of this thesis were devoted to furthering knowledge of the 
number and primary structure of PDEs, an endeavour which, in the long term, should 
also deepen knowledge of the role of different PDEs in compartmentalisation. The 
work described in chapter 5 showed that I was able to identify mammalian
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homologues for the rat PDE RDI. Human RDI (hRDl) is only the second PDE4A
bothwhich has been identified indium an and rat. The putative membrane association 
sequences of RDI are perfectly conserved across a number of mammalian species, 
supporting the notion that the sequences may have a conserved functional role. 
Serendipitously, this work exposed a rodent-lineage specific deletion of apparently 
ancient PDE4A sequence. This finding, which may be associated with functional 
alterations, may be a first step in the production of single state PDE inhibitors, since it 
suggests a possible target for such inhibitors. The deletion may also be of considerable 
interest to molecular taxonomists as a phylogenetic marker with the potential to solve 
previously intractable controversies over rodent phylogeny.
In chapter 6 of this thesis I identified, cloned and expressed a novel human 
PDE4A splice variant, PDE4A10. I have also made a survey of endogenous 
expression of this PDE in native brain and cell lines by RT-PCR. I have isolated 
almost the full open reading frame of the rat homologue of this splice variant. This 
PDE is therefore the third PDE4A which has been identified in both rat and human and 
the work presented in this chapter therefore represents a major contribution to 
understanding of the molecular biology of PDEs. The work in chapter 6 also makes a 
wider contribution, by describing a novel method for producing precise overlaps in 
clones of DNA. The impact that this technique will make remains to be established. If 
the technique supplants less reliable, more laborious existing techniques, the facile 
contig assembly and restriction mapping of very large pieces of DNA that it enables 
could speed large sequencing projects such as the Human Genome Project. The 
technique should also be applicable to smaller sequencing projects, where it can be 
used in conjunction with existing protocols to produce full sequences.
Taken together, the work presented in this thesis represents a significant 
contribution to understanding of phosphodiesterase isozymes.
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APPENDIX: Tested sequences for reverse transcription polymerase 
chain reaction (RT-PCR) detection of PDEs
A first step towards understanding the basis of compartmentalisation is to 
identify which of the possible molecular participants are present in the system under 
investigation. RT-PCR is an attractive technique to employ for this because the 
necessary probes are easily made and the reactions themselves are robust and rapid. 
RNA isolated from tissues is reverse transcribed into cDNA and tlien a fragment of tliis 
cDNA is amplified by repeated rounds of specifically primed DNA polymerisation in 
the PCR reaction.
The primers presented here have been used successfully to detect PDEs from a 
number of rat tissue and cell line sources (Graham Rena, Li Zeng, Mischa Kostic 
unpublished) and also mouse (Alex Peden unpublished). The high conservation of 
PDE sequence between species means that when used at low stiingency they are likely 
to be able to detect the relevant PDE in a range of species, as shown by identification of 
homologues for RDI (RNPDE4A1) in a range of species (82).
Design of primers for each published rat PDE4 splice variant
I have designed and tested primers for RT-PCR detection of PDE4 splice 
variants reported in the rat.
(1) The longest reported sequences for each PDE4 splice variant were downloaded 
from GenBank. These were used in multiple pairwise alignments on the Gene Jockey II 
program (by Biosoft) to delimit how much unique sequence was contained in each 
splice variant. Primer pairs were designed to these unique sequences for RNPDE4A8 
and RNPDE4A5. Even though there was often enough unique sequence for amplifying 
a good-sized fragment from the unique sequence alone, I designed most of my primers 
some way in from the 5' end having found that some primers designed to the extreme 
5' ends are poor amplifiers in PCR (data not shown). Therefore, for RNPDE4A1, 
RNPDE4B2, RNPDE4B1, RNPDE4D1 and RNPDE4D3 we used a splice variant 
specific primer coupled to a gene specific (but not splice variant specific) downstream 
primer. RNPDE4D2 has no unique sequence relative to RNPDE4D3 so primers were
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designed which allow discrimination from RNPDE4D1 by the size of the fragment (see 
below). RNPDE4B1 and RNPDE4C1 are likely to represent truncated sequence 
present in a number of splice variants (85) and so any primers designed to these 
sequences are probably detecting more than one transcript. My primers to RNPDE4D3 
are also likely to be able to cross-detect the as yet uncloned rat homologues of 
HSPDE4D4 and HSPDE4D5.
(3) Candidate primer pairs are screened against a library of PDE sequences to make 
sure that they do not anneal to sequences other than those to which tliey were designed. 
They are also checked for internal or intermolecular complementarity. Primer 
sequences of between 18 and 26 base pairs are chosen and the melting temperature of 
each pair is matched (~65“C)
A pp en d ix  259
Tested primers for splice variant specific RT-PCR in the rat.
S p l i c e
V a r i a n t
S E N S E  p r im e r S t a r t s A N T I S E N S E  p r im e r E n d s  a t S i z e
P D E 4 A
R D I
M 2  6 7 1 5
G R 3 7
t t c t t c t g c g a g a c c t g c t c c a a g c
7 1 G R 3 6
c a g g c c c c a t t t g c t c a a g t t c t c c
4 4 2 3 7 2
R P D E 6
( L 2 7 0 5 7 )
G R l  a a g g a g c c t g t c t c t c t c t c t t c c g 1 4 2 5 G R 2  g g t a c c g g t g c c g t g g a a g g a 1 6 8 3 2 5 9
P D E 4 B
D P D
( J 0 4 5 6 3 )
G R 3
a a a c c t t c a c g g a g c a c c g a a c a a g a g g
3 9 G R 4
g c c a c g t t g a a g a t g t t a a g g c c c c a t t
5 4 5 5 0 7
P D E 4
( M 2 5 3 5 0 )
G R 1 7
t t g R t a g a t c a c t g a c a c c t c a t c c c g
2 0 G R 4
g c c a c g t t g a a g a t g t t a a g g c c c c a t t
6 8 6 6 6 7
P D E 4 C
R P D E 3 6
( L 2 7 0 6 1 )
G S 3 2  c c a t g g c c c a g a t c a c t g g g c t g 4 5 9 G R 9
g g a c t t c c t g g t c c g c a t t a g g c t a a t
1 7 0 8 1 2 5 0
P D E 4 D
P D E 3 .1
( M 2 5 3 4 9 )
G R 7
t c c g g t g a a g c g c t t a a g a a c t g a g t c c
2 3 7 G R 6
c c t g g t t g c c a g a c c g a c t c a t t t c a
4 6 3 2 2 7
P D E 3 .1
( M 2 5 3 4 9 )
G R 8  a c g t c a a g c t g g a g c a t c t c g g c 6 6 G R 6
c c t g g t t g c c a g a c c g a c t c a t t t c a
4 6 3 3 9 8
P D E 3 .2
( U 0 9 4 5 6 )
G R 8  a c g t c a a g c t g g a g c a t c t c g g c 1 G R 6
c c t g g t t g c c a g a c c g a c t c a t t t c a
3 2 1 3 2 1
P D E 3 .3
( U 0 9 4 5 7 )
G R 5
c t a a t t t g c a a g a t c g c g c a c c c a g c
3 2 3 G R 6
c c t g g t t g c c a g a c c g a c t c a t t t c a
5 7 7 2 5 5
A p p en d ix 2 6 0
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